FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Sathe, A
   Chalaud, G
   Oppolzer, I
   Wong, KY
   von Busch, M
   Schmid, SC
   Tong, ZC
   Retz, M
   Gschwend, JE
   Schulz, WA
   Nawroth, R
AF Sathe, Anuja
   Chalaud, Geraldine
   Oppolzer, Immanuel
   Wong, Kit Yeng
   von Busch, Margarita
   Schmid, Sebastian C.
   Tong, Zhichao
   Retz, Margitta
   Gschwend, Juergen E.
   Schulz, Wolfgang A.
   Nawroth, Roman
TI Parallel PI3K, AKT and mTOR inhibition is required to control feedback
   loops that limit tumor therapy
SO PLOS ONE
LA English
DT Article
ID TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; PHASE-II; UROTHELIAL
   CANCER; EVEROLIMUS; TARGET; PHOSPHORYLATION; RESISTANCE; IDENTIFICATION;
   SENSITIVITY
AB Targeting the PI3K pathway has achieved limited success in cancer therapy. One reason for the disappointing activity of drugs that interfere with molecules that are important player in this pathway is the induction of multiple feedback loops that have been only partially understood. To understand these limitations and develop improved treatment strategies, we comprehensively characterized molecular mechanisms of PI3K pathway signaling in bladder cancer cell lines upon using small molecule inhibitors and RNAi technologies against all key molecules and protein complexes within the pathway and analyzed functional and molecular consequences. When targeting either mTORC1, mTOR, AKT or PI3K, only S6K1 phosphorylation was affected in most cell lines examined. Dephosphorylation of 4E-BP1 required combined inhibition of PI3K and mTORC1, independent from AKT, and resulted in a robust reduction in cell viability. Long-term inhibition of PI3K however resulted in a PDK1-dependent, PIP3 and mTORC2 independent rephosphorylation of AKT. AKT rephosphorylation could also be induced by mTOR or PDK1 inhibition. Combining PI3K/mTOR inhibitors with AKT or PDK1 inhibitors suppressed this rephosphorylation, induced apoptosis, decreased colony formation, cell viability and growth of tumor xenografts. Our findings reveal novel molecular mechanisms that explain the requirement for simultaneous targeting of PI3K, AKT and mTORC1 to achieve effective tumor growth inhibition.
C1 [Sathe, Anuja; Chalaud, Geraldine; Oppolzer, Immanuel; Wong, Kit Yeng; von Busch, Margarita; Schmid, Sebastian C.; Tong, Zhichao; Retz, Margitta; Gschwend, Juergen E.; Nawroth, Roman] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany.
   [Schulz, Wolfgang A.] Heinrich Heine Univ Duesseldorf, Dept Urol, Med Fac, Dusseldorf, Germany.
RP Nawroth, R (reprint author), Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany.
EM roman.nawroth@tum.de
OI Schulz, Wolfgang/0000-0002-2196-463X
FU Fritz Thyssen Foundation
FX This work was supported by the Fritz Thyssen Foundation, Postdoctoral
   Fellowship for Anuja Sathe.; AS is supported by a post-doctoral stipend
   from the Fritz Thyssen Stiftung.
CR Alfred Witjes J, 2016, EUR UROL
   Aylett CHS, 2016, SCIENCE, V351, P48, DOI 10.1126/science.aaa3870
   Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7
   Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505
   Brana I, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-161
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Garcia-Echeverria C, 2010, BIOORG MED CHEM LETT, V20, P4308, DOI 10.1016/j.bmcl.2010.05.099
   Gerullis H, 2011, ANTI-CANCER DRUG, V22, P940, DOI 10.1097/CAD.0b013e328347a86a
   Gingras AC, 2001, GENE DEV, V15, P2852
   Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344
   Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Milowsky MI, 2013, BJU INT, V112, P462, DOI 10.1111/j.1464-410X.2012.11720.x
   Mukherjee B, 2012, NEOPLASIA, V14, P34, DOI 10.1593/neo.111512
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732
   Nawroth R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027509
   Niegisch G, 2015, ONCOLOGY-BASEL, V89, P70, DOI 10.1159/000376551
   Park J, 2009, J BIOL CHEM, V284, P6169, DOI 10.1074/jbc.C800210200
   Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898
   Ratner M, 2016, NAT BIOTECHNOL, V34, P789, DOI 10.1038/nbt0816-789
   Ribatti D, 2014, EXP CELL RES, V328, P314, DOI 10.1016/j.yexcr.2014.06.010
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Ross RL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2570-0
   Rozengurt E, 2014, MOL CANCER THER, V13, P2477, DOI 10.1158/1535-7163.MCT-14-0330
   Sathe A, 2014, BRIT J CANCER, V111, P2103, DOI 10.1038/bjc.2014.534
   Sathe A, 2016, J UROLOGY, V195, P771, DOI 10.1016/j.juro.2015.08.082
   Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4
   Seront E, 2012, ANN ONCOL, V23, P2663, DOI 10.1093/annonc/mds057
   Seront E, 2016, BJU INT, V118, P408, DOI 10.1111/bju.13415
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122
   Yap TA, 2015, CURR OPIN PHARMACOL, V23, P98, DOI 10.1016/j.coph.2015.05.016
   Yip CK, 2010, MOL CELL, V38, P768, DOI 10.1016/j.molcel.2010.05.017
NR 48
TC 5
Z9 5
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2018
VL 13
IS 1
AR e0190854
DI 10.1371/journal.pone.0190854
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FT1TP
UT WOS:000422919500007
PM 29357370
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Mason, JS
   Wileman, T
   Chapman, T
AF Mason, Janet S.
   Wileman, Tom
   Chapman, Tracey
TI Lifespan extension without fertility reduction following dietary
   addition of the autophagy activator Torinl in Drosophila melanogaster
SO PLOS ONE
LA English
DT Article
ID MTOR INHIBITORS; FRUIT-FLY; RAPAMYCIN; SPERMIDINE; LONGEVITY; FEMALE;
   RESTRICTION; RESVERATROL; TARGET; MALES
AB Autophagy is a highly conserved mechanism for cellular repair that becomes progressively down-regulated during normal ageing. Hence, manipulations that activate autophagy could increase lifespan. Previous reports show that manipulations to the autophagy pathway can result in longevity extension in yeast, flies, worms and mammals. Under standard nutrition, autophagy is inhibited by the nutrient sensing kinase Target of Rapamycin (TOR). Therefore, manipulations of TOR that increase autophagy may offer a mechanism for extending lifespan. Ideally, such manipulations should be specific and minimise off-target effects, and it is important to discover additional methods for 'clean' lifespan manipulation. Here we report an initial study into the effect of up-regulating autophagy on lifespan and fertility in Drosophila melanogasterby dietary addition of Torin1. Activation of autophagy using this selective TOR inhibitor was associated with significantly increased lifespan in both sexes. Torinl induced a dose-dependent increase in lifespan in once-mated females. There was no evidence of a trade-off between longevity and fecundity or fertility. Torin1-fed females exhibited significantly elevated fecundity, but also elevated egg infertility, resulting in no net change in overall fertility. This supports the idea that lifespan can be extended without tradeoffs in fertility and suggest that Torin1 may be a useful tool with which to pursue anti-ageing research.
C1 [Mason, Janet S.; Chapman, Tracey] Univ East Anglia, Sch Biol Sci, Norwich Res Pk, Norwich, Norfolk, England.
   [Wileman, Tom] Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich, Norfolk, England.
RP Chapman, T (reprint author), Univ East Anglia, Sch Biol Sci, Norwich Res Pk, Norwich, Norfolk, England.
EM tracey.chapman@uea.ac.uk
RI Chapman, Tracey/E-5100-2011
FU Research into Ageing and Age UK (RIA) [363]; NERC [NE/K004697/1]
FX This work was supported by Research into Ageing and Age UK (RIA:363 PhD
   studentship to JSM, TW, Dylan R Edwards and TC) and the NERC
   (NE/K004697/1 to TC).
CR Agarwal B, 2011, ANN NY ACAD SCI, V1215, P138, DOI 10.1111/j.1749-6632.2010.05850.x
   Albert V, 2015, CURR OPIN CELL BIOL, V33, P55, DOI 10.1016/j.ceb.2014.12.001
   Bauer MA, 2013, CELL CYCLE, V12, P346, DOI 10.4161/cc.23199
   Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010
   Carey JR, 2008, AGING CELL, V7, P470, DOI 10.1111/j.1474-9726.2008.00389.x
   Carr TD, 2015, CARCINOGENESIS, V36, P487, DOI 10.1093/carcin/bgv012
   CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   De Loof A, 2011, J INSECT PHYSIOL, V57, P1, DOI 10.1016/j.jinsphys.2010.08.018
   Dean JM, OECOLOGIA, P385
   Dou XW, 2017, AGING CELL, V16, P825, DOI 10.1111/acel.12617
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Evans DS, 2011, AGEING RES REV, V10, P225, DOI 10.1016/j.arr.2010.04.001
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Galluzzi L, 2017, M S-MED SCI, V33, P246, DOI 10.1051/medsci/20173303010
   Gelino S, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006135
   Gonzalez A, 2017, EMBO J, V36, P397, DOI 10.15252/embj.201696010
   Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Hands SL, 2009, AGING-US, V1, P586, DOI 10.18632/aging.100070
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hsieh PN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00899-5
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Laplante M, 2011, COLD SPRING HARB PER, P1
   Leontieva OV, 2016, AGING-US, V8, P3535, DOI 10.18632/aging.101155
   Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485
   Liu QS, 2011, J MED CHEM, V54, P1473, DOI 10.1021/jm101520v
   Magwere T, 2004, J GERONTOL A-BIOL, V59, P3
   Mehrpour M, 2010, AM J PHYSIOL-CELL PH, V298, pC776, DOI 10.1152/ajpcell.00507.2009
   Minnerly J, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006764
   Minois N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.139
   Moorman NJ, 2010, J VIROL, V84, P5260, DOI 10.1128/JVI.02733-09
   Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167
   Morselli E, 2009, AGING-US, V1, P961, DOI 10.18632/aging.100110
   OLIVER B, 1990, GENETICS, V125, P535
   PARTRIDGE L, 1986, J INSECT PHYSIOL, V32, P925, DOI 10.1016/0022-1910(86)90140-X
   PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O
   PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Piper MDW, 2005, EXP GERONTOL, V40, P857, DOI 10.1016/j.exger.2005.06.013
   R Development Core Team, 2015, R FDN STAT COMP
   RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x
   Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005
   SPSS, 2009, PASW STAT WIND
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Vogel KR, 2016, J INHERIT METAB DIS, V39, P877, DOI 10.1007/s10545-016-9959-4
   Wang T, 2009, J CELL BIOL, V186, P703, DOI 10.1083/jcb.200904090
   Yang S, 2015, AGING CELL, V14, P1024, DOI 10.1111/acel.12371
   ZWAAN BJ, 1991, HEREDITY, V66, P29, DOI 10.1038/hdy.1991.4
NR 50
TC 2
Z9 2
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 12
PY 2018
VL 13
IS 1
AR e0190105
DI 10.1371/journal.pone.0190105
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FS7BY
UT WOS:000419954100012
PM 29329306
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Briggs, JW
   Ren, L
   Chakrabarti, KR
   Tsai, YC
   Weissman, AM
   Hansen, RJ
   Gustafson, DL
   Khan, YA
   Dinman, JD
   Khanna, C
AF Briggs, Joseph W.
   Ren, Ling
   Chakrabarti, Kristi R.
   Tsai, Yien Che
   Weissman, Allan M.
   Hansen, Ryan J.
   Gustafson, Daniel L.
   Khan, Yousuf A.
   Dinman, Jonathan D.
   Khanna, Chand
TI Activation of the unfolded protein response in sarcoma cells treated
   with rapamycin or temsirolimus
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA TRANSLATION; STRESSED ENDOPLASMIC-RETICULUM; INDUCED
   GENE-EXPRESSION; P70 S6 KINASE; RIBOSOMAL-SUBUNIT; MAMMALIAN TARGET;
   BINDING PARTNER; TRANSLOCON PORE; CANCER-THERAPY; ER STRESS
AB Activation of the unfolded protein response (UPR) in eukaryotic cells represents an evolutionarily conserved response to physiological stress. Here, we report that the mTOR inhibitors rapamycin (sirolimus) and structurally related temsirolimus are capable of inducing UPR in sarcoma cells. However, this effect appears to be distinct from the classical role for these drugs as mTOR inhibitors. Instead, we detected these compounds to be associated with ribosomes isolated from treated cells. Specifically, temsirolimus treatment resulted in protection from chemical modification of several rRNA residues previously shown to bind rapamycin in prokaryotic cells. As an application for these findings, we demonstrate maximum tumor cell growth inhibition occurring only at doses which induce UPR and which have been shown to be safely achieved in human patients. These results are significant because they challenge the paradigm for the use of these drugs as anticancer agents and reveal a connection to UPR, a conserved biological response that has been implicated in tumor growth and response to therapy. As a result, eIF2 alpha phosphorylation and Xbp-1 splicing may serve as useful biomarkers of treatment response in future clinical trials using rapamycin and rapalogs.
C1 [Briggs, Joseph W.; Ren, Ling; Chakrabarti, Kristi R.; Khanna, Chand] NCI, Tumor Metastasis Biol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.
   [Tsai, Yien Che; Weissman, Allan M.] NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 20892 USA.
   [Hansen, Ryan J.; Gustafson, Daniel L.] Colorado State Univ, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA.
   [Briggs, Joseph W.; Khan, Yousuf A.; Dinman, Jonathan D.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
   [Chakrabarti, Kristi R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Khanna, Chand] Ethos Vet Hlth, Woburn, MA USA.
   [Hansen, Ryan J.] Sierra Oncol, Vancouver, BC, Canada.
RP Briggs, JW (reprint author), NCI, Tumor Metastasis Biol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.; Briggs, JW (reprint author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
EM briggsjw@umd.edu
FU Intramural Research Program of the National Institutes of Health;
   National Cancer Institute, Center for Cancer Research (CK)
   [5R01HL119439-03]; National Heart, Lung and Blood Institute, National
   Institutes of Health (JDD) [3R01HL119439-03S1]; National Heart, Lung and
   Blood Institute, National Institutes of Health (JDD, JWB); Howard Hughes
   Medical Institute/University of Maryland College Park (YAK)
FX This work was supported by the Intramural Research Program of the
   National Institutes of Health, National Cancer Institute, Center for
   Cancer Research (CK) 5R01HL119439-03 National Heart, Lung and Blood
   Institute, National Institutes of Health (JDD) 3R01HL119439-03S1
   National Heart, Lung and Blood Institute, National Institutes of Health
   (JDD, JWB), and partly supported by an undergraduate fellowship from the
   Howard Hughes Medical Institute/University of Maryland College Park
   (YAK). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54
   Amit M, 2005, FEBS LETT, V579, P3207, DOI 10.1016/j.febslet.2005.03.023
   Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185
   Banaszynski LA, 2005, J AM CHEM SOC, V127, P4715, DOI 10.1021/ja043277y
   Ben-Shem A, 2010, SCIENCE, V330, P1203, DOI 10.1126/science.1194294
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326
   Boni J, 2007, J CLIN PHARMACOL, V47, P1430, DOI 10.1177/0091270007306957
   Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197
   Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1
   BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0
   CANNONE JJ, 2002, BMC BIOINFORMATICS, V3
   Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130
   Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Gingras AC, 2001, GENE DEV, V15, P2852
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074
   Hansen JL, 2003, J MOL BIOL, V330, P1061, DOI 10.1016/S0002-2836(03)00668-5
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Harms JM, 2008, MOL CELL, V30, P26, DOI 10.1016/j.molcel.2008.01.009
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693
   JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441
   Jenni S, 2003, CURR OPIN STRUC BIOL, V13, P212, DOI 10.1016/S0959-440X(03)00034-4
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kohno K, 2010, J BIOCHEM, V147, P27, DOI 10.1093/jb/mvp196
   Koritzinsky M, 2007, METHOD ENZYMOL, V435, P247, DOI 10.1016/S0076-6879(07)35013-1
   Kuhn JG, 2007, CLIN CANCER RES, V13, P7401, DOI 10.1158/1078-0432.CCR-07-0781
   Larsson SL, 2001, BIOCHEMISTRY-US, V40, P3222, DOI 10.1021/bi00286q
   Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702
   Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6
   Lin PJ, 2011, J CELL BIOL, V195, P55, DOI 10.1083/jcb.201103118
   Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6
   McConkey DJ, 2017, BIOCHEM BIOPH RES CO, V482, P450, DOI 10.1016/j.bbrc.2016.11.047
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   Niwa M, 2005, GENOME BIOL, V6
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112
   Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x
   Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344
   Pincus D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000415
   Raymond E, 2004, J CLIN ONCOL, V22, P2336, DOI 10.1200/JCO.2004.08.116
   Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Sato N, 2000, NAT CELL BIOL, V2, P863
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2
   Shor B, 2008, CANCER RES, V68, P2934, DOI 10.1158/0008-5472.CAN-07-6487
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   STADE K, 1994, NUCLEIC ACIDS RES, V22, P1394, DOI 10.1093/nar/22.8.1394
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721
   Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135
   Wang XZ, 1996, MOL CELL BIOL, V16, P4273
   Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 66
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2017
VL 12
IS 9
AR e0185089
DI 10.1371/journal.pone.0185089
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FH4XT
UT WOS:000411166600068
PM 28926611
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Kalim, KW
   Zhang, SM
   Chen, XY
   Li, Y
   Yang, JQ
   Zheng, Y
   Guo, FK
AF Kalim, Khalid W.
   Zhang, Shuangmin
   Chen, Xiaoyi
   Li, Yuan
   Yang, Jun-Qi
   Zheng, Yi
   Guo, Fukun
TI mTOR has a developmental stage-specific role in mitochondrial fitness
   independent of conventional mTORC1 and mTORC2 and the kinase activity
SO PLOS ONE
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; MAMMALIAN TARGET; QUIESCENCE; METABOLISM;
   INHIBITORS; RAPAMYCIN; REVEALS; DIFFERENTIATION; PROLIFERATION;
   GLYCOLYSIS
AB The mammalian target of rapamycin (mTOR), present in mTOR complex 1 (mTORC1) and mTORC2, is a serine/threonine kinase that integrates nutrients, growth factors, and cellular energy status to control protein synthesis, cell growth, survival and metabolism. However, it remains elusive whether mTOR plays a developmental stage-specific role in tissue development and whether mTOR can function independent of its complexes and kinase activity. In this study, by inducible genetic manipulation approach, we investigated the role of mTOR and its dependence on mTOR complexes and kinase activity in mitochondrial fitness of early, progenitor stage (lineage-negative; Lin(-)) versus later, lineage-committed stage (lineage-positive; Lin(+)) of hematopoietic cells. We found that oxidative phosphorylation (OXPHOS), ATP production and mitochondrial DNA synthesis were decreased in mTOR(-/-) Lin(-) cells but increased in mTOR(-/-) Lin(+) cells, suggesting that mTOR plays a developmental stage-specific role in OXPHOS, ATP production and mitochondrial DNA synthesis. In contrast to mTOR deletion, simultaneous deletion of Raptor, a key component of mTORC1, and Rictor, a key component of mTORC2, led to increased mitochondrial DNA in Lin(-) cells and decreased mitochondrial DNA and ATP production in Lin(+) cells, suggesting that mTOR regulates mitochondrial DNA synthesis in Lin(-) and Lin(+) cells and ATP production in Lin(+) cells independent of mTORC1 and mTORC2. Similar to mTOR deletion, deletion of Raptor alone attenuated glycolysis and increased mitochondrial mass and mitochondrial membrane potential in Lin(-) cells and increased mitochondrial mass and OXPHOS in Lin(+) cells, whereas deletion of Rictor alone had no effect on these mitochondrial parameters in Lin(-) and Lin(+) cells, suggesting that mTOR regulates glycolysis and mitochondrial membrane potential in Lin(-) cells, OXPHOS in Lin(+) cells, and mitochondrial mass in both Lin(-) and Lin(+) cells dependent on mTORC1, but not mTORC2. Either Raptor deficiency or Rictor deficiency recapitulated mTOR deletion in decreasing OXPHOS in Lin(-) cells and glycolysis in Lin(+) cells, suggesting that mTOR regulates OXPHOS in Lin(-) cells and glycolysis in Lin(+) cells dependent on both mTORC1 and mTORC2. Finally, mice harboring a mTOR kinase dead D2338A knock-in mutant showed decreased glycolysis in Lin(+) cells, as seen in mTOR(-/-) Lin(+) cells, but no change in glycolysis in Lin(-) cells, in contrast to the decreased glycolysis in mTOR(-/-) Lin(-) cells, suggesting that mTOR regulates glycolysis in Lin(+) cells dependent on its kinase activity, whereas mTOR regulates glycolysis in Lin- cells independent of its kinase activity.
C1 [Kalim, Khalid W.; Zhang, Shuangmin; Chen, Xiaoyi; Li, Yuan; Yang, Jun-Qi; Zheng, Yi; Guo, Fukun] Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
   [Yang, Jun-Qi] Jiangsu Inst Parasit Dis, Minist Hlth, Key Lab Parasit Dis Control & Prevent, Wuxi, Jiangsu, Peoples R China.
RP Zheng, Y; Guo, FK (reprint author), Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
EM yi.zheng@cchmc.org; fukun.guo@cchmc.org
FU National Institutes of Health [R01GM108661, R21CA198358]; Natural
   Science Foundation of Guangdong (China) [2014A030313651]; National
   Natural Science Foundation of China [81373116]; Jiangsu Provincial Key
   Laboratory of Parasite Molecular Biology
FX This work was supported in part by grants from the National Institutes
   of Health (R01GM108661 and R21CA198358 to F.G.), Natural Science
   Foundation of Guangdong (China) (2014A030313651), National Natural
   Science Foundation of China (81373116 to J. Q.Y) and Jiangsu Provincial
   Key Laboratory of Parasite Molecular Biology (to J.Q.Y). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Albert V, 2015, CURR OPIN CELL BIOL, V33, P55, DOI 10.1016/j.ceb.2014.12.001
   Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110
   Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99
   Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023
   Dott W, 2014, REDOX BIOL, V2, P224, DOI 10.1016/j.redox.2013.12.028
   Falcon BL, 2011, CANCER RES, V71, P1573, DOI 10.1158/0008-5472.CAN-10-3126
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595
   Gan B, 2009, CELL CYCLE, V8, P1003, DOI 10.4161/cc.8.7.8045
   Guo F, 2013, LEUKEMIA, V27, P2040, DOI 10.1038/leu.2013.93
   Guo FK, 2013, HAEMATOLOGICA, V98, P1353, DOI 10.3324/haematol.2012.080424
   Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572
   Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015
   Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f
   Lo YC, 2014, CURR OPIN ORGAN TRAN, V19, P363, DOI 10.1097/MOT.0000000000000098
   Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08
   Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012
   Risson V, 2009, J CELL BIOL, V187, P859, DOI 10.1083/jcb.200903131
   Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013
   Shor B, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-28
   Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011
   Yang K, 2013, IMMUNITY, V39, P1043, DOI 10.1016/j.immuni.2013.09.015
   Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299
   Yu WM, 2013, CELL STEM CELL, V12, P62, DOI 10.1016/j.stem.2012.11.022
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297
NR 27
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 16
PY 2017
VL 12
IS 8
AR e0183266
DI 10.1371/journal.pone.0183266
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD6XW
UT WOS:000407672200074
PM 28813526
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Bertuzzi, A
   Conte, F
   Mingrone, G
   Papa, F
   Salinari, S
   Sinisgalli, C
AF Bertuzzi, Alessandro
   Conte, Federica
   Mingrone, Geltrude
   Papa, Federico
   Salinari, Serenella
   Sinisgalli, Carmela
TI Insulin Signaling in Insulin Resistance States and Cancer: A Modeling
   Analysis
SO PLOS ONE
LA English
DT Article
ID STIMULATED GLUCOSE-TRANSPORT; ACUTE MYELOID-LEUKEMIA; MTOR COMPLEX;
   ANTITUMOR-ACTIVITY; GLUT4 EXOCYTOSIS; SKELETAL-MUSCLE; IN-VITRO; AKT;
   RECEPTOR; KINASE
AB Insulin resistance is the common denominator of several diseases including type 2 diabetes and cancer, and investigating the mechanisms responsible for insulin signaling impairment is of primary importance. A mathematical model of the insulin signaling network (ISN) is proposed and used to investigate the dose-response curves of components of this network. Experimental data of C2C12 myoblasts with phosphatase and tensin homologue (PTEN) suppressed and data of L6 myotubes with induced insulin resistance have been analyzed by the model. We focused particularly on single and double Akt phosphorylation and pointed out insulin signaling changes related to insulin resistance. Moreover, a new characterization of the upstream signaling of the mammalian target of rapamycin complex 2 (mTORC2) is presented. As it is widely recognized that ISN proteins have a crucial role also in cell proliferation and death, the ISN model was linked to a cell population model and applied to data of a cell line of acute myeloid leukemia treated with a mammalian target of rapamycin inhibitor with antitumor activity. The analysis revealed simple relationships among the concentrations of ISN proteins and the parameters of the cell population model that characterize cell cycle progression and cell death.
C1 [Bertuzzi, Alessandro; Conte, Federica; Papa, Federico; Sinisgalli, Carmela] CNR, Inst Syst Anal & Comp Sci A Ruberti, I-00185 Rome, Italy.
   [Conte, Federica; Salinari, Serenella] Univ Roma La Sapienza, Dept Comp & Syst Sci, I-00185 Rome, Italy.
   [Mingrone, Geltrude] Univ Cattolica Sacro Cuore, Sch Med, Dept Internal Med, I-00168 Rome, Italy.
   [Papa, Federico] SYSBIO Ctr Syst Biol, Milan, Italy.
RP Mingrone, G (reprint author), Univ Cattolica Sacro Cuore, Sch Med, Dept Internal Med, I-00168 Rome, Italy.
EM geltrude.mingrone@unicatt.it
OI Conte, Federica/0000-0003-0427-1476; BERTUZZI,
   ALESSANDRO/0000-0003-4969-7366
FU SysBioNet, Italian Roadmap Research Infrastructures; Epigenomics
   Flagship Project (Progetto Bandiera Epigenomica), EPIGEN - Italian
   Ministry of Education, University and Research (MIUR); National Research
   Council (CNR)
FX FP was supported by SysBioNet, Italian Roadmap Research Infrastructures
   2012. Federica Conte was supported by The Epigenomics Flagship Project
   (Progetto Bandiera Epigenomica), EPIGEN, funded by the Italian Ministry
   of Education, University and Research (MIUR), and the National Research
   Council (CNR). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bertuzzi A, 1997, MATH BIOSCI, V143, P61, DOI 10.1016/S0025-5564(97)00002-3
   Brannmark C, 2013, J BIOL CHEM, V288, P9867, DOI 10.1074/jbc.M112.432062
   Brannmark C, 2010, J BIOL CHEM, V285, P20171, DOI 10.1074/jbc.M110.106849
   Cangiani A, 2010, J THEOR BIOL, V267, P614, DOI 10.1016/j.jtbi.2010.08.017
   Castellani GC, 2009, P NATL ACAD SCI USA, V106, P14091, DOI 10.1073/pnas.0905988106
   Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Cybulski N, 2009, TRENDS BIOCHEM SCI, V34, P620, DOI 10.1016/j.tibs.2009.09.004
   Dalle Pezze Piero, 2012, Sci Signal, V5, pra25, DOI 10.1126/scisignal.2002469
   Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002
   Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Giri L, 2004, THEOR BIOL MED MODEL, P1
   GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840
   Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069
   Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08
   Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217
   Ijuin T, 2012, J BIOL CHEM, V287, P6991, DOI 10.1074/jbc.M111.335539
   Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09
   Kim SJ, 2012, MOL CELL, V48, P875, DOI 10.1016/j.molcel.2012.09.029
   Kiselyov VV, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.78
   Klip A, 2014, AM J PHYSIOL-CELL PH, V306, pC879, DOI 10.1152/ajpcell.00069.2014
   Kondapaka SB, 2004, CLIN CANCER RES, V10, P7192, DOI 10.1158/1078-0432.CCR-04-0772
   Kumar A, 2008, MOL CELL BIOL, V28, P61, DOI 10.1128/MCB.01405-07
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lequieu J, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002263
   Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892
   Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991
   Mingrone G, 2012, NEW ENGL J MED, V366, P1577, DOI 10.1056/NEJMoa1200111
   Miyata T, 1998, EUR J ENDOCRINOL, V138, P344, DOI 10.1530/eje.0.1380344
   Nascimento EBM, 2006, DIABETES, V55, P3221, DOI 10.2337/db05-1390
   Novak M, 2004, J THEOR BIOL, V230, P563, DOI 10.1016/j.jtbi.2004.04.039
   Nyman E, 2011, J BIOL CHEM, V286, P26028, DOI 10.1074/jbc.M110.188987
   Park S, 2010, HAEMATOL-HEMATOL J, V95, P819, DOI [10.3324/haemato1.2009.013797, 10.3324/haematol.2009.013797]
   Prakash S, 2009, NAT CHEM BIOL, V5, P29, DOI 10.1038/nchembio.130
   Salinari S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056258
   Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sasaoka T, 2005, DIABETOLOGIA, V48, P336, DOI 10.1007/s00125-004-1636-8
   Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352
   Sedaghat AR, 2002, AM J PHYSIOL-ENDOC M, V283, pE1084, DOI 10.1152/ajpendo.00571.2001
   Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108
   Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139
   Stockli J, 2011, J CELL SCI, V124, P4147, DOI 10.1242/jcs.097063
   Sturrock M, 2011, J THEOR BIOL, V273, P15, DOI 10.1016/j.jtbi.2010.12.016
   Thong FSL, 2005, PHYSIOLOGY, V20, P271, DOI 10.1152/physiol.00017.2005
   Wanant S, 2000, J THEOR BIOL, V205, P355, DOI 10.1006/jtbi.2000.2069
   Wang GY, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/4/046015
   Willems L, 2012, LEUKEMIA, V26, P1195, DOI 10.1038/leu.2011.339
   Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 55
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 5
PY 2016
VL 11
IS 5
AR e0154415
DI 10.1371/journal.pone.0154415
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DL5KV
UT WOS:000375676800030
PM 27149630
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yu, CC
   Huang, HB
   Hung, SK
   Liao, HF
   Lee, CC
   Lin, HY
   Li, SC
   Ho, HC
   Hung, CL
   Su, YC
AF Yu, Chih-Chia
   Huang, Hsien-bin
   Hung, Shih-Kai
   Liao, Hui-Fen
   Lee, Ching-Chih
   Lin, Hon-Yi
   Li, Szu-Chin
   Ho, Hsu-Chueh
   Hung, Chung-Lin
   Su, Yu-Chieh
TI AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting
   AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest
SO PLOS ONE
LA English
DT Article
ID MTORC2; GROWTH; CANCER; RESISTANCE
AB Background
   Oral squamous cell carcinoma (OSCC) is one of the most common malignant neoplasms in Taiwan. Activation of the mTOR signaling pathway has been linked to decreased radiation responsiveness in human oral cancer, thus it limits efficacy of radiotherapy. To address this question, we investigated the effect of AZD2014, a novel small molecular ATP-competitive inhibitor of mTORC1 and mTORC2 kinase, as a radiosensitizer in primary OSCC and OSCC-derived cell line models.
   Methods
   We isolated primary tumor cells from OSCC tissues and cell lines. AZD2014 was administered with and without ionizing radiation. The radiosensitizing effect of AZD2014 were then assessed using cell viability assays, clonogenic survival assays, and cell cycle analyses. Western blotting was used to detect protein expression.
   Results
   Combination treatment with AZD2014 and irradiation resulted in significant reduction in OSCC cell line and primary OSCC cell colony formation due to the enhanced inhibition of AKT and both mTORC1 and mTORC2 activity. Pre-treatment with AZD2014 in irradiated oral cancer cells induced tumor cell cycle arrest at the G1 and G2/M phases, which led to disruption of cyclin D1-CDK4 and cyclin B1-CDC2 complexes. Moreover, AZD2014 synergized with radiation to promote both apoptosis and autophagy by increasing caspase-3 and LC3 in primary OSCC cells.
   Conclusions
   These findings suggest that in irradiated OSCC cells, co-treatment with AZD2014, which targets mTORC1 and mTORC2 blockade, is an effective radiosensitizing strategy for oral squamous cell carcinoma.
C1 [Yu, Chih-Chia; Huang, Hsien-bin; Li, Szu-Chin] Natl Chung Cheng Univ, Dept Life Sci, Chiayi 621, Taiwan.
   [Yu, Chih-Chia; Huang, Hsien-bin; Li, Szu-Chin] Natl Chung Cheng Univ, Inst Mol Biol, Chiayi 621, Taiwan.
   [Yu, Chih-Chia; Li, Szu-Chin; Hung, Chung-Lin; Su, Yu-Chieh] Buddhist Dalin Tzu Chi Hosp, Dept Internal Med, Div Hematol Oncol, Chiayi, Taiwan.
   [Hung, Shih-Kai; Lee, Ching-Chih; Lin, Hon-Yi; Ho, Hsu-Chueh; Su, Yu-Chieh] Tzu Chi Univ, Sch Med, Hualien, Taiwan.
   [Hung, Shih-Kai; Lin, Hon-Yi] Buddhist Dalin Tzu Chi Hosp, Dept Radiat Oncol, Chiayi, Taiwan.
   [Lee, Ching-Chih; Ho, Hsu-Chueh] Buddhist Dalin Tzu Chi Hosp, Dept Otolaryngol, Chiayi, Taiwan.
   [Liao, Hui-Fen] Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi 60004, Taiwan.
RP Su, YC (reprint author), Buddhist Dalin Tzu Chi Hosp, Dept Internal Med, Div Hematol Oncol, Chiayi, Taiwan.; Su, YC (reprint author), Tzu Chi Univ, Sch Med, Hualien, Taiwan.
EM hepatoma@gmail.com
OI Hung, Shih-Kai/0000-0002-4945-528X
FU Buddhist Dalin Tzu Chi Hospital [DTCRD102(2)-I-15, DTCRD103(2)-I-02]
FX This study was supported by research grants from the Buddhist Dalin Tzu
   Chi Hospital (DTCRD102(2)-I-15 and DTCRD103(2)-I-02). The funder had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Advani SH, 2010, INDIAN J MED PAEDIAT, V31, P132, DOI 10.4103/0971-5851.76197
   Altman JK, 2011, CLIN CANCER RES, V17, P4378, DOI 10.1158/1078-0432.CCR-10-2285
   Anandharaj A, 2011, ACTA BIOCH BIOPH SIN, V43, P292, DOI 10.1093/abbs/gmr012
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107
   Chen BW, 2015, MOL CANCER THER, V14, P1805, DOI 10.1158/1535-7163.MCT-15-0029
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Gao Wei, 2012, ISRN Otolaryngol, V2012, P953089, DOI 10.5402/2012/953089
   Gogineni VR, 2011, CANCER LETT, V313, P64, DOI 10.1016/j.canlet.2011.08.022
   Health Do, 2010, EX YUAN RCRA
   Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021
   Kahn J, 2014, NEURO-ONCOLOGY, V16, P29, DOI 10.1093/neuonc/not139
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Kim KW, 2009, CLIN CANCER RES, V15, P6096, DOI 10.1158/1078-0432.CCR-09-0589
   Koo J, 2014, CANCER RES, V74, P2555, DOI 10.1158/0008-5472.CAN-13-2946
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Liao H, 2015, AM J CANCER RES, V5, P125
   Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223
   MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066
   Nassim R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065257
   Peyressatre M, 2015, CANCERS, V7, P179, DOI 10.3390/cancers7010179
   Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4
   Smrz D, 2011, BLOOD, V118, P6803, DOI 10.1182/blood-2011-06-359984
   Wei F, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-81
   Willems L, 2012, CURR ONCOL REP, V14, P129, DOI 10.1007/s11912-012-0227-y
   Wu Si-Han, 2014, Cancer Biology Medicine, V11, P255, DOI 10.7497/j.issn.2095-3941.2014.04.004
   Yano T, 2014, CIRC RES, V114, P1268, DOI 10.1161/CIRCRESAHA.114.303562
   Yardley DA, 2013, BREAST CANCER-BASIC, V7, P7, DOI 10.4137/BCBCR.S10071
   Yu CC, 2014, ANTICANCER RES, V34, P2927
NR 30
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 31
PY 2016
VL 11
IS 3
AR e0151942
DI 10.1371/journal.pone.0151942
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH9NC
UT WOS:000373121800024
PM 27031247
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Pallis, M
   Harvey, T
   Russell, N
AF Pallis, Monica
   Harvey, Tamsin
   Russell, Nigel
TI Phenotypically Dormant and Immature Leukaemia Cells Display Increased
   Ribosomal Protein S6 Phosphorylation
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; MESSENGER-RNA TRANSLATION; MAMMALIAN TARGET;
   RAPAMYCIN MTOR; SELF-RENEWAL; STEM-CELLS; CANCER; METABOLISM; KINASE;
   GROWTH
AB Mechanistic/mammalian target of rapamycin (mTOR) activity drives a number of key metabolic processes including growth and protein synthesis. Inhibition of the mTOR pathway promotes cellular dormancy. Since cells from patients with acute myeloid leukaemia (AML) can be phenotypically dormant (quiescent), we examined biomarkers of their mTOR pathway activity concurrently with Ki-67 and CD71 (indicators of cycling cells) by quantitative flow cytometry. Using antibodies to phosphorylated epitopes of mTOR (S2448) and its downstream targets ribosomal protein S6 (rpS6, S235/236) and 4E-BP1 (T36/45), we documented that these phosphorylations were negligible in lymphocytes, but evident in dormant as well as proliferating subsets of both mobilised normal stem cell harvest CD34+ cells and AML blasts. Although mTOR phosphorylation in AML blasts was lower than that of the normal CD34+ cells, p-4E-BP1 was 2.6-fold higher and p-rpS6 was 22-fold higher. Moreover, in contrast to 4E-BP1, rpS6 phosphorylation was higher in dormant than proliferating AML blasts, and was also higher in the immature CD34+ CD38-blast subset. Data from the Cancer Genome Atlas show that rpS6 expression is associated with that of respiratory chain enzymes in AML. We conclude that phenotypic quiescence markers do not necessarily predict metabolic dormancy and that elevated rpS6 ser235/236 phosphorylation is characteristic of AML.
C1 [Pallis, Monica; Russell, Nigel] Univ Nottingham Hosp, Clin Haematol, Nottingham NG7 2UH, England.
   [Harvey, Tamsin; Russell, Nigel] Univ Nottingham, Dept Haematol, Nottingham NG7 2RD, England.
RP Pallis, M (reprint author), Univ Nottingham Hosp, Clin Haematol, Nottingham NG7 2UH, England.
EM monica.pallis@nottingham.ac.uk
FU Nottinghamshire Leukaemia Appeal
FX This study was supported by Nottinghamshire Leukaemia Appeal,
   http://www.nlaappeal.org/ (Chair and address, professor John Fletcher,
   Medical Research Centre, NUH City Hospital Campus, Nottingham NG5 1PB,
   UK). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041
   Blagosklonny MV, 2006, J CELL PHYSIOL, V209, P592, DOI 10.1002/jcp.20750
   BOROWITZ MJ, 1993, AM J CLIN PATHOL, V100, P534, DOI 10.1093/ajcp/100.5.534
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Cargnello M, 2015, MUTAGENESIS, V30, P169, DOI 10.1093/mutage/geu045
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chauvin C, 2014, ONCOGENE, V33, P474, DOI 10.1038/onc.2012.606
   Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Chow S, 2006, EXP HEMATOL, V34, P1183, DOI 10.1016/j.exphem.2006.05.002
   Coller HA, 2006, PLOS BIOL, V4, P329, DOI 10.1371/journal.pbio.0040083
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014
   Dieterlen MT, 2012, CYTOM PART B-CLIN CY, V82B, P151, DOI 10.1002/cyto.b.21005
   Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485
   Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989
   Gerdes J, 1984, Hematol Oncol, V2, P365
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422
   Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062
   Guo FK, 2013, HAEMATOLOGICA, V98, P1353, DOI 10.3324/haematol.2012.080424
   Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200
   Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080
   Hoshii T, 2014, J BIOCHEM, V156, P73, DOI 10.1093/jb/mvu037
   Hoshii T, 2012, J CLIN INVEST, V122, P2114, DOI 10.1172/JCI62279
   Hutchinson JA, 2011, J BIOL CHEM, V286, P8688, DOI 10.1074/jbc.M110.141754
   Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713
   Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013
   Laurenti E, 2015, CELL STEM CELL, V16, P302, DOI 10.1016/j.stem.2015.01.017
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Meyuhas O, 2008, INT REV CEL MOL BIO, V268, P1, DOI 10.1016/S1937-6448(08)00801-0
   Mony U, 2008, LEUKEMIA, V22, P1395, DOI 10.1038/leu.2008.125
   Pallis M, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-32
   Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004
   Perl AE, 2012, CLIN CANCER RES, V18, P1716, DOI 10.1158/1078-0432.CCR-11-2346
   RAINER RO, 1995, CYTOMETRY, V22, P139, DOI 10.1002/cyto.990220210
   Rosner M, 2011, AMINO ACIDS, V40, P595, DOI 10.1007/s00726-010-0684-2
   Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200
   Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003
   Ruvinsky I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005618
   Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Shults Keith, 2009, Cancer Manag Res, V1, P49
   Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126
   Sujobert P, 2015, CELL REP, V11, P1446, DOI 10.1016/j.celrep.2015.04.063
   TAFURI A, 1990, LEUKEMIA, V4, P826
   Valcourt JR, 2012, CELL CYCLE, V11, P1680, DOI 10.4161/cc.19879
   Vander HM, 2011, NAT REV DRUG DISCOV, V10, P671, DOI DOI 10.1038/NRD3504
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Zeng H, 2013, CURR OPIN IMMUNOL, V25, P347, DOI 10.1016/j.coi.2013.05.002
   Zhang F, 2009, CANCER BIOL THER, V8, P846, DOI 10.4161/cbt.8.9.8210
NR 56
TC 1
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 17
PY 2016
VL 11
IS 3
AR e0151480
DI 10.1371/journal.pone.0151480
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH1YG
UT WOS:000372580300075
PM 26985829
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Chasse, H
   Mulner-Lorillon, O
   Boulben, S
   Glippa, V
   Morales, J
   Cormier, P
AF Chasse, Heloise
   Mulner-Lorillon, Odile
   Boulben, Sandrine
   Glippa, Virginie
   Morales, Julia
   Cormier, Patrick
TI Cyclin B Translation Depends on mTOR Activity after Fertilization in Sea
   Urchin Embryos
SO PLOS ONE
LA English
DT Article
ID CAP-BINDING PROTEIN; CELL-CYCLE; MESSENGER-RNA; INITIATION-FACTOR;
   STRONGYLOCENTROTUS-PURPURATUS; EIF4E-BINDING PROTEINS; EGGS; KINASE;
   PHOSPHORYLATION; MITOSIS
AB The cyclin B/CDK1 complex is a key regulator of mitotic entry. Using PP242, a specific ATP-competitive inhibitor of mTOR kinase, we provide evidence that the mTOR signalling pathway controls cyclin B mRNA translation following fertilization in Sphaerechinus granularis and Paracentrotus lividus. We show that PP242 inhibits the degradation of the cap-dependent translation repressor 4E-BP (eukaryotic initiation factor 4E-Binding Protein). PP242 inhibits global protein synthesis, delays cyclin B accumulation, cyclin B/CDK1 complex activation and consequently entry into the mitotic phase of the cell cycle triggered by fertilization. PP242 inhibits cyclin B mRNA recruitment into active polysomes triggered by fertilization. An amount of cyclin B mRNA present in active polysomes appears to be insensitive to PP242 treatment. Taken together, our results suggest that, following sea urchin egg fertilization, cyclin B mRNA translation is controlled by two independent mechanisms: a PP242-sensitive and an additional PP242-insentitive mechanism.
C1 [Chasse, Heloise; Mulner-Lorillon, Odile; Boulben, Sandrine; Glippa, Virginie; Morales, Julia; Cormier, Patrick] Univ Paris 06, Sorbonne Univ, UMR 8227,Stn Biol Roscoff, Integrat Biol Marine Models,Translat Cell Cycle &, CS 90074, F-29688 Roscoff, France.
   [Chasse, Heloise; Mulner-Lorillon, Odile; Boulben, Sandrine; Glippa, Virginie; Morales, Julia; Cormier, Patrick] CNRS, UMR 8227, Stn Biol Roscoff, Integrat Biol Marine Models, CS 90074, F-29688 Roscoff, France.
RP Mulner-Lorillon, O; Morales, J; Cormier, P (reprint author), Univ Paris 06, Sorbonne Univ, UMR 8227,Stn Biol Roscoff, Integrat Biol Marine Models,Translat Cell Cycle &, CS 90074, F-29688 Roscoff, France.; Mulner-Lorillon, O; Morales, J; Cormier, P (reprint author), CNRS, UMR 8227, Stn Biol Roscoff, Integrat Biol Marine Models, CS 90074, F-29688 Roscoff, France.
EM mulner@sb-roscoff.fr; morales@sb-roscoff.fr; cormier@sb-roscoff.fr
OI Morales, Julia/0000-0003-1632-5419
FU La Ligue contre le Cancer (coordination du Grand Ouest [comites
   Finistere, Cotes d'Armor, Deux-Sevres, Morbihan]); Region Bretagne;
   Conseil General du Finistere; ITMO AVIESAN CNRS/INSERM
FX This work was supported by research grants from "La Ligue contre le
   Cancer (coordination du Grand Ouest [comites Finistere, Cotes d'Armor,
   Deux-Sevres, Morbihan])", the "Region Bretagne", and the "Conseil
   General du Finistere"; by ITMO AVIESAN CNRS/INSERM for equipment grant.
   H. Chasse is a PhD fellow supported by the Region Bretagne.
CR Bah A, 2015, NATURE, V519, P106, DOI 10.1038/nature13999
   BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390
   Cameron RA, 2009, NUCLEIC ACIDS RES, V37, pD750, DOI 10.1093/nar/gkn887
   Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206
   Cormier Patrick, 2003, Prog Cell Cycle Res, V5, P469
   Elia A, 2008, ONCOGENE, V27, P811, DOI 10.1038/sj.onc.1210678
   Eltschinger S, 2016, TRENDS CELL BIOL, V26, P148, DOI 10.1016/j.tcb.2015.10.003
   EPEL D, 1967, P NATL ACAD SCI USA, V57, P899, DOI 10.1073/pnas.57.4.899
   EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8
   Faye MD, 2014, JOVE-J VIS EXP, DOI 10.3791/52295
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fernandez-Guerra A, 2006, DEV BIOL, V300, P238, DOI 10.1016/j.ydbio.2006.09.012
   Fonseca BD, 2014, SEMIN CELL DEV BIOL, V36, P102, DOI 10.1016/j.semcdb.2014.09.014
   GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693
   Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913
   Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Hernandez G, 2009, TRENDS BIOCHEM SCI, V34, P166, DOI 10.1016/j.tibs.2009.02.001
   JAGUS R, 1992, J BIOL CHEM, V267, P15530
   Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905
   Kang Q, 2012, MOL BIOL CELL, V23, P284, DOI 10.1091/mbc.E11-09-0768
   Kronja I, 2011, PHILOS T R SOC B, V366, P3638, DOI 10.1098/rstb.2011.0084
   Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168
   Lapasset L, 2008, MOL REPROD DEV, V75, P1617, DOI 10.1002/mrd.20905
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laurent S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00117
   Le Breton M, 2005, BIOCHIMIE, V87, P805, DOI 10.1016/j.biochi.2005.04.014
   Lewis CW, 2013, FEBS LETT, V587, P3089, DOI 10.1016/j.febslet.2013.08.003
   LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721
   LOPO AC, 1989, BIOCHEM J, V258, P553, DOI 10.1042/bj2580553
   Lozano JC, 1998, J CELL BIOL, V140, P283, DOI 10.1083/jcb.140.2.283
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184
   Martineau Y, 2013, ONCOGENE, V32, P671, DOI 10.1038/onc.2012.116
   Merrick W C, 2001, Curr Protoc Cell Biol, VChapter 11, DOI 10.1002/0471143030.cb1109s08
   Minshall N, 2007, J BIOL CHEM, V282, P37389, DOI 10.1074/jbc.M704629200
   Morales J, 2006, DEV BIOL, V300, P293, DOI 10.1016/j.ydbio.2006.07.036
   Oulhen N, 2007, J CELL SCI, V120, P425, DOI 10.1242/jcs.03339
   Oulhen N, 2014, GENESIS, V52, P279, DOI 10.1002/dvg.22737
   Oulhen N, 2010, MOL REPROD DEV, V77, P83, DOI 10.1002/mrd.21110
   Oulhen N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005070
   PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0
   Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002
   Rousseau D, 1996, ONCOGENE, V13, P2415
   Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4
   Sea Urchin Genome Sequencing Consortium, 2006, SCIENCE, V314, P941, DOI DOI 10.1126/SCIENCE.1133609
   Smith AB, 2006, MOL BIOL EVOL, V23, P1832, DOI 10.1093/molbev/msl039
   Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801
   SPIETH J, 1980, DEV BIOL, V79, P95, DOI 10.1016/0012-1606(80)90075-5
   Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0
   Topisirovic I, 2011, WIRES RNA, V2, P277, DOI 10.1002/wrna.52
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Vardy L, 2007, DEV CELL, V12, P157, DOI 10.1016/j.devcel.2006.10.017
   Voronina E, 2003, DEV BIOL, V256, P258, DOI 10.1016/S0012-1606(02)00134-3
   Voronina E, 2008, DEV BIOL, V314, P276, DOI 10.1016/j.ydbio.2007.11.039
   WAGENAAR EB, 1983, EXP CELL RES, V144, P393, DOI 10.1016/0014-4827(83)90419-6
   WILT FH, 1977, CELL, V11, P673, DOI 10.1016/0092-8674(77)90084-8
   Yajima M, 2011, DEVELOPMENT, V138, P2217, DOI 10.1242/dev.065052
   Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004
NR 59
TC 6
Z9 6
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 10
PY 2016
VL 11
IS 3
AR e0150318
DI 10.1371/journal.pone.0150318
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG3TL
UT WOS:000371993000031
PM 26962866
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Farhan, MA
   Carmine-Simmen, K
   Lewis, JD
   Moore, RB
   Murray, AG
AF Farhan, Maikel A.
   Carmine-Simmen, Katia
   Lewis, John D.
   Moore, Ronald B.
   Murray, Allan G.
TI Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis
SO PLOS ONE
LA English
DT Article
ID FOCAL ADHESION KINASE; MAMMALIAN TARGET; IN-VITRO; TUMOR-GROWTH;
   RAPAMYCIN; INHIBITOR; PHOSPHORYLATION; CANCER; VEGF; RICTOR
AB Tumor neovascularization is targeted by inhibition of vascular endothelial growth factor (VEGF) or the receptor to prevent tumor growth, but drug resistance to angiogenesis inhibition limits clinical efficacy. Inhibition of the phosphoinositide 3 kinase pathway intermediate, mammalian target of rapamycin (mTOR), also inhibits tumor growth and may prevent escape from VEGF receptor inhibitors. mTOR is assembled into two separate multi-molecular complexes, mTORC1 and mTORC2. The direct effect of mTORC2 inhibition on the endothelium and tumor angiogenesis is poorly defined. We used pharmacological inhibitors and RNA interference to determine the function of mTORC2 versus Akt1 and mTORC1 in human endothelial cells (EC). Angiogenic sprouting, EC migration, cytoskeleton re-organization, and signaling events regulating matrix adhesion were studied. Sustained inactivation of mTORC1 activity up-regulated mTORC2-dependent Akt1 activation. In turn, ECs exposed to mTORC1-inhibition were resistant to apoptosis and hyper-responsive to renal cell carcinoma (RCC)-stimulated angiogenesis after relief of the inhibition. Conversely, mTORC1/2 dual inhibition or selective mTORC2 inactivation inhibited angiogenesis in response to RCC cells and VEGF. mTORC2-inactivation decreased EC migration more than Akt1- or mTORC1-inactivation. Mechanistically, mTORC2 inactivation robustly suppressed VEGF-stimulated EC actin polymerization, and inhibited focal adhesion formation and activation of focal adhesion kinase, independent of Akt1. Endothelial mTORC2 regulates angiogenesis, in part by regulation of EC focal adhesion kinase activity, matrix adhesion, and cytoskeletal remodeling, independent of Akt/mTORC1.
C1 [Farhan, Maikel A.; Murray, Allan G.] Univ Alberta, Dept Med, Edmonton, AB, Canada.
   [Carmine-Simmen, Katia; Lewis, John D.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
   [Moore, Ronald B.] Univ Alberta, Dept Surg, Edmonton, AB, Canada.
RP Murray, AG (reprint author), Univ Alberta, Dept Med, Edmonton, AB, Canada.
EM allan.murray@ualberta.ca
OI Moore, Ronald/0000-0003-2027-2428
FU Canadian Institutes of Health Research; Alberta Innovates Health
   Solutions; Alberta Innovates [201201250]
FX The work was supported by a grant from the Canadian Institutes of Health
   Research, and Alberta Innovates Health Solutions to AGM. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Cacheux W, 2008, ANN ONCOL, V19, P1659, DOI 10.1093/annonc/mdn540
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008-5472.CAN-05-2825
   Duval M, 2007, MOL BIOL CELL, V18, P4659, DOI 10.1091/mbc.E07-05-0467
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079
   Falcon BL, 2011, CANCER RES, V71, P1573, DOI 10.1158/0008-5472.CAN-10-3126
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Giubellino A, 2013, ENDOCRINOLOGY, V154, P646, DOI 10.1210/en.2012-1854
   Gokmen-Polar Y, 2012, BREAST CANCER RES TR, V136, P673, DOI 10.1007/s10549-012-2298-8
   Griffioen AW, 2012, CLIN CANCER RES, V18, P3961, DOI 10.1158/1078-0432.CCR-12-0002
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Hutson TE, 2014, J CLIN ONCOL, V32, P760, DOI 10.1200/JCO.2013.50.3961
   Hutson TE, 2011, CRIT REV ONCOL HEMAT, V77, P49, DOI 10.1016/j.critrevonc.2010.07.018
   ILLC D, 1995, NATURE, V377, P539
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Kapoor A, 2009, CANCER, V115, P3618, DOI 10.1002/cncr.24409
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Lane HA, 2009, CLIN CANCER RES, V15, P1612, DOI 10.1158/1078-0432.CCR-08-2057
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200
   Luchman HA, 2014, CLIN CANCER RES, V20, P5756, DOI 10.1158/1078-0432.CCR-13-3389
   Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2
   McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Nakatsu MN, 2008, METHOD ENZYMOL, V443, P65, DOI 10.1016/S0076-6879(08)02004-1
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003
   Powles T, 2013, ANN ONCOL, V24, P2098, DOI 10.1093/annonc/mdt130
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Ruan GX, 2012, EMBO J, V31, P1692, DOI 10.1038/emboj.2012.21
   Saito K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049456
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489
   SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680
   Takahara T, 2013, J BIOCHEM, V154, P1, DOI 10.1093/jb/mvt047
   Wary KK, 2012, MICROVASC RES, V83, P64, DOI 10.1016/j.mvr.2011.05.002
   Xue Q, 2009, ARTERIOSCL THROM VAS, V29, P1172, DOI 10.1161/ATVBAHA.109.185918
   Zhang HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054510
   Zhang QX, 2011, AM J PHYSIOL-RENAL, V301, pF1242, DOI 10.1152/ajprenal.00662.2010
   Zijlstra A, 2012, TXN ANGIOGENESIS LYM, P217
NR 49
TC 21
Z9 21
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2015
VL 10
IS 8
AR e0135245
DI 10.1371/journal.pone.0135245
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP5MR
UT WOS:000359926900021
PM 26295809
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Livingstone, M
   Sikstrom, K
   Robert, PA
   Uze, G
   Larsson, O
   Pellegrini, S
AF Livingstone, Mark
   Sikstrom, Kristina
   Robert, Philippe A.
   Uze, Gilles
   Larsson, Ola
   Pellegrini, Sandra
TI Assessment of mTOR-Dependent Translational Regulation of Interferon
   Stimulated Genes
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA TRANSLATION; KINASE-C-DELTA; P70 S6 KINASE; I INTERFERONS;
   GENOME-WIDE; DIFFERENTIAL TRANSLATION; MAMMALIAN TARGET; HUMAN CANCER;
   CELL-SIZE; PKC-DELTA
AB Type-I interferon (IFN)-induced activation of the mammalian target of rapamycin (mTOR) signaling pathway has been implicated in translational control of mRNAs encoding interferon-stimulated genes (ISGs). However, mTOR-sensitive translatomes commonly include mRNAs with a 5' terminal oligopyrimidine tract (TOP), such as those encoding ribosomal proteins, but not ISGs. Because these translatomes were obtained under conditions when ISG expression is not induced, we examined the mTOR-sensitive translatome in human WISH cells stimulated with IFN beta. The mTOR inhibitor Torin1 resulted in a repression of global protein synthesis, including that of ISG products, and translation of all but 3 ISG mRNAs (TLR3, NT5C3A, and RNF19B) was not selectively more sensitive to mTOR inhibition. Detailed studies of NT5C3A revealed an IFN-induced change in transcription start site resulting in a switch from a non-TOP to a TOP-like transcript variant and mTOR sensitive translation. Thus, we show that, in the cell model used, translation of the vast majority of ISG mRNAs is not selectively sensitive to mTOR activity and describe an uncharacterized mechanism wherein the 5'-UTR of an mRNA is altered in response to a cytokine, resulting in a shift from mTOR-insensitive to mTOR-sensitive translation.
C1 [Livingstone, Mark; Robert, Philippe A.; Pellegrini, Sandra] Inst Pasteur, CNRS URA1961, Cytokine Signaling Unit, Paris, France.
   [Sikstrom, Kristina; Larsson, Ola] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
   [Uze, Gilles] Univ Montpellier 2, CNRS UMR5235, Montpellier, France.
RP Pellegrini, S (reprint author), Inst Pasteur, CNRS URA1961, Cytokine Signaling Unit, Paris, France.
EM Ola.Larsson@ki.se; sandra.pellegrini@pasteur.fr
RI Uze, Gilles/O-6383-2019
OI Uze, Gilles/0000-0002-4150-5772; Larsson, Ola/0000-0003-1412-1308;
   Livingstone, Mark/0000-0002-2757-7008
FU Pasteur Foundation; Swedish Research Council; Wallenberg Academy Fellows
   program
FX This research was supported by funding (to ML) from the Pasteur
   Foundation, institutional support from Institut Pasteur and CNRS, and
   grants from the Swedish Research Council and the Wallenberg Academy
   Fellows program (to OL).
CR Aksoy P, 2009, PHARMACOGENET GENOM, V19, P567, DOI 10.1097/FPC.0b013e32832c14b8
   Borden EC, 2011, J INTERF CYTOK RES, V31, P1, DOI 10.1089/jir.2010.0129
   Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]
   Colman H, 2013, J VIROL, V87, P6668, DOI 10.1128/JVI.00538-13
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898
   Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267
   Eliseeva IA, 2013, TRANSLATION, V1, P18
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182
   Francois-Newton V, 2012, BIOCHEM J, V446, P509, DOI 10.1042/BJ20120541
   Francois-Newton V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022200
   Furic L, 2009, CURR ONCOL, V16, P59
   Genolet R, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-33
   Gingras AC, 2001, GENE DEV, V15, P2852
   Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200
   Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Joshi S, 2010, CYTOKINE, V52, P123, DOI 10.1016/j.cyto.2010.03.019
   Joshi S, 2009, P NATL ACAD SCI USA, V106, P12097, DOI 10.1073/pnas.0900562106
   Kaur S, 2005, EXP HEMATOL, V33, P550, DOI 10.1016/j.exphem.2005.01.014
   Kaur S, 2008, J IMMUNOL, V181, P7316, DOI 10.4049/jimmunol.181.10.7316
   Kaur S, 2008, P NATL ACAD SCI USA, V105, P4808, DOI 10.1073/pnas.0710907105
   Kaur S, 2007, J BIOL CHEM, V282, P1757, DOI 10.1074/jbc.M607365200
   Kaur S, 2014, J BIOL CHEM, V289, P6581, DOI 10.1074/jbc.M113.537852
   Kroczynska B, 2011, J BIOL CHEM, V286, P1147, DOI 10.1074/jbc.M110.183566
   Kroczynska B, 2009, MOL CELL BIOL, V29, P2865, DOI 10.1128/MCB.01537-08
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Larsson O, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012302
   Larsson O, 2012, P NATL ACAD SCI USA, V109, P8977, DOI 10.1073/pnas.1201689109
   Larsson O, 2011, BIOINFORMATICS, V27, P1440, DOI 10.1093/bioinformatics/btr146
   Larsson O, 2010, P NATL ACAD SCI USA, V107, P21487, DOI 10.1073/pnas.1006821107
   Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200
   Li YZ, 2005, J BIOL CHEM, V280, P10001, DOI 10.1074/jbc.M410972200
   Livingstone Mark, 2012, F1000Res, V1, P4, DOI 10.12688/f1000research.1-4.v1
   Marijanovic Z, 2007, BIOCHEM J, V407, P141, DOI 10.1042/BJ20070605
   MARUYAMA K, 1994, GENE, V138, P171
   Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5
   Miloslavski R, 2014, J MOL CELL BIOL, V6, P255, DOI 10.1093/jmcb/mju008
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001
   Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000
   Piccirillo CA, 2014, NAT IMMUNOL, V15, P503, DOI 10.1038/ni.2891
   Rastogi R, 2013, J BIOL CHEM, V288, P33966, DOI 10.1074/jbc.M113.492702
   Rees DC, 2003, BRIT J HAEMATOL, V120, P375, DOI 10.1046/j.1365-2141.2003.03980.x
   Rich SA, 1996, J BIOL CHEM, V271, P1118, DOI 10.1074/jbc.271.2.1118
   Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605
   Samarajiwa SA, 2009, NUCLEIC ACIDS RES, V37, pD852, DOI 10.1093/nar/gkn732
   Sandberg R, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-48
   Schmeisser H, 2014, J INTERF CYTOK RES, V34, P71, DOI 10.1089/jir.2013.0128
   Schmeisser H, 2013, AUTOPHAGY, V9, P683, DOI 10.4161/auto.23921
   Srivastava KK, 2004, J BIOL CHEM, V279, P29911, DOI 10.1074/jbc.M401997200
   Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013
   Tait S, 2010, P NATL ACAD SCI USA, V107, P17627, DOI 10.1073/pnas.1008242107
   Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400
   Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001
   Tcherkezian J, 2014, GENE DEV, V28, P357, DOI 10.1101/gad.231407.113
   Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Tomoo K, 2005, BBA-PROTEINS PROTEOM, V1753, P191, DOI 10.1016/j.bbapap.2005.07.023
   Tomoo K, 2006, J BIOCHEM, V140, P237, DOI 10.1093/jb/mvj143
   Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200
   Wang XR, 2008, CANCER BIOL THER, V7, P1952, DOI 10.4161/cbt.7.12.6944
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Zhao JW, 2010, MOL IMMUNOL, V48, P294, DOI 10.1016/j.molimm.2010.07.014
NR 65
TC 8
Z9 8
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2015
VL 10
IS 7
AR e0133482
DI 10.1371/journal.pone.0133482
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN7NT
UT WOS:000358622000093
PM 26207988
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Harter, PN
   Jennewein, L
   Baumgarten, P
   Ilina, E
   Burger, MC
   Thiepold, AL
   Tichy, J
   Zornig, M
   Senft, C
   Steinbach, JP
   Mittelbronn, M
   Ronellenfitsch, MW
AF Harter, Patrick N.
   Jennewein, Lukas
   Baumgarten, Peter
   Ilina, Elena
   Burger, Michael C.
   Thiepold, Anna-Luisa
   Tichy, Julia
   Zoernig, Martin
   Senft, Christian
   Steinbach, Joachim P.
   Mittelbronn, Michel
   Ronellenfitsch, Michael W.
TI Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins
   in Human Brain Tumors
SO PLOS ONE
LA English
DT Article
ID GIANT-CELL ASTROCYTOMAS; PHASE-II TRIAL; RAPAMYCIN AY-22,989; MAMMALIAN
   TARGET; MTOR; TEMSIROLIMUS; INHIBITION; THERAPY; PATHWAY; AKT
AB Background
   Current pathological diagnostics include the analysis of (epi-) genetic alterations as well as oncogenic pathways. Deregulated mammalian target of rapamycin complex 1 (mTORC1) signaling has been implicated in a variety of cancers including malignant gliomas and is considered a promising target in cancer treatment. Monitoring of mTORC1 activity before and during inhibitor therapy is essential. The aim of our study is to provide a recommendation and report on pitfalls in the use of phospho-specific antibodies against mTORC1-targets phospho-RPS6 (Ser235/236; Ser240/244) and phospho-4EBP1 (Thr37/46) in formalin fixed, paraffin embedded material.
   Methods and Findings
   Primary, established cell lines and brain tumor tissue from routine diagnostics were assessed by immunocyto-, immunohistochemistry, immunofluorescent stainings and immunoblotting. For validation of results, immunoblotting experiments were performed. mTORC-pathway activation was pharmacologically inhibited by torin2 and rapamycin. Torin2 treatment led to a strong reduction of signal intensity and frequency of all tested antibodies. In contrast phospho-4EBP1 did not show considerable reduction in staining intensity after rapamycin treatment, while immunocytochemistry with both phospho-RPS6-specific antibodies showed a reduced signal compared to controls. Staining intensity of both phospho-RPS6-specific antibodies did not show considerable decrease in stability in a timeline from 0-230 minutes without tissue fixation, however we observed a strong decrease of staining intensity in phospho-4EBP1 after 30 minutes. Detection of phospho-signals was strongly dependent on tissue size and fixation gradient. mTORC1-signaling was significantlyinduced in glioblastomas although not restricted to cancer cells but also detectable in nonneoplastic cells.
   Conclusion
   Here we provide a recommendation for phospho-specific immunohistochemistry for patient-orientated therapy decisions and monitoring treatment response.
C1 [Harter, Patrick N.; Jennewein, Lukas; Baumgarten, Peter; Ilina, Elena; Mittelbronn, Michel] Goethe Univ Frankfurt, Inst Neurol, Edinger Inst, D-60054 Frankfurt, Germany.
   [Harter, Patrick N.; Burger, Michael C.; Senft, Christian; Steinbach, Joachim P.; Mittelbronn, Michel; Ronellenfitsch, Michael W.] German Canc Consortium DKTK, Heidelberg, Germany.
   [Harter, Patrick N.; Burger, Michael C.; Senft, Christian; Steinbach, Joachim P.; Mittelbronn, Michel; Ronellenfitsch, Michael W.] German Canc Res Ctr, Heidelberg, Germany.
   [Baumgarten, Peter; Senft, Christian] Goethe Univ Frankfurt, Dept Neurosurg, D-60054 Frankfurt, Germany.
   [Burger, Michael C.; Thiepold, Anna-Luisa; Tichy, Julia; Steinbach, Joachim P.; Ronellenfitsch, Michael W.] Goethe Univ Frankfurt, Senckenberg Inst Neurooncol, D-60054 Frankfurt, Germany.
   [Zoernig, Martin] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany.
RP Harter, PN (reprint author), Goethe Univ Frankfurt, Inst Neurol, Edinger Inst, D-60054 Frankfurt, Germany.
EM patrick.harter@kgu.de; m.ronellenfitsch@gmx.net
RI Senft, Christian/F-4252-2010
OI Senft, Christian/0000-0003-1288-6913; Jennewein,
   Lukas/0000-0001-6919-9394; Harter, Patrick N./0000-0001-5530-6910;
   Ronellenfitsch, Michael W./0000-0002-1402-6290; Ilina,
   Elena/0000-0001-8774-8465
FU LOEWE Center for Cell and Gene Therapy (State of Hessen); German Federal
   Ministry of Health (BMG); Ministry of Higher Education, Research; Arts
   of the state of Hessen (HMWK); Dr. Senckenberg Foundation; Hertie
   Foundation
FX MZ is supported by the LOEWE Center for Cell and Gene Therapy (State of
   Hessen). The Georg-Speyer-Haus is funded jointly by the German Federal
   Ministry of Health (BMG) and the Ministry of Higher Education, Research
   and the Arts of the state of Hessen (HMWK). The Dr. Senckenberg
   Institute of Neurooncology is supported by the Dr. Senckenberg
   Foundation and the Hertie Foundation. JPS is "Hertie Professor of
   Neurooncology".
CR Ahmed M, 2014, CARCINOGENESIS, V35, P1564, DOI 10.1093/carcin/bgu051
   Ayuso MI, 2010, J BIOL CHEM, V285, P34355, DOI 10.1074/jbc.M110.135103
   Baker AF, 2005, CLIN CANCER RES, V11, P4338, DOI 10.1158/1078-0432.CCR-05-0422
   Chang SM, 2005, INVEST NEW DRUG, V23, P357, DOI 10.1007/s10637-005-1444-0
   Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008
   DEMPSTER WT, 1960, AM J ANAT, V107, P59, DOI 10.1002/aja.1001070105
   ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9
   Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622
   Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947
   Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272
   KRIEG J, 1988, J BIOL CHEM, V263, P11473
   Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671
   Lisi L, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-125
   Liu QS, 2013, CANCER RES, V73, P2574, DOI 10.1158/0008-5472.CAN-12-1702
   Liu QS, 2011, J MED CHEM, V54, P1473, DOI 10.1021/jm101520v
   Malik SN, 2002, CLIN CANCER RES, V8, P1168
   MARTEL RR, 1977, CAN J PHYSIOL PHARM, V55, P48, DOI 10.1139/y77-007
   MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926
   Orlova KA, 2010, ANN NY ACAD SCI, V1184, P87, DOI 10.1111/j.1749-6632.2009.05117.x
   Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131
   Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004
   Qian ZR, 2013, J CLIN ONCOL, V31, P3418, DOI 10.1200/JCO.2012.46.6946
   Ronellenfitsch MW, 2009, BRAIN, V132, P1509, DOI 10.1093/brain/awp093
   SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727
   START RD, 1992, J CLIN PATHOL, V45, P1120, DOI 10.1136/jcp.45.12.1120
   Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083
   van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984
   Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145
   Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492
NR 33
TC 6
Z9 6
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2015
VL 10
IS 5
AR e0127123
DI 10.1371/journal.pone.0127123
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7BT
UT WOS:000354918600049
PM 25993328
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Pollizzi, KN
   Waickman, AT
   Patel, CH
   Sun, IH
   Powell, JD
AF Pollizzi, Kristen N.
   Waickman, Adam T.
   Patel, Chirag H.
   Sun, Im Hong
   Powell, Jonathan D.
TI Cellular Size as a Means of Tracking mTOR Activity and Cell Fate of
   CD4+T Cells upon Antigen Recognition
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; MAMMALIAN TARGET; IN-VIVO; RESPIRATORY CAPACITY;
   DIFFERENTIATION; ACTIVATION; INDUCTION; RAPAMYCIN; MEMORY; GENE
AB mTOR is a central integrator of metabolic and immunological stimuli, dictating immune cell activation, proliferation and differentiation. In this study, we demonstrate that within a clonal population of activated T cells, there exist both mTOR(hi) and mTOR(lo) cells exhibiting highly divergent metabolic and immunologic functions. By taking advantage of the role of mTOR activation in controlling cellular size, we demonstrate that upon antigen recognition, mTORhi CD4+ T cells are destined to become highly glycolytic effector cells. Conversely, mTOR(lo) T cells preferentially develop into long-lived cells that express high levels of Bcl-2, CD25, and CD62L. Furthermore, mTOR(lo) T cells have a greater propensity to differentiate into suppressive Foxp3+ T regulatory cells, and this paradigm was also observed in human CD4+ T cells. Overall, these studies provide the opportunity to track the development of effector and memory T cells from naive precursors, as well as facilitate the interrogation of immunologic and metabolic programs that inform these fates.
C1 [Pollizzi, Kristen N.; Waickman, Adam T.; Patel, Chirag H.; Sun, Im Hong; Powell, Jonathan D.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA.
RP Powell, JD (reprint author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA.
EM poweljo@jhmi.edu
FU National Institutes of Health/National Institute of Allergy and
   Infectious Diseases [AI072677, AI77610, AI091481]
FX This work was supported by the National Institutes of Health/National
   Institute of Allergy and Infectious Diseases: AI072677, AI77610 and
   AI091481 to JDP. The funder had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204
   Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804
   Choi SW, 2009, J NEUROCHEM, V109, P1179, DOI 10.1111/j.1471-4159.2009.06055.x
   Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005
   Delgoffe GM, 2009, MOL IMMUNOL, V46, P2694, DOI 10.1016/j.molimm.2009.05.185
   Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x
   Gottschalk RA, 2010, J EXP MED, V207, P1701, DOI 10.1084/jem.20091999
   Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017
   Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477
   He S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020107
   Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867
   Hernandez O, 2007, GENESIS, V45, P101, DOI 10.1002/dvg.20271
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Kang J, 2008, J LEUKOCYTE BIOL, V83, P1230, DOI 10.1189/jlb.1207851
   King CG, 2012, IMMUNITY, V37, P709, DOI 10.1016/j.immuni.2012.06.021
   Kuczma M, 2009, J IMMUNOL, V183, P3731, DOI 10.4049/jimmunol.0800601
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359
   Miskov-Zivanov N, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004217
   Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097
   Pollizzi KN, 2014, NAT REV IMMUNOL, V14, P435, DOI 10.1038/nri3701
   Powell Jonathan D, 2013, Cold Spring Harb Symp Quant Biol, V78, P125, DOI 10.1101/sqb.2013.78.020214
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024
   Procaccini C, 2010, IMMUNITY, V33, P929, DOI 10.1016/j.immuni.2010.11.024
   Qiao GL, 2013, J IMMUNOL, V191, P632, DOI 10.4049/jimmunol.1202068
   Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010
   Sauer S, 2008, P NATL ACAD SCI US
   Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200
   Smigiel KS, 2014, J EXP MED, V211, P121, DOI 10.1084/jem.20131142
   Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083
   van der Windt GJW, 2013, P NATL ACAD SCI USA, V110, P14336, DOI 10.1073/pnas.1221740110
   van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007
   van Panhuys N, 2014, IMMUNITY, V41, P63, DOI 10.1016/j.immuni.2014.06.003
   Waickman AT, 2012, J IMMUNOL, V188, P4721, DOI 10.4049/jimmunol.1103143
   West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990
   YAMAGATA K, 1994, J BIOL CHEM, V269, P16333
   Zeiser R, 2008, BLOOD, V111, P453, DOI 10.1182/blood-2007-06-094482
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297
   Zhang LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030592
   Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999
NR 49
TC 14
Z9 14
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2015
VL 10
IS 4
AR e0121710
DI 10.1371/journal.pone.0121710
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF3VU
UT WOS:000352477800073
PM 25849206
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU McKinley, ET
   Zhao, P
   Coffey, RJ
   Washington, MK
   Manning, HC
AF McKinley, Eliot T.
   Zhao, Ping
   Coffey, Robert J.
   Washington, M. Kay
   Manning, H. Charles
TI 3 '-Deoxy-3 '-[F-18]-Fluorothymidine PET Imaging Reflects
   PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in
   Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; PRECLINICAL MODELS; BRAF
   INHIBITION; TUMOR RESPONSE; BREAST-CANCER; SOLID TUMORS; FLT-PET;
   RESISTANCE; PROLIFERATION
AB Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illustrate that [F-18]-FLT PET, a non-invasive molecular imaging readout of thymidine salvage, closely reflects pro-survival responses to targeted therapy that are mediated by PI3K-mTOR activity. Activation of pro-survival mechanisms forms the basis of numerous modes of resistance. Therefore, we conclude that [F-18]-FLT PET may serve a novel and potentially critical role to predict tumors that exhibit molecular features that tend to reflect recalcitrance to MAPK-targeted therapy. Though these studies focused on colorectal cancer, we envision that the results may be applicable to other solid tumors as well.
C1 [McKinley, Eliot T.; Zhao, Ping; Manning, H. Charles] Vanderbilt Univ, Sch Med, Inst Imaging Sci, Nashville, TN 37235 USA.
   [McKinley, Eliot T.; Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Biomed Engn, Nashville, TN 37235 USA.
   [McKinley, Eliot T.; Coffey, Robert J.; Washington, M. Kay] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37235 USA.
   [Coffey, Robert J.; Washington, M. Kay; Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA.
   [Washington, M. Kay] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37235 USA.
   [Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Radiol & Radiol Sci, Nashville, TN 37235 USA.
   [Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Neurosurg, Nashville, TN 37235 USA.
   [Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Chem & Phys Biol, Nashville, TN 37235 USA.
RP Manning, HC (reprint author), Vanderbilt Univ, Sch Med, Inst Imaging Sci, 221 Kirkland Hall, Nashville, TN 37235 USA.
EM henry.c.manning@vanderbilt.edu
FU Kleberg Foundation [R25 CA136440, K25 CA127349, P50 CA128323, P50
   CA095103, R25 CA092043, R01 CA140628, RC1 CA145138, R01 CA046413, P30
   DK058404]
FX Research funding: R25 CA136440, K25 CA127349, P50 CA128323, P50
   CA095103, R25 CA092043, R01 CA140628, RC1 CA145138, R01 CA046413, P30
   DK058404, The Kleberg Foundation. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Barthel H, 2003, CANCER RES, V63, P3791
   Bermudez O, 2008, ONCOGENE, V27, P3685, DOI 10.1038/sj.onc.1211040
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Buck JR, 2012, TETRAHEDRON LETT, V53, P4161, DOI 10.1016/j.tetlet.2012.05.137
   Choi SJ, 2005, EUR J NUCL MED MOL I, V32, P653, DOI 10.1007/s00259-004-1742-3
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Katz SI, 2011, INT J ONCOL, V39, P91, DOI 10.3892/ijo.2011.1019
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Manning HC, 2008, CLIN CANCER RES, V14, P7413, DOI 10.1158/1078-0432.CCR-08-0239
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   McKinley ET, 2013, J NUCL MED, V54, P424, DOI 10.2967/jnumed.112.108456
   McKinley ET, 2012, ANN NUCL MED, V26, P757, DOI 10.1007/s12149-012-0636-x
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   OGRIS E, 1993, J VIROL, V67, P1765
   OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239
   PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0
   Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6
   Shah C, 2009, CLIN CANCER RES, V15, P4712, DOI 10.1158/1078-0432.CCR-08-2635
   Shields AF, 2003, J NUCL MED, V44, P1432
   Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337
   Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704
   Soloviev D, 2012, EUR J CANCER, V48, P416, DOI 10.1016/j.ejca.2011.11.035
   Villanueva J, 2011, CANCER RES, V71, P7137, DOI 10.1158/0008-5472.CAN-11-1243
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
   Zhang CC, 2012, CLIN CANCER RES, V18, P1303, DOI 10.1158/1078-0432.CCR-11-1433
NR 32
TC 10
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2014
VL 9
IS 9
AR e108193
DI 10.1371/journal.pone.0108193
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP8TL
UT WOS:000342351800070
PM 25247710
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Bailey, ST
   Zhou, B
   Damrauer, JS
   Krishnan, B
   Wilson, HL
   Smith, AM
   Li, MQ
   Yeh, JJ
   Kim, WY
AF Bailey, Sean T.
   Zhou, Bing
   Damrauer, Jeffrey S.
   Krishnan, Bhavani
   Wilson, Harper L.
   Smith, Aleisha M.
   Li, Mingqing
   Yeh, Jen Jen
   Kim, William Y.
TI mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK
   Activation in Renal Cell Carcinoma
SO PLOS ONE
LA English
DT Article
ID IN-VIVO ACTIVITY; MAMMALIAN TARGET; COMBINED PI3K/MTOR; RAPAMYCIN;
   PATHWAYS; GROWTH; PHOSPHORYLATION; PI3K/AKT/MTOR; SUPPRESSION; SURVIVAL
AB Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus catalytic mTOR inhibition, evaluate the crosstalk between the mTOR and MEK/ERK pathways, as well as the therapeutic potential of dual mTOR and MEK inhibition in RCC. Pharmacologic (rapamycin and BEZ235) and genetic manipulation of the mTOR pathway were evaluated by in vitro assays as monotherapy as well as in combination with MEK inhibition (GSK1120212). Catalytic mTOR inhibition with BEZ235 decreased proliferation and increased apoptosis better than allosteric mTOR inhibition with rapamycin. While mTOR inhibition upregulated MEK/ERK signaling, concurrent inhibition of both pathways had enhanced therapeutic efficacy. Finally, primary RCC tumors could be classified into subgroups [(I) MEK activated, (II) Dual MEK and mTOR activated, (III) Not activated, and (IV) mTOR activated] based on their relative activation of the PI3K/mTOR and MEK pathways. Patients with mTOR only activated tumors had the worst prognosis. In summary, dual targeting of the mTOR and MEK pathways in RCC can enhance therapeutic efficacy and primary RCC can be subclassified based on their relative levels of mTOR and MEK activation with potential therapeutic implications.
C1 [Bailey, Sean T.; Zhou, Bing; Damrauer, Jeffrey S.; Krishnan, Bhavani; Wilson, Harper L.; Smith, Aleisha M.; Li, Mingqing; Yeh, Jen Jen; Kim, William Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Kim, William Y.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Bailey, Sean T.; Damrauer, Jeffrey S.; Kim, William Y.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   [Yeh, Jen Jen] Univ N Carolina, Dept Surg, Chapel Hill, NC USA.
   [Yeh, Jen Jen] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA.
RP Kim, WY (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
EM wykim@med.unc.edu
FU NIH [R01 CA142794, T32-GM007092, F31 CA159897, CA140424]; AACR Kure; DoD
   [CA120297]; University Cancer Research Fund; Integrative Vascular
   Biology Training [T32-HL069768]
FX This work was supported by the NIH R01 CA142794 (WYK), NIH T32-GM007092
   (STB), NIH F31 CA159897 (STB), NIH CA140424 (JJY) Integrative Vascular
   Biology Training Grant T32-HL069768 (JSD), the AACR Kure It grant for
   Kidney Cancer Research, DoD CA120297 (BK), and the University Cancer
   Research Fund. WYK is a Damon Runyon Merck Clinical Investigator. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Carracedo A, 2008, J CLIN INVEST, DOI [10.1172/JCI34739DS1, DOI 10.1172/JCI34739DS1]
   Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Conti A, 2013, BIOMED RES INT, DOI 10.1155/2013/419176
   Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Haagensen EJ, 2012, BRIT J CANCER, V106, P1386, DOI 10.1038/bjc.2012.70
   Hanna SC, 2008, EXPERT REV ANTICANC, V8, P283, DOI 10.1586/14737140.8.2.283
   Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783
   Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117
   Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502
   Kim WY, 2006, SEMIN ONCOL, V33, P588, DOI 10.1053/j.seminoncol.2006.06.001
   Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
   Kinross KM, 2011, MOL CANCER THER, V10, P1440, DOI 10.1158/1535-7163.MCT-11-0240
   Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083
   Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0
   Krieg M, 2000, UP REGULATION HYPOXI, P1
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Maxwell PH, 1999, NATURE, P1
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683
   Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Renshaw J, 2013, CLIN CANCER RES, V19, P5940, DOI 10.1158/1078-0432.CCR-13-0850
   Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098
   Sheppard KE, 2013, EUR J CANCER, V49, P3936, DOI 10.1016/j.ejca.2013.08.007
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Soares HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057289
   Wang XR, 2008, CANCER BIOL THER, V7, P1952, DOI 10.4161/cbt.7.12.6944
   Xu CX, 2011, CANCER BIOL THER, V12, P549, DOI 10.4161/cbt.12.6.16397
   Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122
   Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299
   Zhong H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077243
   Zimmer M, 2004, MOL CANCER RES, V2, P89
NR 46
TC 13
Z9 13
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 2
PY 2014
VL 9
IS 9
AR e104413
DI 10.1371/journal.pone.0104413
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3LR
UT WOS:000341231500011
PM 25180793
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Zhou, Y
   Wang, DY
   Gao, XF
   Lew, K
   Richards, AM
   Wang, PP
AF Zhou, Yue
   Wang, Daying
   Gao, Xiufang
   Lew, Karsheng
   Richards, Arthur Mark
   Wang, Peipei
TI mTORC2 Phosphorylation of Akt1: A Possible Mechanism for Hydrogen
   Sulfide-Induced Cardioprotection
SO PLOS ONE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; PERMEABILITY TRANSITION PORE; HEART;
   KINASE; BAX; INHIBITOR; PROTECTS; SURVIVAL; GROWTH; MITOCHONDRIAL
AB Hydrogen sulfide (H2S) is known to have cardiac protective effects through Akt activation. Akt acts as a 'central sensor' for myocyte survival or death; its activity is regulated by multiple kinases including PI3K, mTORC2, PDK1 and phosphatases including PTEN, PP2A and PHLPPL. Based on the previous finding that PI3K inhibitor LY294002 abolishes H2S-induced Akt phosphorylation and cardioprotection, it is accepted that PI3K is the mediator of H2S-induced Akt phosphorylation. However, LY294002 inhibits both PI3K and mTOR, and PI3K only recruits Akt to the membrane where Akt is phosphorylated by Akt kinases. We undertook a series of experiments to further evaluate the role of mTORC2, PDK1, PTEN, PP2A and PHLPPL in H2S-induced Akt phosphorylation and cardioprotection, which, we believe, has not been investigated before. Hearts from adult Sprague-Dawley rats were isolated and subjected to (i) normoxia, (ii) global ischemia and (iii) ischemia/reperfusion in the presence or absence of 50 mu M of H2S donor NaHS. Cardiac mechanical function and lactate dehydrogenase (LDH) release were assessed. All hearts also were Western analyzed at the end of perfusion for Akt and a panel of appropriate Akt regulators and targets. Hearts pretreated with 50 mM NaHS had improved function at the end of reperfusion (Rate pressure product; 19 +/- 4x10(3) vs. 10 +/- 3x10(3) mmHg/min, p < 0.05) and reduced cell injury (LDH release 19 +/- 10 vs. 170 +/- 87 mU/ml p<0.05) compared to untreated hearts. NaHS significantly increased phospho-Akt, phospho-mTOR, phospho-Bim and Bcl-2 in reperfused hearts (P<0.05). Furthermore using H9c2 cells we demonstrate that NaHS pretreatment reduces apoptosis following hypoxia/re-oxygenation. Importantly, PP242, a specific mTOR inhibitor, abolished both cardioprotection and protein phosphorylation in isolated heart and reduced apoptotic effects in H9c2 cells. Treating hearts with NaHS only during reperfusion produced less cardioprotection through a similar mechanism. These data suggest mTORC2 phosphorylation of Akt is a key mediator of H2S-induced cardioprotection in I/R.
C1 [Zhou, Yue; Lew, Karsheng; Richards, Arthur Mark; Wang, Peipei] Natl Univ Singapore, Cardiovasc Res Inst, Singapore 117548, Singapore.
   [Wang, Daying] Putuo Hosp, Dept Cardiol, Shanghai, Peoples R China.
   [Gao, Xiufang] Fudan Univ, Huashan Hosp, Dept Cardiol, Shanghai 200433, Peoples R China.
RP Wang, PP (reprint author), Natl Univ Singapore, Cardiovasc Res Inst, Singapore 117548, Singapore.
EM mdcwp@nus.edu.sg
FU Cardiovascular Research Institute Start-up Fund (National University of
   Singapore, Singapore); NMRC Centre Grant (National Medical Research
   Council, Ministry of Health, Singapore)
FX The present work was supported by Cardiovascular Research Institute
   Start-up Fund (National University of Singapore, Singapore) and NMRC
   Centre Grant (National Medical Research Council, Ministry of Health,
   Singapore). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abe K, 1996, J NEUROSCI, V16, P1066
   Aoyagi T, 2012, AM J PHYSIOL-HEART C, V303, pH75, DOI 10.1152/ajpheart.00241.2012
   Ballou LM, 2007, J BIOL CHEM, V282, P24463, DOI 10.1074/jbc.M704741200
   Bar N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010859
   Bian JS, 2006, J PHARMACOL EXP THER, V316, P670
   Bliksoen M, 2008, EUR J CARDIO-THORAC, V34, P344, DOI 10.1016/j.ejcts.2008.03.017
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017
   Chen L, 2007, CHINESE MED J-PEKING, V120, P389, DOI 10.1097/00029330-200703010-00008
   Chung EJ, 2010, INVEST OPHTH VIS SCI, V51, P6232, DOI 10.1167/iovs.10-5747
   Das S, 2005, AM J PHYSIOL-HEART C, V288, pH328, DOI 10.1152/ajpheart.00453.2004
   Degrande ST, 2012, J BIOL CHEM
   Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200
   Eden M, 2013, CIRCULATION, V128
   Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665
   Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885
   Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094
   Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101
   Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024
   Hochhauser E, 2003, AM J PHYSIOL-HEART C, V284, pH2351, DOI 10.1152/ajpheart.00783.2002
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   Hu Y, 2008, PFLUG ARCH EUR J PHY, V455, P607, DOI 10.1007/s00424-007-0321-4
   Hwang SK, 2011, BMB REP, V44, P506, DOI 10.5483/BMBRep.2011.44.8.506
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373
   Meller R, 2009, NEUROSCIENTIST, V15, P243, DOI 10.1177/1073858408327809
   Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681
   Osipov RM, 2009, J CARDIOVASC PHARM, V54, P287, DOI 10.1097/FJC.0b013e3181b2b72b
   Pan LL, 2011, AMINO ACIDS, V41, P205, DOI 10.1007/s00726-011-0834-1
   Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200
   Salloum FN, 2009, CIRCULATION, V120, pS31, DOI 10.1161/CIRCULATIONAHA.108.843979
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sen U, 2008, PHARMACOLOGY, V82, P201, DOI 10.1159/000156486
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   Walsh K, 2006, CIRCULATION, V113, P2032, DOI 10.1161/CIRCULATIONAHA.106.615138
   Wang PP, 2007, J PHARMACOL EXP THER, V321, P213, DOI 10.1124/jpet.106.115519
   Wang PP, 2008, LIFE SCI, V83, P836, DOI 10.1016/j.lfs.2008.09.024
   Wang PP, 2005, CIRCULATION, V111, P2066, DOI 10.1161/01.CIR.0000162466.06150.D4
   Whiteman M, 2009, J CELL MOL MED, V13, P488, DOI 10.1111/j.1582-4934.2009.00645.x
   Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667
   Yong QC, 2008, AM J PHYSIOL-HEART C, V295, pH1330, DOI 10.1152/ajpheart.00244.2008
NR 46
TC 52
Z9 56
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2014
VL 9
IS 6
AR e99665
DI 10.1371/journal.pone.0099665
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK2UZ
UT WOS:000338276300017
PM 24949720
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Misra, UK
   Pizzo, SV
AF Misra, Uma Kant
   Pizzo, Salvatore Vincent
TI Activated alpha(2)-Macroglobulin Binding to Cell Surface GRP78 Induces
   T-Loop Phosphorylation of Akt1 by PDK1 in Association with Raptor
SO PLOS ONE
LA English
DT Article
ID RECEPTOR-RECOGNIZED FORMS; PROSTATE-CANCER CELLS; UNFOLDED PROTEIN
   RESPONSE; NF-KAPPA-B; PDK1-INTERACTING PROTEIN; ENDOPLASMIC-RETICULUM;
   SIGNAL-TRANSDUCTION; TERMINAL DOMAIN; REGULATES AKT; KINASE
AB PDK1 phosphorylates multiple substrates including Akt by PIP3-dependent mechanisms. In this report we provide evidence that in prostate cancer cells stimulated with activated alpha(2)-macroglobulin (alpha M-2*) PDK1 phosphorylates Akt in the T-loop at Thr(308) by using Raptor in the mTORC1 complex as a scaffold protein. First we demonstrate that PDK1, Raptor, and mTOR co-immunoprecipitate. Silencing the expression, not only of PDK1, but also Raptor by RNAi nearly abolished Akt phosphorylation at Akt(Thr308) in Raptor-immunoprecipitates of alpha 2M*-stimulated prostate cancer cells. Immunodepleting Raptor or PDK from cell lysates of cells treated with alpha 2M* drastically reduced Akt phosphorylation at Thr(308), which was recovered by adding the supernatant of Raptor- or PDK1-depleted cell lysates, respectively. Studies of insulin binding to its receptor on prostate cancer cells yielded similar results. We thus demonstrate that phosphorylating the T-loop Akt residue Thr(308) by PDK1 requires Raptor of the mTORC1 complex as a platform or scaffold protein.
C1 [Misra, Uma Kant; Pizzo, Salvatore Vincent] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
RP Pizzo, SV (reprint author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
EM salvatore.pizzo@duke.edu
CR Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515
   Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810
   Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002
   Biondi RM, 2004, TRENDS BIOCHEM SCI, V29, P136, DOI 10.1016/j.tibs.2004.01.005
   Boulbes DR, 2011, BIOCHEM BIOPH RES CO, V413, P46, DOI 10.1016/j.bbrc.2011.08.034
   Bracho-Valdes I, 2011, IUBMB LIFE, V63, P896, DOI 10.1002/iub.558
   Bridges D, 2012, MOL BIOL CELL, V23, P2955, DOI 10.1091/mbc.E11-12-1034
   Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Ding ZY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009910
   Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200
   Engstrom W, 2010, CELL PROLIFERAT, V43, P56, DOI 10.1111/j.1365-2184.2009.00654.x
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700
   Gao XX, 2011, P NATL ACAD SCI USA, V108, P14509, DOI 10.1073/pnas.1019386108
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Hart JP, 2006, HEMOSTASIS THROMBOSI
   Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774
   Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795
   Huang BX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061430
   Kikani CK, 2005, J CELL BIOCHEM, V96, P1157, DOI 10.1002/jcb.20651
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   King CC, 2004, J BIOL CHEM, V279, P37518, DOI 10.1074/jbc.M405340200
   Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379
   Kurata A, 2008, CANCER SCI, V99, P1827, DOI 10.1111/j.1349-7006.2008.00874.x
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387
   Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107
   Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003
   Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100
   Masters TA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000738
   McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218
   Michel JJC, 2005, MOL CELL, V20, P661, DOI 10.1016/j.molcel.2005.10.013
   Misra UK, 2010, APOPTOSIS, V15, P173, DOI 10.1007/s10495-009-0430-y
   Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200
   Misra UK, 2005, J IMMUNOL, V175, P2525, DOI 10.4049/jimmunol.175.4.2525
   Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200
   Misra UK, 2004, J CELL BIOCHEM, V93, P1020, DOI 10.1002/jcb.20233
   Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399
   Misra UK, 2004, CELL SIGNAL, V16, P487, DOI 10.1016/j.cellsig.2003.09.010
   Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200
   Misra UK, 2013, J CANC THERAPY, V4, P74
   Misra UK, 2013, J BIOCH PHARM RES, V4, P219
   Misra UK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051735
   Misra UK, 2012, J CELL BIOCHEM, V113, P1488, DOI 10.1002/jcb.24018
   Misra UK, 2011, J BIOL CHEM, V286, P1248, DOI 10.1074/jbc.M110.129767
   Misra UK, 2009, MOL CANCER THER, V8, P1350, DOI 10.1158/1535-7163.MCT-08-0990
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022
   Mora A, 2005, BIOCHEM J, V385, P639, DOI 10.1042/BJ20041782
   Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732
   Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08
   Okamoto Y, 2007, DIABETES, V56, P1000, DOI 10.2337/db06-1322
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43
   Rosner M, 2012, METHODS MOL BIOL, V821, P105, DOI 10.1007/978-1-61779-430-8_8
   Shen XC, 2010, J BIOL CHEM, V285, P29416, DOI 10.1074/jbc.M110.155325
   Shende P, 2011, CIRCULATION, V123, P1073, DOI 10.1161/CIRCULATIONAHA.110.977066
   Sinha D, 2004, J BIOL CHEM, V279, P10962, DOI 10.1074/jbc.M312048200
   Sundin T, 2013, MOL CELL BIOCHEM, V375, P97, DOI 10.1007/s11010-012-1532-3
   Tian XJ, 2002, EMBO J, V21, P1327, DOI 10.1093/emboj/21.6.1327
   Toker Alex, 2012, Subcell Biochem, V58, P95, DOI 10.1007/978-94-007-3012-0_4
   Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6
   Ziemba BP, 2013, BIOCHEMISTRY-US, V52, P4820, DOI 10.1021/bi400488f
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 68
TC 9
Z9 11
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2014
VL 9
IS 2
AR e88373
DI 10.1371/journal.pone.0088373
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA1BH
UT WOS:000330830700065
PM 24516643
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Wang, WJ
   Yan, JQ
   Wang, HK
   Shi, MM
   Zhang, MJ
   Yang, WP
   Peng, CH
   Li, HW
AF Wang, Weijie
   Yan, Jiqi
   Wang, Huakai
   Shi, Minmin
   Zhang, Mingjun
   Yang, Weiping
   Peng, Chenghong
   Li, Hongwei
TI Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of
   Cirrhotic Portal Hypertension in Rats through Inhibition of mTORC1 but
   Not mTORC2
SO PLOS ONE
LA English
DT Article
ID HEPATIC STELLATE CELL; GROWTH-FACTOR RECEPTOR; LIVER FIBROSIS;
   HEPATOCYTE PROLIFERATION; INDUCED APOPTOSIS; PATHWAYS; ACTIVATION;
   EXPRESSION; SURVIVAL; KINASE
AB Objective: Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes the pathogenetic mechanisms leading to cholestatic liver fibrosis and portal hypertension, and focuses on mammalian target of rapamycin (mTOR) pathway as a potential modulator in the early phase of cirrhotic portal hypertension.
   Methods: Early cirrhotic portal hypertension was induced by bile duct ligation (BDL) for three weeks. One week after operation, sham-operated (SHAM) and BDL rats received rapamycin (2 mg/kg/day) by intraperitoneal injection for fourteen days. Vehicle-treated SHAM and BDL rats served as controls. Fibrosis, inflammation, and portal pressure were evaluated by histology, morphometry, and hemodynamics. Expressions of pro-fibrogenic and pro-inflammatory genes in liver were measured by RT-PCR; alpha smooth muscle actin (alpha-SMA) and antigen Ki67 were detected by immunohistochemistry; expressions of AKT/mTOR signaling molecules, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, and interleukin-1 beta (IL-1 beta) were assessed by western blot.
   Results: The AKT/mTOR signaling pathway was markedly activated in the early phase of cirrhotic portal hypertension induced by BDL in rats. mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure. Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats. Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin. Interestingly, we also found that the level of p-ERK1/2 to ERK1/2 was significantly increased in BDL rats, which was little affected by rapamycin.
   Conclusions: The AKT/mTOR signaling pathway played an important role in the early phase of cirrhotic portal hypertension in rats, which could be a potential target for therapeutic intervention in the early phase of such pathophysiological progress.
C1 [Wang, Weijie; Yan, Jiqi; Wang, Huakai; Yang, Weiping; Peng, Chenghong; Li, Hongwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China.
   [Wang, Weijie; Yan, Jiqi; Wang, Huakai; Shi, Minmin; Zhang, Mingjun] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Digest Surg,Key Lab Syst Biomed Ver, Shanghai 200030, Peoples R China.
RP Yan, JQ (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China.
EM jiqiyan@yahoo.com
FU Foundation of Shanghai Natural Science [09ZR1418600]; National Natural
   Science of China [81070358]
FX This study was jointly supported by the Foundation of Shanghai Natural
   Science (09ZR1418600) and the National Natural Science (81070358) of
   China. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alvaro D, 2002, HEPATOLOGY, V36, P297, DOI 10.1053/jhep.2002.34741
   Biecker E, 2005, J PHARMACOL EXP THER, V313, P952, DOI 10.1124/jpet.104.079616
   Bridle KR, 2009, LIVER TRANSPLANT, V15, P1315, DOI [10.1002/It.21804, 10.1002/lt.21804]
   Chen GQG, 2012, ACTA MATH SCI, V32, P1
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Cichoz-Lach H, 2008, J PHYSIOL PHARMACOL, V59, P231
   Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160
   Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fernandez M, 2007, HEPATOLOGY, V46, P1208, DOI 10.1002/hep.21785
   Friedman SL, 2008, TOXICOLOGY, V254, P120, DOI 10.1016/j.tox.2008.06.013
   Gabele E, 2005, J BIOL CHEM, V280, P13374, DOI 10.1074/jbc.M409444200
   Gabele E, 2003, FRONT BIOSCI, V8, pD69, DOI 10.2741/887
   Geerts AM, 2008, HEPATOL RES, V38, P1130, DOI 10.1111/j.1872-034X.2008.00369.x
   Giron-Gonzalez JA, 2004, LIVER INT, V24, P437, DOI 10.1111/j.1478-3231.2004.0951.x
   Gujral JS, 2003, HEPATOLOGY, V38, P355, DOI 10.1053/jhep.2003.50341
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002
   Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568
   Lee DF, 2007, CELL CYCLE, V6, P3011, DOI 10.4161/cc.6.24.5085
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Mehal WZ, 2007, LIVER IMMUNOLOGY PRI, V9, P111
   Mejias M, 2010, J HEPATOL, V52, P529, DOI 10.1016/j.jhep.2010.01.004
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Neef M, 2006, J HEPATOL, V45, P786, DOI 10.1016/j.jhep.2006.07.030
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Patsenker E, 2011, J HEPATOL, V55, P388, DOI 10.1016/j.jhep.2010.10.044
   Qiao L, 2002, HEPATOLOGY, V35, P779, DOI 10.1053/jhep.2002.32533
   Rao YP, 2002, HEPATOLOGY, V35, P307, DOI 10.1053/jhep.2002.31104
   Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Schoemaker MH, 2004, HEPATOLOGY, V39, P1563, DOI 10.1002/hep.20246
   Shegogue D, 2004, J BIOL CHEM, V279, P23166, DOI 10.1074/jbc.M401238200
   Svegliati-Baroni G, 2005, GASTROENTEROLOGY, V128, P1042, DOI 10.1053/j.gastro.2005.01.007
   Svegliati-Baroni G, 2003, J HEPATOL, V39, P528, DOI 10.1016/S0168-8278(03)00291-5
   Tao YX, 2005, J AM SOC NEPHROL, V16, P46, DOI 10.1681/ASN.2004080660
   Tugues S, 2007, HEPATOLOGY, V46, P1919, DOI 10.1002/hep.21921
   Wang Y, 2008, WORLD J GASTROENTERO, V14, P5186, DOI 10.3748/wjg.14.5186
   Werneburg NW, 2003, AM J PHYSIOL-GASTR L, V285, pG31, DOI 10.1152/ajpgi.00536.2002
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019
NR 44
TC 104
Z9 108
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 3
PY 2014
VL 9
IS 1
AR e83908
DI 10.1371/journal.pone.0083908
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 286IH
UT WOS:000329460800022
PM 24404143
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Badura, S
   Tesanovic, T
   Pfeifer, H
   Wystub, S
   Nijmeijer, BA
   Liebermann, M
   Falkenburg, JHF
   Ruthardt, M
   Ottmann, OG
AF Badura, Susanne
   Tesanovic, Tamara
   Pfeifer, Heike
   Wystub, Sylvia
   Nijmeijer, Bart A.
   Liebermann, Marcus
   Falkenburg, J. H. Frederik
   Ruthardt, Martin
   Ottmann, Oliver G.
TI Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR
   Pathway in Acute Lymphoblastic Leukemia
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; T-CELL LEUKEMIA; IN-VIVO; MOLECULAR-MECHANISMS;
   KINASE INHIBITORS; MAMMALIAN TARGET; CANCER-THERAPY; MTOR COMPLEX;
   PIK3CA GENE; RAPAMYCIN
AB Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase (TK) contributes to the pathogenesis and development of resistance to ABLTK inhibitors (TKI). The PI3K pathway thus is an attractive therapeutic target in BCR-ABL positive leukemias, but its role in BCR-ABL negative ALL is conjectural. Moreover, the functional contribution of individual components of the PI3K pathway in ALL has not been established.
   Experimental Design: We compared the activity of the ATP-competitive pan-PI3K inhibitor NVP-BKM120, the allosteric mTORC1 inhibitor RAD001, the ATP-competitive dual PI3K/mTORC1/C2 inhibitors NVP-BEZ235 and NVP-BGT226 and the combined mTORC1 and mTORC2 inhibitors Torin 1, PP242 and KU-0063794 using long-term cultures of ALL cells (ALL-LTC) from patients with B-precursor ALL that expressed the BCR-ABL or TEL-ABL oncoproteins or were BCR-ABL negative.
   Results: Dual PI3K/mTOR inhibitors profoundly inhibited growth and survival of ALL cells irrespective of their genetic subtype and their responsiveness to ABL-TKI. Combined suppression of PI3K, mTORC1 and mTORC2 displayed greater antileukemic activity than selective inhibitors of PI3K, mTORC1 or mTORC1 and mTORC2.
   Conclusions: Inhibition of the PI3K/mTOR pathway is a promising therapeutic approach in patients with ALL. Greater antileukemic activity of dual PI3K/mTORC1/C2 inhibitors appears to be due to the redundant function of PI3K and mTOR. Clinical trials examining dual PI3K/mTORC1/C2 inhibitors in patients with B-precursor ALL are warranted, and should not be restricted to particular genetic
C1 [Badura, Susanne; Tesanovic, Tamara; Pfeifer, Heike; Wystub, Sylvia; Liebermann, Marcus; Ruthardt, Martin; Ottmann, Oliver G.] Goethe Univ Frankfurt, Dept Med Hematol & Oncol, D-60054 Frankfurt, Germany.
   [Nijmeijer, Bart A.; Falkenburg, J. H. Frederik] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands.
RP Ottmann, OG (reprint author), Goethe Univ Frankfurt, Dept Med Hematol & Oncol, D-60054 Frankfurt, Germany.
EM ottmann@em.uni-frankfurt.de
RI Ottmann, Oliver/D-5007-2016
OI Ottmann, Oliver/0000-0001-9559-1330; Ruthardt,
   Martin/0000-0003-1021-3811
FU Deutsche Krebshilfe Verbundprojekt [108690]
FX This research was funded and supported by the Deutsche Krebshilfe
   Verbundprojekt 108690. OGO holds an endowed professorship of the DJCLS
   (H06/06). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abraham RT, 2008, EXPERT OPIN THER TAR, V12, P209, DOI [10.1517/14728222.12.2.209, 10.1517/14728222.12.2.209 ]
   Ahmad EI, 2011, ONCOTARGETS THER, V4, P115, DOI 10.2147/OTT.S12602
   Baeumler J, 2008, CANCER GENET CYTOGEN, V185, P37, DOI 10.1016/j.cancergencyto.2008.05.001
   Breuleux M, 2009, MOL CANCER THER, V8, P742, DOI 10.1158/1535-7163.MCT-08-0668
   Brown VI, 2003, P NATL ACAD SCI USA, V100, P15113, DOI 10.1073/pnas.2436348100
   Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616
   Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898
   Chang KY, 2011, CLIN CANCER RES, V17, P7116, DOI 10.1158/1078-0432.CCR-11-0796
   Chapuis N, 2010, CLIN CANCER RES, V16, P5424, DOI 10.1158/1078-0432.CCR-10-1102
   De P, 2013, CANCER TREAT REV, V39, P403, DOI 10.1016/j.ctrv.2012.12.002
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Faderl S, 1998, BLOOD, V91, P3995
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   He YL, 2010, EUR J HAEMATOL, V84, P87, DOI 10.1111/j.1600-0609.2009.01350.x
   Hofmann WK, 2004, LEUKEMIA LYMPHOMA, V45, P655, DOI 10.1080/10428190310001625755
   Hummerdal P, 2006, EUR J HAEMATOL, V77, P86, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2605.x
   Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091
   Kharas MG, 2004, BLOOD, V103, P4268, DOI 10.1182/blood-2003-07-2193
   Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337
   Kharas NG, 2005, CANCER RES, V65, P2047
   Lane HA, 2009, CURR OPIN CELL BIOL, V21, P219, DOI 10.1016/j.ceb.2009.01.016
   Lebwohl D, 2011, EXPERT OPIN DRUG DIS, V6, P323, DOI 10.1517/17460441.2011.558079
   Levy DS, 2009, BLOOD, V113, P1723, DOI 10.1182/blood-2008-02-137737
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Mahmoud IS, 2008, BRIT J CANCER, V99, P488, DOI 10.1038/sj.bjc.6604512
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474
   Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874
   Montiel-Duarte C, 2008, LEUKEMIA RES, V32, P709, DOI 10.1016/j.leukres.2007.09.005
   Muller CI, 2007, LEUKEMIA RES, V31, P27, DOI 10.1016/j.leukres.2006.04.011
   Nawroth R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027509
   Nijimeijer BA, 2009, EXP HEMATOL, V37, P376, DOI 10.1016/j.exphem.2008.11.002
   Ottmann Oliver G, 2005, Hematology Am Soc Hematol Educ Program, P118
   Ottmann Oliver G, 2009, Hematology Am Soc Hematol Educ Program, P371, DOI 10.1182/asheducation-2009.1.371
   Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636
   QUENTMEIER H, 2011, HEMATOL ONCOL, V4, P6, DOI DOI 10.1186/1756-8722-4-6.PUBMED:21299849
   Recher C, 2005, BLOOD, V105, P2527, DOI 10.1128/blood-2004-06-2494
   Ren SY, 2005, MOL CELL BIOL, V25, P8001, DOI 10.1128/MCB.25.18.8001-8008.2005
   Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shortt J, 2013, BLOOD, V121, P2964, DOI 10.1182/blood-2012-08-446096
   Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616
   Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151
   Soverini S, 2011, BLOOD, V118, P1208, DOI 10.1182/blood-2010-12-326405
   Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139
   Tamburini J, 2008, BLOOD, V111, P379, DOI 10.1182/blood-2007-03-080796
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9
   Xing HY, 2012, LEUKEMIA RES, V36, P509, DOI 10.1016/j.leukres.2011.12.018
NR 55
TC 38
Z9 43
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 14
PY 2013
VL 8
IS 11
AR UNSP e80070
DI 10.1371/journal.pone.0080070
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 254DJ
UT WOS:000327143800118
PM 24244612
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Wang, Q
   Wei, F
   Li, CS
   Lv, GY
   Wang, GY
   Liu, TJ
   Bellail, AC
   Hao, CH
AF Wang, Quan
   Wei, Feng
   Li, Chunsheng
   Lv, Guoyue
   Wang, Guangyi
   Liu, Tongjun
   Bellail, Anita C.
   Hao, Chunhai
TI Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2
   Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
SO PLOS ONE
LA English
DT Article
ID ADVANCED SOLID TUMORS; MAMMALIAN TARGET; PHASE-II; MOTIF
   PHOSPHORYLATION; SIGNALING PATHWAYS; INDUCED APOPTOSIS; BINDING PARTNER;
   CANCER-THERAPY; CELL-GROWTH; ACTIVATION
AB Mammalian target of rapamycin complex 1 and 2 (mTORC1/2) are overactive in colorectal carcinomas; however, the first generation of mTOR inhibitors such as rapamycin have failed to show clinical benefits in treating colorectal carcinoma in part due to their effects only on mTORC1. The second generation of mTOR inhibitors such as PP242 targets mTOR kinase; thus, they are capable of inhibiting both mTORC1 and mTORC2. To examine the therapeutic potential of the mTOR kinase inhibitors, we treated a panel of colorectal carcinoma cell lines with PP242. Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment. Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)). The parallel increase of AKT(S473) and EGFR(T1068) in the cells following PP242 treatment raised the possibility that EGFR phosphorylation might contribute to the PP242 incomplete inhibition of mTORC2. To test this notion, we showed that the combination of PP242 with erlotinib, an EGFR small molecule inhibitor, blocked both mTORC1 and mTORC2 kinase activity. In addition, we showed that the combination treatment inhibited colony formation, blocked cell growth and induced apoptotic cell death. A systemic administration of PP242 and erlotinib resulted in the progression suppression of colorectal carcinoma xenografts in mice. This study suggests that the combination of mTOR kinase and EGFR inhibitors may provide an effective treatment of colorectal carcinoma.
C1 [Wang, Quan] Jilin Univ, Dept Gastrointestinal Surg, Hosp 1, Changchun 130023, Jilin, Peoples R China.
   [Wei, Feng; Lv, Guoyue; Wang, Guangyi] Jilin Univ, Dept Hepatopancreatobiliary Surg, Hosp 1, Changchun 130023, Jilin, Peoples R China.
   [Li, Chunsheng; Liu, Tongjun] Jilin Univ, Dept Colorectal Surg, Hosp 3, Changchun 130023, Jilin, Peoples R China.
   [Bellail, Anita C.; Hao, Chunhai] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
RP Wang, Q (reprint author), Jilin Univ, Dept Gastrointestinal Surg, Hosp 1, Changchun 130023, Jilin, Peoples R China.
EM wangquan-jlcc@hotmail.com; chao@emory.edu
FU National Institutes of Health [CA129687]
FX This work was supported in part by the National Institutes of Health
   grant CA129687 (CH). No additional external funding received for this
   study. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Altomare I, 2013, EXPERT OPIN PHARMACO, V14, P505, DOI 10.1517/14656566.2013.770473
   Bajetta E, 2009, CANCER CHEMOTH PHARM, V64, P67, DOI 10.1007/s00280-008-0852-1
   Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172
   Blaser B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-86
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Don ASA, 2011, REV RECENT CLIN TRIA, V6, P24, DOI 10.2174/157488711793980147
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Foster DA, 2009, CELL CYCLE, V8, P1026, DOI 10.4161/cc.8.7.8044
   Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Hezel AF, 2007, EXPERT OPIN INV DRUG, V16, P867, DOI 10.1517/13543784.16.6.867
   Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626
   Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091
   Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353
   Kozuch P, 2009, CLIN COLORECTAL CANC, V8, P38, DOI 10.3816/CCC.2009.n.006
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Li B, 2012, ONCOL REP, V28, P15, DOI 10.3892/or.2012.1786
   Li HY, 2012, BREAST CANCER RES TR, V134, P1057, DOI 10.1007/s10549-012-2036-2
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Meyerhardt JA, 2007, ANN ONCOL, V18, P1185, DOI 10.1093/annonc/mdm124
   Meyerhardt JA, 2006, J CLIN ONCOL, V24, P1892, DOI 10.1200/JCO.2005.05.3728
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   O'Donnell A, 2008, J CLIN ONCOL, V26, P1588, DOI 10.1200/JCO.2007.14.0988
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026
   She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Soares HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057289
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Thimmaiah KN, 2003, CANCER RES, V63, P364
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Townsley CA, 2006, BRIT J CANCER, V94, P1136, DOI 10.1038/sj.bjc.6603055
   Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006
   Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522
   Wei F, 2012, CANCER LETT, V322, P58, DOI 10.1016/j.canlet.2012.02.005
   Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484
   Zeng ZH, 2012, BLOOD, V120, P2679, DOI 10.1182/blood-2011-11-393934
   Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9
   Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096
   Zhou HY, 2010, ANTI-CANCER AGENT ME, V10, P571, DOI 10.2174/187152010793498663
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 69
TC 9
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2013
VL 8
IS 8
AR e73175
DI 10.1371/journal.pone.0073175
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 218ZA
UT WOS:000324470700058
PM 23991179
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Huang, CCY
   Ko, ML
   Ko, GYP
AF Huang, Cathy Chia-Yu
   Ko, Michael Lee
   Ko, Gladys Yi-Ping
TI A New Functional Role for Mechanistic/Mammalian Target of Rapamycin
   Complex 1 (mTORC1) in the Circadian Regulation of L-Type Voltage-Gated
   Calcium Channels in Avian Cone Photoreceptors
SO PLOS ONE
LA English
DT Article
ID CALCINEURIN PHOSPHATASE-ACTIVITY; PEPTIDYL-PROLYL ISOMERASE; MAMMALIAN
   TARGET; CYCLOSPORINE-A; MESSENGER-RNA; IMMUNOSUPPRESSANT FK506;
   RETINOMOTOR MOVEMENTS; ROD PHOTORECEPTORS; SIGNALING PATHWAY; AXON
   REGENERATION
AB In the retina, the L-type voltage-gated calcium channels (L-VGCCs) are responsible for neurotransmitter release from photoreceptors and are under circadian regulation. Both the current densities and protein expression of L-VGCCs are significantly higher at night than during the day. However, the underlying mechanisms of circadian regulation of L-VGCCs in the retina are not completely understood. In this study, we demonstrated that the mechanistic/mammalian target of rapamycin complex (mTORC) signaling pathway participated in the circadian phase-dependent modulation of L-VGCCs. The activities of the mTOR cascade, from mTORC1 to its downstream targets, displayed circadian oscillations throughout the course of a day. Disruption of mTORC1 signaling dampened the L-VGCC current densities, as well as the protein expression of L-VGCCs at night. The decrease of L-VGCCs at night by mTORC1 inhibition was in part due to a reduction of L-VGCC alpha 1 subunit translocation from the cytosol to the plasma membrane. Finally, we showed that mTORC1 was downstream of the phosphatidylionositol 3 kinase-protein kinase B (PI3K-AKT) signaling pathway. Taken together, mTORC1 signaling played a role in the circadian regulation of L-VGCCs, in part through regulation of ion channel trafficking and translocation, which brings to light a new functional role for mTORC1: the modulation of ion channel activities.
C1 [Huang, Cathy Chia-Yu; Ko, Michael Lee; Ko, Gladys Yi-Ping] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Integrat Biosci, College Stn, TX USA.
RP Ko, GYP (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Integrat Biosci, College Stn, TX USA.
EM gko@cvm.tamu.edu
FU National Eye Institute [NIHR01EY017452]
FX This work was supported by NIHR01EY017452 (National Eye Institute) to
   G.K. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751
   ADLER R, 1984, J CELL BIOL, V99, P1173, DOI 10.1083/jcb.99.3.1173
   Adly MA, 1999, INVEST OPHTH VIS SCI, V40, P2165
   Ballou Lisa M, 2008, J Chem Biol, V1, P27, DOI 10.1007/s12154-008-0003-5
   Barnes S, 2002, ADV EXP MED BIOL, V514, P465
   BeleckyAdams T, 1996, DEV BIOL, V178, P304, DOI 10.1006/dbio.1996.0220
   Besharse JC, 2003, ADV EXP MED BIOL, V533, P157
   BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Burnside B, 2001, Prog Brain Res, V131, P477
   CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y
   Cao R, 2011, NEUROSCIENCE, V181, P79, DOI 10.1016/j.neuroscience.2011.03.005
   Cao RF, 2008, MOL CELL NEUROSCI, V38, P312, DOI 10.1016/j.mcn.2008.03.005
   Cao RF, 2010, J NEUROSCI, V30, P6302, DOI 10.1523/JNEUROSCI.5482-09.2010
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200
   CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56
   DUMONT FJ, 1990, J IMMUNOL, V144, P251
   Fain GL, 2001, PHYSIOL REV, V81, P117
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485
   FINDLAY JA, 1980, CAN J CHEM, V58, P579, DOI 10.1139/v80-090
   Firth SI, 2001, CLIN EXP OPHTHALMOL, V29, P183, DOI 10.1046/j.1442-9071.2001.00401.x
   Fox TE, 2012, INVEST OPHTH VIS SCI, V53, P7257, DOI 10.1167/iovs.11-7626
   FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686
   Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106
   Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004
   Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847
   Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422
   GLEASON E, 1992, VISUAL NEUROSCI, V8, P315, DOI 10.1017/S0952523800005058
   Green CB, 2004, J BIOL RHYTHM, V19, P91, DOI 10.1177/0748730404263002
   Haque R, 2002, NEUROREPORT, V13, P2247, DOI 10.1097/01.wnr.0000044218.09266.c9
   HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200
   Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200
   Huang CCY, 2012, J CELL BIOCHEM, V113, P911, DOI 10.1002/jcb.23419
   Hull C, 2006, J NEUROPHYSIOL, V96, P2025, DOI 10.1152/jn.00364.2006
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Johnson JE, 2007, MOL VIS, V13, P887
   Karaganis SP, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-206
   Kersten FFJ, 2010, INVEST OPHTH VIS SCI, V51, P2338, DOI 10.1167/iovs.09-4650
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   Ko GYP, 2004, J NEUROSCI, V24, P1296, DOI 10.1523/JNEUROSCI.3560-03.2004
   Ko GYP, 2003, J NEUROSCI, V23, P3145
   Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7
   Ko ML, 2007, J NEUROCHEM, V103, P784, DOI 10.1111/j.1471-4159.2007.04816.x
   Ko ML, 2009, J NEUROCHEM, V108, P1607, DOI 10.1111/j.1471-4159.2009.05931.x
   KORENBROT JI, 1989, NATURE, V337, P454, DOI 10.1038/337454a0
   KORENBROT JI, 1995, CELL CALCIUM, V18, P285, DOI 10.1016/0143-4160(95)90025-X
   Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73
   Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj
   la Fleur SE, 2001, DIABETES, V50, P1237, DOI 10.2337/diabetes.50.6.1237
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   LAVAIL MM, 1980, INVEST OPHTH VIS SCI, V19, P407
   Leibinger M, 2012, NEUROBIOL DIS, V46, P314, DOI 10.1016/j.nbd.2012.01.004
   Lhuillier L, 2002, J NEUROPHYSIOL, V88, P954, DOI 10.1152/jn.00976.2001
   LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H
   LIU XY, 2012, PLOS ONE, V134, DOI DOI 10.1371/J0URNAL.P0NE.0050602.PUBMED:23189207
   Menger GJ, 2005, VISUAL NEUROSCI, V22, P203, DOI 10.1017/S0952523805222083
   MOORE RY, 1983, FED PROC, V42, P2783
   Morgans CW, 1999, EUR J NEUROSCI, V11, P2989, DOI 10.1046/j.1460-9568.1999.00719.x
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Nozue K, 2007, NATURE, V448, P358, DOI 10.1038/nature05946
   Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566
   Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416
   PIERCE ME, 1993, NEURON, V10, P579, DOI 10.1016/0896-6273(93)90161-J
   PIERCE ME, 1985, J GEN PHYSIOL, V86, P671, DOI 10.1085/jgp.86.5.671
   Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889
   Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200
   Ribelayga C, 2008, NEURON, V59, P790, DOI 10.1016/j.neuron.2008.07.017
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4
   Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772
   Shi L, 2009, J BIOL CHEM, V284, P3966, DOI 10.1074/jbc.M806333200
   SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0
   Sterling P, 2005, TRENDS NEUROSCI, V28, P20, DOI 10.1016/j.tins.2004.11.009
   TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050
   Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300
   Wei T, 2012, J NEUROSCI, V32, P6981, DOI 10.1523/JNEUROSCI.6432-11.2012
   Wu XH, 2004, J BIOL CHEM, V279, P9167, DOI 10.1074/jbc.M312397200
   Yu DY, 2006, IUBMB LIFE, V58, P429, DOI 10.1080/15216540600791555
   Zheng XZ, 2010, CURR BIOL, V20, P1203, DOI 10.1016/j.cub.2010.05.027
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 90
TC 8
Z9 8
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2013
VL 8
IS 8
AR UNSP e73315
DI 10.1371/journal.pone.0073315
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 205ER
UT WOS:000323425700195
PM 23977383
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Fei, SJ
   Zhang, XC
   Dong, S
   Cheng, H
   Zhang, YF
   Huang, L
   Zhou, HY
   Xie, Z
   Chen, ZH
   Wu, YL
AF Fei, Shi-Jiang
   Zhang, Xu-Chao
   Dong, Song
   Cheng, Hua
   Zhang, Yi-Fang
   Huang, Ling
   Zhou, Hai-Yu
   Xie, Zhi
   Chen, Zhi-Hong
   Wu, Yi-Long
TI Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine
   Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
SO PLOS ONE
LA English
DT Article
ID PROSPECTIVE PHASE-II; MET AMPLIFICATION; COLORIMETRIC ASSAY; MAMMALIAN
   TARGET; RAPAMYCIN MTOR; EGFR MUTANTS; GEFITINIB; MUTATIONS; AKT; RICTOR
AB Aims: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown dramatic clinical benefits in advanced non-small cell lung cancer (NSCLC); however, resistance remains a serious problem in clinical practice. The present study analyzed mTOR-associated signaling-pathway differences between the EGFR TKI-sensitive and -resistant NSCLC cell lines and investigated the feasibility of targeting mTOR with specific mTOR inhibitor in EGFR TKI resistant NSCLC cells.
   Methods: We selected four different types of EGFR TKI-sensitive and -resistant NSCLC cells: PC9, PC9GR, H1650 and H1975 cells as models to detect mTOR-associated signaling-pathway differences by western blot and Immunoprecipitation and evaluated the antiproliferative effect and cell cycle arrest of ku-0063794 by MTT method and flow cytometry.
   Results: In the present study, we observed that mTORC2-associated Akt ser473-FOXO1 signaling pathway in a basal state was highly activated in resistant cells. In vitro mTORC1 and mTORC2 kinase activities assays showed that EGFR TKI-resistant NSCLC cell lines had higher mTORC2 kinase activity, whereas sensitive cells had higher mTORC1 kinase activity in the basal state. The ATP-competitive mTOR inhibitor ku-0063794 showed dramatic antiproliferative effects and G1-cell cycle arrest in both sensitive and resistant cells. Ku-0063794 at the IC50 concentration effectively inhibited both mTOR and p70S6K phosphorylation levels; the latter is an mTORC1 substrate and did not upregulate Akt ser473 phosphorylation which would be induced by rapamycin and resulted in partial inhibition of FOXO1 phosphorylation. We also observed that EGFR TKI-sensitive and -resistant clinical NSCLC tumor specimens had higher total and phosphorylated p70S6K expression levels.
   Conclusion: Our results indicate mTORC2-associated signaling-pathway was hyperactivated in EGFR TKI-resistant cells and targeting mTOR with specific mTOR inhibitors is likely a good strategy for patients with EGFR mutant NSCLC who develop EGFR TKI resistance; the potential specific roles of mTORC2 in EGFR TKI-resistant NSCLC cells were still unknown and should be further investigated.
C1 [Fei, Shi-Jiang; Zhang, Xu-Chao; Dong, Song; Zhang, Yi-Fang; Huang, Ling; Zhou, Hai-Yu; Xie, Zhi; Chen, Zhi-Hong; Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Med Res Ctr, Guangzhou, Guangdong, Peoples R China.
   [Fei, Shi-Jiang; Zhang, Xu-Chao; Dong, Song; Zhang, Yi-Fang; Huang, Ling; Zhou, Hai-Yu; Xie, Zhi; Chen, Zhi-Hong; Wu, Yi-Long] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China.
   [Fei, Shi-Jiang] Southern Med Univ, Grad Sch, Guangzhou, Guangdong, Peoples R China.
   [Cheng, Hua] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Guangdong, Peoples R China.
RP Wu, YL (reprint author), Guangdong Gen Hosp, Guangdong Lung Canc Inst, Med Res Ctr, Guangzhou, Guangdong, Peoples R China.
EM syylwu@live.cn
RI Wu, Yi-Long/C-3396-2008
OI Wu, Yi-Long/0000-0002-3611-0258
FU National Natural Science Foundation of China [30772531, 81071699];
   Guangdong social development of science and technology plan projects
   [2011A030400010]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (No. 30772531 and No. 81071699, www.nsfc.gov.cn),
   Guangdong social development of science and technology plan projects
   (No: 2011A030400010, www.gdstc.gov.cn/). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdelnour-Berchtold E, 2010, ANTICANCER RES, V30, P799
   Araujo A, 2007, ONCOLOGIST, V12, P201, DOI 10.1634/theoncologist.12-2-201
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Breuleux M, 2009, MOL CANCER THER, V8, P742, DOI 10.1158/1535-7163.MCT-08-0668
   Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159
   Cheng H, 2011, CANCER CHEMOTH PHARM, V67, P637, DOI 10.1007/s00280-010-1347-4
   Choi SH, 2007, ONCOGENE, V26, P1567, DOI 10.1038/sj.onc.1209957
   Choo AY, 2009, CELL CYCLE, V8, P567, DOI 10.4161/cc.8.4.7659
   Costa DB, 2007, LUNG CANCER, V58, P95, DOI 10.1016/j.lungcan.2007.05.017
   Dong S, 2012, CANCER CHEMOTH PHARM, V70, P707, DOI 10.1007/s00280-012-1946-3
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Ghobrial IM, 2010, CLIN CANCER RES, V16, P1033, DOI 10.1158/1078-0432.CCR-09-1837
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119
   Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jeong EH, 2012, TUBERC RESPIR DIS, V72, P343, DOI 10.4046/trd.2012.72.4.343
   Kimura H, 2006, CANCER SCI, V97, P642, DOI 10.1111/j.1349-7006.2006.00216.x
   La Monica S, 2009, BIOCHEM PHARMACOL, V78, P460, DOI 10.1016/j.bcp.2009.04.033
   Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pines G, 2010, FEBS LETT, V584, P2699, DOI 10.1016/j.febslet.2010.04.019
   Riely GJ, 2008, J THORAC ONCOL, V3, pS146, DOI 10.1097/JTO.0b013e318174e96e
   Roulin D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-57
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shih JY, 2005, NEW ENGL J MED, V353, P207, DOI 10.1056/NEJM200507143530217
   Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503
   Soria JC, 2009, ANN ONCOL, V20, P1674, DOI 10.1093/annonc/mdp060
   Tamura K, 2008, BRIT J CANCER, V98, P907, DOI 10.1038/sj.bjc.6604249
   Taylor CR, 2006, APPL IMMUNOHISTO M M, V14, P253, DOI 10.1097/00129039-200609000-00001
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yamada T, 2010, CLIN CANCER RES, V16, P174, DOI 10.1158/1078-0432.CCR-09-1204
   Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043
   Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105
NR 48
TC 26
Z9 27
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2013
VL 8
IS 7
AR e69104
DI 10.1371/journal.pone.0069104
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 186SF
UT WOS:000322064300086
PM 23874880
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Hosseini, A
   Espona-Fiedler, M
   Soto-Cerrato, V
   Quesada, R
   Perez-Tomas, R
   Guallar, V
AF Hosseini, Ali
   Espona-Fiedler, Margarita
   Soto-Cerrato, Vanessa
   Quesada, Roberto
   Perez-Tomas, Ricardo
   Guallar, Victor
TI Molecular Interactions of Prodiginines with the BH3 Domain of
   Anti-Apoptotic Bcl-2 Family Members
SO PLOS ONE
LA English
DT Article
ID CARCINOMA CELL-LINES; BREAST-CANCER CELLS; BH3-ONLY LIGANDS;
   MELANOMA-CELLS; MCL-1; OBATOCLAX; PRODIGIOSIN; PROTEINS; INHIBITORS;
   GX15-070
AB Prodigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question. Combining experimental and computational techniques we find that prodigiosin binds to the BH3 domain in some BCL-2 protein families, which play an important role in the apoptotic programmed cell death. In particular, our results indicate a large affinity of prodigiosin for MCL-1, an anti-apoptotic member of the BCL-2 family. In melanoma cells, we demonstrate that prodigiosin activates the mitochondrial apoptotic pathway by disrupting MCL-1/BAK complexes. Computer simulations with the PELE software allow the description of the induced fit process, obtaining a detailed atomic view of the molecular interactions. These results provide new data to understand the mechanism of action of these molecules, and assist in the development of more specific inhibitors of anti-apoptotic BCL-2 proteins.
C1 [Hosseini, Ali; Guallar, Victor] Joint BSC IRB Res Program Computat Biol, Barcelona, Spain.
   [Espona-Fiedler, Margarita; Soto-Cerrato, Vanessa; Perez-Tomas, Ricardo] Univ Barcelona, Canc Cell Biol Res Grp, Dept Pathol & Expt Therapeut, Barcelona, Spain.
   [Quesada, Roberto] Univ Burgos, Dept Chem, Burgos, Spain.
   [Guallar, Victor] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
RP Guallar, V (reprint author), Joint BSC IRB Res Program Computat Biol, Barcelona, Spain.
EM victor.guallar@bsc.es
RI Quesada, Roberto/C-6965-2008; Guallar, Victor/B-1579-2013
OI Quesada, Roberto/0000-0003-2764-7157; Guallar,
   Victor/0000-0002-4580-1114; Soto-Cerrato, Vanessa/0000-0001-5835-3595;
   Perez-Tomas, Ricardo/0000-0003-3226-1240
FU Spanish government; European Union [FIS-PI10/00338]; ERC-2009-Adg
   25027-PELE European project; ICREA
FX This work was supported by a research grant from the Spanish government
   and the European Union (FIS-PI10/00338) and from the ERC-2009-Adg
   25027-PELE European project. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Acoca S, 2011, PROTEINS, V79, P2624, DOI 10.1002/prot.23083
   [Anonymous], 2011, PROT PREP WIZ EP VER
   [Anonymous], 2010, GLID
   [Anonymous], 2011, SITEMAP
   Bernardo PH, 2010, J MED CHEM, V53, P2314, DOI 10.1021/jm901469p
   Boersma MD, 2011, J AM CHEM SOC, V134, P315
   Borrelli KW, 2010, J COMPUT CHEM, V31, P1224, DOI 10.1002/jcc.21409
   Borrelli KW, 2005, J CHEM THEORY COMPUT, V1, P1304, DOI 10.1021/ct0501811
   Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Chonghaile TN, 2008, ONCOGENE, V27, pS149, DOI 10.1038/onc.2009.52
   Cossins BP, 2012, J CHEM THEORY COMPUT, V8, P959, DOI 10.1021/ct200675g
   Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104
   Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200
   Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87
   Espona-Fiedler M, 2012, BIOCHEM PHARMACOL, V83, P489, DOI 10.1016/j.bcp.2011.11.027
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208
   Grenu B. D. D., 2011, CHEM-EUR J, V17, P14074
   Ho TF, 2009, TOXICOL APPL PHARM, V235, P253, DOI 10.1016/j.taap.2008.12.009
   Hsieh HY, 2012, BRIT J PHARMACOL, V166, P2095, DOI 10.1111/j.1476-5381.2012.01921.x
   Kazi A, 2011, J BIOL CHEM, V286, P9382, DOI 10.1074/jbc.M110.203638
   Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919
   Ku B, 2011, CELL RES, V21, P627, DOI 10.1038/cr.2010.149
   Lee EF, 2007, CELL DEATH DIFFER, V14, P1711, DOI 10.1038/sj.cdd.4402178
   Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3
   Lu CH, 2012, TOXICOL LETT, V212, P83, DOI 10.1016/j.toxlet.2012.05.002
   Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309
   Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Parikh SA, 2010, CL LYMPH MYELOM LEUK, V10, P285, DOI 10.3816/CLML.2010.n.059
   Perez-Tomas R, 2010, CURR MED CHEM, V17, P2222, DOI 10.2174/092986710791331103
   Rahmani M, 2012, BLOOD, V119, P6089, DOI 10.1182/blood-2011-09-378141
   Smits C, 2008, STRUCTURE, V16, P818, DOI 10.1016/j.str.2008.02.009
   Soto-Cerrato V, 2004, BIOCHEM PHARMACOL, V68, P1345, DOI 10.1016/j.bcp.2004.05.056
   Soto-Cerrato V, 2007, MOL CANCER THER, V6, P362, DOI 10.1158/1535-7163.MCT-06-0266
   Trudel S, 2007, BLOOD, V109, P5430, DOI 10.1182/blood-2006-10-047951
   van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027
   Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937
NR 44
TC 26
Z9 26
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2013
VL 8
IS 2
AR e57562
DI 10.1371/journal.pone.0057562
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098BN
UT WOS:000315519000129
PM 23460874
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Soares, HP
   Ni, Y
   Kisfalvi, K
   Sinnett-Smith, J
   Rozengurt, E
AF Soares, Heloisa P.
   Ni, Yang
   Kisfalvi, Krisztina
   Sinnett-Smith, James
   Rozengurt, Enrique
TI Different Patterns of Akt and ERK Feedback Activation in Response to
   Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic
   Cancer Cells
SO PLOS ONE
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; COMPETITIVE MAMMALIAN TARGET;
   INSULIN-RECEPTOR; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PATHWAY ACTIVATION;
   SIGNALING SYSTEMS; DIABETIC-PATIENTS; KINASE; RISK
AB The mTOR pathway is aberrantly stimulated in many cancer cells, including pancreatic ductal adenocarcinoma (PDAC), and thus it is a potential target for therapy. However, the mTORC1/S6K axis also mediates negative feedback loops that attenuate signaling via insulin/IGF receptor and other tyrosine kinase receptors. Suppression of these feed-back loops unleashes over-activation of upstream pathways that potentially counterbalance the antiproliferative effects of mTOR inhibitors. Here, we demonstrate that treatment of PANC-1 or MiaPaCa-2 pancreatic cancer cells with either rapamycin or active-site mTOR inhibitors suppressed S6K and S6 phosphorylation induced by insulin and the GPCR agonist neurotensin. Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site. Conversely, active-site inhibitors of mTOR cause a marked increase in ERK activation whereas rapamycin did not have any stimulatory effect on ERK activation. The results imply that first and second generation of mTOR inhibitors promote over-activation of different pro-oncogenic pathways in PDAC cells, suggesting that suppression of feed-back loops should be a major consideration in the use of these inhibitors for PDAC therapy. In contrast, metformin abolished mTORC1 activation without over-stimulating Akt phosphorylation on Ser(473) and prevented mitogen-stimulated ERK activation in PDAC cells. Metformin induced a more pronounced inhibition of proliferation than either KU63794 or rapamycin while, the active-site mTOR inhibitor was more effective than rapamycin. Thus, the effects of metformin on Akt and ERK activation are strikingly different from allosteric or active-site mTOR inhibitors in PDAC cells, though all these agents potently inhibited the mTORC1/S6K axis.
C1 [Soares, Heloisa P.; Ni, Yang; Kisfalvi, Krisztina; Sinnett-Smith, James; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr,Div Digest Dis, Los Angeles, CA 90095 USA.
   [Soares, Heloisa P.; Ni, Yang; Kisfalvi, Krisztina; Sinnett-Smith, James; Rozengurt, Enrique] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
   [Soares, Heloisa P.] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
   [Ni, Yang] Shandong Univ, Prov Hosp, Dept Thorac Surg, Jinan, Shandong, Peoples R China.
RP Rozengurt, E (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr,Div Digest Dis, Los Angeles, CA 90095 USA.
EM erozengurt@mednet.ucla.edu
FU National Institutes of Health [P30DK41301, P01CA163200, R01DK55003];
   Department of Veterans Affair Grant [1I01BX001473]; Ronald S. Hirshberg
   Chair of Pancreatic Cancer Research
FX This study was supported by National Institutes of Health Grants
   P30DK41301, P01CA163200 and R01DK55003, Department of Veterans Affair
   Grant 1I01BX001473 and funds from the endowed Ronald S. Hirshberg Chair
   of Pancreatic Cancer Research all to ER. (http://www.nih.gov/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arslan AA, 2010, ARCH INTERN MED, V170, P791, DOI 10.1001/archinternmed.2010.63
   Asano T, 2005, CANCER RES, V65, P9164, DOI 10.1158/0008-5472.CAN-05-0779
   Asano T, 2005, BIOCHEM BIOPH RES CO, V331, P295, DOI 10.1016/j.bbrc.2005.03.166
   Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Chong CR, 2009, ONCOLOGIST, V14, P1178, DOI 10.1634/theoncologist.2009-0286
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   Dong XQ, 2010, GASTROENTEROLOGY, V139, P464, DOI 10.1053/j.gastro.2010.04.042
   Easton JB, 2006, CANCER CELL, V9, P153, DOI 10.1016/j.ccr.2006.02.027
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Guha S, 2003, CANCER RES, V63, P2379
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304
   Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069
   Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jamieson S, 2011, BIOCHEM J, V438, P53, DOI 10.1042/BJ20110502
   Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368
   Kisfalvi K, 2005, J CELL PHYSIOL, V202, P880, DOI 10.1002/jcp.20187
   Kisfalvi K, 2007, ENDOCRINOLOGY, V148, P3246, DOI 10.1210/en.2006-1711
   Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418
   Kolb S, 2007, CANCER RES, V67, P4679, DOI 10.1158/0008-5472.CAN-06-3308
   Kornmann M, 1998, CANCER RES, V58, P4250
   Kwon J, 2009, CANCER RES, V69, P1350, DOI 10.1158/0008-5472.CAN-08-1328
   Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380
   Lane HA, 2009, CURR OPIN CELL BIOL, V21, P219, DOI 10.1016/j.ceb.2009.01.016
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20
   Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485
   Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Ning JY, 2010, MOL ENDOCRINOL, V24, P1218, DOI 10.1210/me.2009-0474
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pham NA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-43
   Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229
   Ryder NM, 2001, J CELL PHYSIOL, V186, P53, DOI 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q
   Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Sinnett-Smith J, 2012, BIOCH BIOPH IN PRESS
   Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006
   Tzatsos A, 2007, J BIOL CHEM, V282, P18069, DOI 10.1074/jbc.M610101200
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866
   Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031
   Young SH, 2010, BIOCHEM BIOPH RES CO, V401, P154, DOI 10.1016/j.bbrc.2010.09.036
   Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299
   Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484
   Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 73
TC 78
Z9 80
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2013
VL 8
IS 2
AR e57289
DI 10.1371/journal.pone.0057289
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IT
UT WOS:000315186000095
PM 23437362
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Salinari, S
   Debard, C
   Bertuzzi, A
   Durand, C
   Zimmet, P
   Vidal, H
   Mingrone, G
AF Salinari, Serenella
   Debard, Cyrille
   Bertuzzi, Alessandro
   Durand, Christine
   Zimmet, Paul
   Vidal, Hubert
   Mingrone, Geltrude
TI Jejunal Proteins Secreted by db/db Mice or Insulin-Resistant Humans
   Impair the Insulin Signaling and Determine Insulin Resistance
SO PLOS ONE
LA English
DT Article
ID GLYCOGEN-SYNTHASE KINASE-3; SKELETAL-MUSCLE CELLS; BARIATRIC SURGERY;
   RECEPTOR SUBSTRATE-1; GLUCOSE-TRANSPORT; MEDICAL THERAPY;
   BYPASS-SURGERY; OBESE-PATIENTS; PHOSPHORYLATION; MTOR
AB Background: Two recent studies demonstrated that bariatric surgery induced remission of type 2 diabetes very soon after surgery and far too early to be attributed to weight loss. In this study, we sought to explore the mechanism/s of this phenomenon by testing the effects of proteins from the duodenum-jejunum conditioned-medium (CM) of db/db or Swiss mice on glucose uptake in vivo in Swiss mice and in vitro in both Swiss mice soleus and L6 cells. We studied the effect of sera and CM proteins from insulin resistant (IR) and insulin-sensitive subjects on insulin signaling in human myoblasts.
   Methodology/Principal Findings: db/db proteins induced massive IR either in vivo or in vitro, while Swiss proteins did not. In L6 cells, only db/db proteins produced a noticeable increase in basal (473)Ser-Akt phosphorylation, lack of GSK3 beta inhibition and a reduced basal (389)Thr-p70-S6K1 phosphorylation. Human IR serum markedly increased basal (473)Ser-Akt phosphorylation in a dose-dependent manner. Human CM IR proteins increased by about twofold both basal and insulin-stimulated (473)Ser-Akt. Basal (9)Ser-GSK3 beta phosphorylation was increased by IR subjects serum with a smaller potentiating effect of insulin.
   Conclusions: These findings show that jejunal proteins either from db/db mice or from insulin resistant subjects impair muscle insulin signaling, thus inducing insulin resistance.
C1 [Salinari, Serenella] Univ Roma La Sapienza, Dept Comp & Syst Sci, Rome, Italy.
   [Debard, Cyrille; Durand, Christine; Vidal, Hubert] Univ Lyon 1, CarMeN Lab, INSERM, U1060, Oullins, France.
   [Bertuzzi, Alessandro] CNR, Inst Syst Anal & Comp Sci, Rome, Italy.
   [Zimmet, Paul] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia.
   [Mingrone, Geltrude] Univ Cattolica Sacro Cuore, Dept Internal Med, Sch Med, Rome, Italy.
RP Mingrone, G (reprint author), Univ Cattolica Sacro Cuore, Dept Internal Med, Sch Med, Rome, Italy.
EM gmingrone@rm.unicatt.it
RI Zimmet, Paul/H-7635-2013; Zimmet, Paul/O-8486-2019; Vidal,
   Hubert/M-6674-2017
OI Zimmet, Paul/0000-0003-0627-0776; Vidal, Hubert/0000-0002-9467-0317;
   BERTUZZI, ALESSANDRO/0000-0003-4969-7366
FU Catholic University
FX Financed by the Catholic University. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9
   BERGMAN RN, 1979, AM J PHYSIOL, V236, pE667
   Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319
   Breen DM, 2012, NAT MED, V18, P950, DOI 10.1038/nm.2745
   Brozinick JT, 2001, DIABETES, V50, P593, DOI 10.2337/diabetes.50.3.593
   Burcelin M, 2002, AM J PHYSIOL-ENDOC M, V282, pE834, DOI 10.1152/ajpendo.00332.2001
   Capristo E, 1998, J INTERN MED, V243, P339
   Ciaraldi TP, 2007, ENDOCRINOLOGY, V148, P4393, DOI 10.1210/en.2006-0932
   Cozzone D, 2008, DIABETOLOGIA, V51, P512, DOI 10.1007/s00125-007-0913-8
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Cybulski N, 2009, TRENDS BIOCHEM SCI, V34, P620, DOI 10.1016/j.tibs.2009.09.004
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   DeFronzo RA, 2004, MED CLIN N AM, V88, P787, DOI 10.1016/j.mcna.2004.04.013
   Dixon JB, 2012, LANCET, V379, P2300, DOI 10.1016/S0140-6736(12)60401-2
   Dokken BB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1188, DOI 10.1152/ajpendo.00547.2004
   Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662
   EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fraenkel M, 2008, DIABETES, V57, P945, DOI 10.2337/db07-0922
   Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001
   Goni-Oliver P, 2007, J BIOL CHEM, V282, P22406, DOI 10.1074/jbc.M702793200
   Guidone C, 2006, DIABETES, V55, P2025, DOI 10.2337/db06-0068
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08
   Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217
   HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127
   Kasuga M, 2006, J CLIN INVEST, V116, P1756, DOI 10.1172/JCI29189
   KODAMA H, 1994, DIABETOLOGIA, V37, P739, DOI 10.1007/s001250050173
   KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615
   Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351
   Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200
   Mari A, 2006, DIABETOLOGIA, V49, P2136, DOI 10.1007/s00125-006-0337-x
   McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633
   Mingrone G, 2012, NEW ENGL J MED, V366, P1577, DOI 10.1056/NEJMoa1200111
   Montori-Grau M, 2007, BIOCHEM J, V405, P107, DOI 10.1042/BJ20061572
   Mora A, 2005, FEBS LETT, V579, P3632, DOI 10.1016/j.febslet.2005.05.040
   Pacini G, 2001, AM J PHYSIOL-ENDOC M, V281, pE693
   Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103
   Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588
   Rubino FA, 2004, ANN SURG, V239, P1, DOI 10.1097/01.sla.0000102989.54824.fc
   Rubino F, 2006, ANN SURG, V244, P741, DOI 10.1097/01.sla.0000224726.61448.1b
   Russell M S, 2006, Drugs R D, V7, P111, DOI 10.2165/00126839-200607020-00005
   Salinari S, 2009, DIABETES CARE, V32, P375, DOI 10.2337/dc08-1314
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Schauer PR, 2012, NEW ENGL J MED, V366, P1567, DOI 10.1056/NEJMoa1200225
   SHEINER LB, 1980, J PHARMACOKINET BIOP, V8, P553, DOI 10.1007/BF01060053
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710
   Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572
   WANG QM, 1994, J BIOL CHEM, V269, P14566
   WENTE SR, 1990, P NATL ACAD SCI USA, V87, P2805, DOI 10.1073/pnas.87.7.2805
NR 50
TC 36
Z9 36
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2013
VL 8
IS 2
AR e56258
DI 10.1371/journal.pone.0056258
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IE
UT WOS:000315184200053
PM 23437106
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Bogani, C
   Bartalucci, N
   Martinelli, S
   Tozzi, L
   Guglielmelli, P
   Bosi, A
   Vannucchi, AM
AF Bogani, Costanza
   Bartalucci, Niccolo
   Martinelli, Serena
   Tozzi, Lorenzo
   Guglielmelli, Paola
   Bosi, Alberto
   Vannucchi, Alessandro M.
CA Associazione Italiana Ric Canc AGI
TI mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors
   Effectively Inhibit Cells of Myeloproliferative Neoplasms
SO PLOS ONE
LA English
DT Article
ID VERA-LIKE DISEASE; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; PRIMARY
   MYELOFIBROSIS; HEMATOPOIETIC STEM; PROGENITOR CELLS; EXPRESSION;
   MUTATION; MICE; DISORDERS
AB Background: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patients with myelofibrosis but meaningful molecular responses were not documented. Accordingly, there remains a need for exploring new treatment strategies of MPN. A potential additional target for treatment is represented by the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway that has been found constitutively activated in MPN cells; proof-of-evidence of efficacy of the mTOR inhibitor RAD001 has been obtained recently in a Phase I/II trial in patients with myelofibrosis. The aim of the study was to characterize the effects in vitro of mTOR inhibitors, used alone and in combination with JAK2 inhibitors, against MPN cells.
   Findings: Mouse and human JAK2V617F mutated cell lines and primary hematopoietic progenitors from MPN patients were challenged with an allosteric (RAD001) and an ATP-competitive (PP242) mTOR inhibitor and two JAK2 inhibitors (AZD1480 and ruxolitinib). mTOR inhibitors effectively reduced proliferation and colony formation of cell lines through a slowed cell division mediated by changes in cell cycle transition to the S-phase. mTOR inhibitors also impaired the proliferation and prevented colony formation from MPN hematopoietic progenitors at doses significantly lower than healthy controls. JAK2 inhibitors produced similar antiproliferative effects in MPN cell lines and primary cells but were more potent inducers of apoptosis, as also supported by differential effects on cyclinD1, PIM1 and BcLxL expression levels. Co-treatment of mTOR inhibitor with JAK2 inhibitor resulted in synergistic activity against the proliferation of JAK2V617F mutated cell lines and significantly reduced erythropoietin-independent colony growth in patients with polycythemia vera.
   Conclusions/Significance: These findings support mTOR inhibitors as novel potential drugs for the treatment of MPN and advocate for clinical trials exploiting the combination of mTOR and JAK2 inhibitor.
C1 [Bogani, Costanza; Bartalucci, Niccolo; Martinelli, Serena; Tozzi, Lorenzo; Guglielmelli, Paola; Bosi, Alberto; Vannucchi, Alessandro M.; Associazione Italiana Ric Canc AGI] Univ Florence, Sect Hematol, Dept Med & Surg Care, Florence, Italy.
RP Vannucchi, AM (reprint author), Univ Florence, Sect Hematol, Dept Med & Surg Care, Florence, Italy.
EM amvannucchi@unifi.it
RI Guglielmelli, Paola/K-7509-2016
OI Guglielmelli, Paola/0000-0003-1809-284X; Tozzi,
   Lorenzo/0000-0002-0679-5030; Bartalucci, Niccolo/0000-0002-9328-3948;
   BOSI, ALBERTO/0000-0002-5486-4838
FU Associazione Italiana per la Ricerca sul Cancro-"AIRC 5 per Mille";
   Ministero Italiano della Universita e della Ricerca (MIUR)
   [FIRB-RBAP11CZLK]
FX This study was supported by a special grant from Associazione Italiana
   per la Ricerca sul Cancro-"AIRC 5 per Mille''- to AGIMM, "AIRC-Gruppo
   Italiano Malattie Mieloproliferative''. Supported by Ministero Italiano
   della Universita e della Ricerca (MIUR), project FIRB-RBAP11CZLK. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akada H, 2010, BLOOD, V115, P3589, DOI 10.1182/blood-2009-04-215848
   Beer PA, 2008, BLOOD, V112, P141, DOI 10.1182/blood-2008-01-131664
   Bumm TGP, 2006, CANCER RES, V66, P11156, DOI 10.1158/0008-5472.CAN-06-2210
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Drayer AL, 2006, STEM CELLS, V24, P105, DOI 10.1634/stemcells.2005-0062
   Dupont S, 2007, BLOOD, V110, P1013, DOI 10.1182/blood-2006-10-054940
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Ghaffari S, 2006, BLOOD, V107, P1888, DOI 10.1182/blood-2005-06-2304
   Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548
   Grimwade LF, 2009, BRIT J HAEMATOL, V147, P495, DOI 10.1111/j.1365-2141.2009.07870.x
   Guglielmelli P, 2011, BLOOD, V118, P2069, DOI 10.1182/blood-2011-01-330563
   Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556
   Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015
   James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546
   Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091
   Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113
   Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030
   Levine RL, 2007, NAT REV CANCER, V7, P673, DOI 10.1038/nrc2210
   Li G, 2010, LEUKEMIA, V24, P1397, DOI 10.1038/leu.2010.131
   Li G, 2009, BLOOD, V114, p3902A
   Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747
   Liu PCC, 2009, CLIN CANCER RES, V15, P6891, DOI 10.1158/1078-0432.CCR-09-1298
   Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063
   Maruani DM, 2012, ONCOGENE
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015
   Nussenzveig RH, 2007, EXP HEMATOL, V35, P32, DOI 10.1016/j.exphem.2006.11.012
   Pardanani A, 2011, LEUKEMIA, V25, P1834, DOI 10.1038/leu.2011.161
   Pardanani AD, 2008, BLOOD, V112, P97
   Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021
   Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270
   PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382
   Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957
   Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202
   Shide K, 2008, LEUKEMIA, V22, P87, DOI 10.1038/sj.leu.2405043
   Tefferi A, 2007, BLOOD, V110, P1092, DOI 10.1182/blood-2007-04-083501
   Tefferi A, 2012, BLOOD, V119, P2721, DOI 10.1182/blood-2011-11-395228
   Tefferi A, 2011, J CLIN ONCOL, V29, P1356, DOI 10.1200/JCO.2010.32.9490
   Tefferi A, 2011, J CLIN ONCOL, V29, P573, DOI 10.1200/JCO.2010.29.8711
   Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748
   Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003
   Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102
   Vannucchi AM, 2008, BLOOD, V112, P844, DOI 10.1182/blood-2008-01-135897
   Vannucchi AM, 2009, CA-CANCER J CLIN, V59, P171, DOI 10.3322/caac.20009
   Vannucchi AM, 2005, AM J PATHOL, V167, P849, DOI 10.1016/S0002-9440(10)62056-1
   VERSTOVSEK S, 2010, BLOOD, V116, P313
   Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557
   Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028
   Wang YC, 2009, BLOOD, V114, P5024, DOI 10.1182/blood-2009-05-222133
   Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824
   Xing S, 2008, BLOOD, V111, P5109, DOI 10.1182/blood-2007-05-091579
   Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018
   Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516
NR 57
TC 41
Z9 44
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 31
PY 2013
VL 8
IS 1
AR e54826
DI 10.1371/journal.pone.0054826
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 085JH
UT WOS:000314610600046
PM 23382981
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Zhang, H
   Berel, D
   Wang, YP
   Li, P
   Bhowmick, NA
   Figlin, RA
   Kim, HL
AF Zhang, Hao
   Berel, Dror
   Wang, Yanping
   Li, Ping
   Bhowmick, Neil A.
   Figlin, Robert A.
   Kim, Hyung L.
TI A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and
   Temsirolimus in Preclinical Renal Cell Carcinoma Models
SO PLOS ONE
LA English
DT Article
ID COMPETITIVE MAMMALIAN TARGET; HYPOXIA-INDUCIBLE FACTORS; RAPAMYCIN MTOR;
   INTERFERON-ALPHA; KINASE INHIBITOR; CANCER; THERAPY; TUMORS; TRIAL;
   EVEROLIMUS
AB Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists in two distinct multiprotein complexes, mTORC1 and mTORC2, and both complexes may be critical regulators of cell metabolism, growth and proliferation. Furthermore, it has been proposed that drug resistance develops due to compensatory activation of mTORC2 signaling during treatment with temsirolimus or everolimus. We evaluated Ku0063794, which is a small molecule that inhibits both mTOR complexes. Ku0063794 was compared to temsirolimus in preclinical models for renal cell carcinoma. Ku0063794 was effective in inhibiting the phosphorylation of signaling proteins downstream of both mTORC1 and mTORC2, including p70 S6K, 4E-BP1 and Akt. Ku0063794 was more effective than temsirolimus in decreasing the viability and growth of RCC cell lines, Caki-1 and 786-O, in vitro by inducing cell cycle arrest and autophagy, but not apoptosis. However, in a xenograft model there was no difference in the inhibition of tumor growth by Ku0063794 or temsirolimus. A potential explanation is that temsirolimus has additional effects on the tumor microenvironment. Consistent with this possibility, temsirolimus, but not Ku0063794, decreased tumor angiogenesis in vivo, and decreased the viability of HUVEC (Human Umbilical Vein Endothelial Cells) cells in vitro at pharmacologically relevant concentrations. Furthermore, expression levels of VEGF and PDGF were lower in Caki-1 and 786-O cells treated with temsirolimus than cells treated with Ku0063794.
C1 [Zhang, Hao; Wang, Yanping; Li, Ping; Kim, Hyung L.] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA.
   [Berel, Dror] Cedars Sinai Med Ctr, Biostat Core, Los Angeles, CA 90048 USA.
   [Bhowmick, Neil A.; Figlin, Robert A.] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90048 USA.
   [Berel, Dror; Kim, Hyung L.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
RP Kim, HL (reprint author), Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA.
EM kimhl@cshs.org
RI Zhang, Hao/L-3197-2015
FU Winnick Family Foundation; AUA foundation/NCI/NIDDK; NIH/NCI
   [K23CA120075]; Kure It Cancer Research Foundation; Lauhlere Family Fund
FX This work was supported by Winnick Family Foundation, AUA
   foundation/NCI/NIDDK, and NIH/NCI grant K23CA120075
   (http://grants.nih.gov/grants/oer.htm), Kure It Cancer Research
   Foundation, and Lauhlere Family Fund. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Creighton CJ, 2007, ONCOGENE, V26, P4648, DOI 10.1038/sj.onc.1210245
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Furge KA, 2010, LANCET ONCOL, V11, P571, DOI 10.1016/S1470-2045(09)70380-8
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Glenn ST, 2007, BIOTECHNIQUES, V43, P639, DOI 10.2144/000112562
   Glenn ST, 2010, J BIOMOL SCREEN, V15, P80, DOI 10.1177/1087057109355059
   Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
   Hidalgo M, 2006, CLIN CANCER RES, V12, P5755, DOI 10.1158/1078-0432.CCR-06-0118
   Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091
   Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083
   Kuhn JG, 2007, CLIN CANCER RES, V13, P7401, DOI 10.1158/1078-0432.CCR-07-0781
   Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47
   Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485
   Liu Qingsong, 2009, Drug Discov Today Ther Strateg, V6, P47
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2
   Mizushima N, 2007, AUTOPHAGY, V3, P542
   Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   Motzer RJ, 2007, J CLIN ONCOL, V25, P3958, DOI 10.1200/JCO.2006.10.5916
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Neufeld TP, 2010, CURR OPIN CELL BIOL, V22, P157, DOI 10.1016/j.ceb.2009.11.005
   Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2
   Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4
   Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139
   Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200
   Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wang Y, 2011, BRIT J CANCER, V104, P643, DOI 10.1038/bjc.2011.15
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 37
TC 15
Z9 15
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2013
VL 8
IS 1
AR e54918
DI 10.1371/journal.pone.0054918
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 077HS
UT WOS:000314019100111
PM 23349989
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Lyabin, DN
   Eliseeva, IA
   Ovchinnikov, LP
AF Lyabin, Dmitry N.
   Eliseeva, Irina A.
   Ovchinnikov, Lev P.
TI YB-1 Synthesis Is Regulated by mTOR Signaling Pathway
SO PLOS ONE
LA English
DT Article
ID Y-BOX PROTEIN-1; TRANSCRIPTION FACTOR YB-1; MESSENGER-RNA; DEPENDENT
   TRANSLATION; GENE-EXPRESSION; CELL GROWTH; IN-VITRO; CANCER; PROMOTES;
   DNA
AB YB-1 is a eukaryotic protein with numerous intra-and extracellular functions based on its ability to interact with RNA, DNA, and many proteins. In spite of achievements in studying its functions, regulation of YB-1 synthesis in the cell remains poorly understood. In the current study Western and Northern blotting were used to determine the amounts of YB-1 and YB-1 mRNA in rabbit organs and several cell lines. As found, in the majority of studied eukaryotic cells a considerable proportion of YB-1 mRNA was stored in free mRNPs, i.e., was poorly translated. Also, we demonstrated that YB-1 synthesis depended on conditions that determined the rate of cell division. Specific suppression of YB-1 synthesis resulted from inhibition of the mTOR signaling pathway with inhibitor PP242, but not rapamycin. Experiments on reporter constructs showed that dependence of YB-1 mRNA translation on activity of the mTOR signaling pathway was dictated by 59 untranslated regions of this mRNA, irrelatively of the TOP-like sequences at the beginning of 5' UTR.
C1 [Lyabin, Dmitry N.; Eliseeva, Irina A.; Ovchinnikov, Lev P.] Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.
RP Ovchinnikov, LP (reprint author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.
EM ovchinn@vega.protres.ru
RI Irina, Eliseeva/J-8175-2015; Ovchinnikov, Lev/L-2397-2015; Lyabin,
   Dmitry/K-3178-2013
FU Russian Academy of Sciences; Russian Foundation for Basic Research
   [11-04-00267, 12-04-31018]
FX This work was supported by Programs on "Molecular and Cellular Biology"
   and "Basic Sciences to Medicine" of the Russian Academy of Sciences and
   Russian Foundation for Basic Research (http://www.rfbr.ru/rffi/ru/),
   (#11-04-00267, #12-04-31018). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005
   Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447
   Basaki Y, 2010, EUR J CANCER, V46, P954, DOI 10.1016/j.ejca.2009.12.024
   Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056
   Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221
   Chansky HA, 2001, CANCER RES, V61, P3586
   Dmitriev SE, 2007, MOL CELL BIOL, V27, P4685, DOI 10.1128/MCB.02138-06
   Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049
   Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491
   Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006
   Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Feng QC, 2009, NEPHRON EXP NEPHROL, V113, pE16, DOI 10.1159/000228079
   Frye BC, 2009, EMBO REP, V10, P783, DOI 10.1038/embor.2009.81
   Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170
   Gens G. P., 2010, Klinicheskaya Laboratornaya Diagnostika, P29
   Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912
   Kato M, 2010, J BIOL CHEM, V285, P34004, DOI 10.1074/jbc.M110.165027
   Knosel T, 2005, NEOPLASIA, V7, P741, DOI 10.1593/neo.05178
   Kuwano M, 2004, MOL CANCER THER, V3, P1485
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Levenson VV, 2000, CANCER RES, V60, P5027
   Lovett DH, 2010, BIOCHEM BIOPH RES CO, V398, P482, DOI 10.1016/j.bbrc.2010.06.104
   Lyabin DN, 2011, RNA BIOL, V8
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Nekrasov MP, 2003, J BIOL CHEM, V278, P13936, DOI 10.1074/jbc.M209145200
   Ohashi S, 2009, MOL CELL BIOCHEM, V327, P267, DOI 10.1007/s11010-009-0065-x
   Ohga T, 1996, CANCER RES, V56, P4224
   Pestryakov P, 2012, J MOL RECOGNIT, V25, P224, DOI 10.1002/jmr.2182
   POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360
   Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200
   Rauen T, 2009, J BIOL CHEM, V284, P26928, DOI 10.1074/jbc.M109.046599
   Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981
   Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334
   Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200
   Skabkina OV, 2005, MOL CELL BIOL, V25, P3317, DOI 10.1128/MCB.25.8.3317-3323.2005
   Skabkina OV, 2003, J BIOL CHEM, V278, P18191, DOI 10.1074/jbc.M209073200
   Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200
   Svitkin YV, 2009, EMBO J, V28, P58, DOI 10.1038/emboj.2008.259
   Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083
   Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200
   Wakiyama M, 1997, BIOCHIMIE, V79, P781, DOI 10.1016/S0300-9084(97)86937-4
   Wu Y, 2012, J SURG ONCOL, V105, P724, DOI 10.1002/jso.23030
   Yokoyama H, 2003, BIOCHEM BIOPH RES CO, V303, P140, DOI 10.1016/S0006-291X(03)00296-1
NR 44
TC 10
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e52527
DI 10.1371/journal.pone.0052527
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500189
PM 23285076
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Nyfeler, B
   Chen, Y
   Li, XY
   Pinzon-Ortiz, M
   Wang, ZC
   Reddy, A
   Pradhan, E
   Das, R
   Lehar, J
   Schlegel, R
   Finan, PM
   Cao, ZA
   Murphy, LO
   Huang, A
AF Nyfeler, Beat
   Chen, Yan
   Li, Xiaoyan
   Pinzon-Ortiz, Maria
   Wang, Zuncai
   Reddy, Anupama
   Pradhan, Elina
   Das, Rita
   Lehar, Joseph
   Schlegel, Robert
   Finan, Peter M.
   Cao, Z. Alexander
   Murphy, Leon O.
   Huang, Alan
TI RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and
   Tumor Growth
SO PLOS ONE
LA English
DT Article
ID MAMMALIAN TARGET; RAPAMYCIN; NVP-BEZ235; PATHWAY
AB The mammalian target of rapamycin (mTOR) is regulated by oncogenic growth factor signals and plays a pivotal role in controlling cellular metabolism, growth and survival. Everolimus (RAD001) is an allosteric mTOR inhibitor that has shown marked efficacy in certain cancers but is unable to completely inhibit mTOR activity. ATP-competitive mTOR inhibitors such as NVP-BEZ235 can block rapamycin-insensitive mTOR readouts and have entered clinical development as anti-cancer agents. Here, we show the degree to which RAD001 and BEZ235 can be synergistically combined to inhibit mTOR pathway activation, cell proliferation and tumor growth, both in vitro and in vivo. RAD001 and BEZ235 synergized in cancer lines representing different lineages and genetic backgrounds. Strong synergy is seen in neuronal, renal, breast, lung, and haematopoietic cancer cells harboring abnormalities in PTEN, VHL, LKB1, Her2, or KRAS. Critically, in the presence of RAD001, the mTOR-4EBP1 pathway and tumorigenesis can be fully inhibited using lower doses of BEZ235. This is relevant since RAD001 is relatively well tolerated in patients while the toxicity profiles of ATP-competitive mTOR inhibitors are currently unknown.
C1 [Nyfeler, Beat; Chen, Yan; Li, Xiaoyan; Pinzon-Ortiz, Maria; Wang, Zuncai; Reddy, Anupama; Pradhan, Elina; Das, Rita; Lehar, Joseph; Schlegel, Robert; Finan, Peter M.; Cao, Z. Alexander; Murphy, Leon O.; Huang, Alan] Novartis Inst BioMed Res, Cambridge, MA USA.
RP Nyfeler, B (reprint author), Novartis Inst BioMed Res, Cambridge, MA USA.
EM alan.huang@novartis.com
OI Wilson, Christopher/0000-0002-9146-522X
CR Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Garcia-Echeverria C, 2011, BIOCHEM SOC T, V39, P451, DOI 10.1042/BST0390451
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017
   Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021
   Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Nyfeler B, 2011, MOL CELL BIOL, V31, P2867, DOI 10.1128/MCB.05430-11
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Vilar E, 2011, MOL CANCER THER, V10, P395, DOI 10.1158/1535-7163.MCT-10-0905
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xu CX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020899
   Yip CK, 2010, MOL CELL, V38, P768, DOI 10.1016/j.molcel.2010.05.017
   Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299
   Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675
   Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008
NR 25
TC 24
Z9 24
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 14
PY 2012
VL 7
IS 11
AR e48548
DI 10.1371/journal.pone.0048548
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038CD
UT WOS:000311151900026
PM 23155392
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Goo, CK
   Lim, HY
   Ho, QS
   Too, HP
   Clement, MV
   Wong, KP
AF Goo, Chong Kiat
   Lim, Hwee Ying
   Ho, Qin Shi
   Too, Heng-Phon
   Clement, Marie-Veronique
   Wong, Kim Ping
TI PTEN/Akt Signaling Controls Mitochondrial Respiratory Capacity through
   4E-BP1
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE-PHOSPHORYLATION; DIRECT INHIBITION; TUMOR-SUPPRESSOR;
   CANCER-CELLS; COMPLEXES I; PROTEIN; AKT; MTOR; ACTIVATION; MECHANISM
AB Akt, a serine/threonine kinase has been shown to stimulate glycolysis in cancer cells but its role in mitochondrial respiration is unknown. Using PTEN-knockout mouse embryonic fibroblasts (MEFPTEN-/-) with hyper-activated Akt as a cell model, we observed a higher respiratory capacity in MEFPTEN-/- compared to the wildtype (MEFWT). The respiratory phenotype observed in MEFPTEN-/- was reproduced in MEFWT by gene silencing of PTEN which substantiated its role in regulating mitochondrial function. The increased activities of the respiratory complexes (RCs) I, III and IV were retained in the same relative proportions as those present in MEFWT, alluding to a possible co-ordinated regulation by PTEN/Akt. Using LY294002 (a PI3K inhibitor) and Akt inhibitor IV, we showed that the regulation of enzyme activities and protein expressions of the RCs was dependent on PI3K/Akt. There was insignificant difference in the protein expressions of mitochondrial transcription factor: peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha) and its downstream targets, the nuclear respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (mtTFA) between MEFPTEN-/- and MEFWT. Similarly, mRNA levels of the same subunits of the RCs detected in Western blots were not significantly different between MEFPTEN-/- and MEFWT suggesting that the regulation by Akt on mitochondrial function was probably not via gene transcription. On the other hand, a decrease of total 4E-BP1 with a higher expression of its phosphorylated form relative to total 4E-BP1 was found in MEFPTEN-/-, which inferred that the regulation of mitochondrial respiratory activities by Akt was in part through this protein translation pathway. Notably, gene silencing of 4E-BP1 up-regulated the protein expressions of all RCs and the action of 4E-BP1 appeared to be specific to these mitochondrial proteins. In conclusion, PTEN inactivation bestowed a bioenergetic advantage to the cells by up-regulating mitochondrial respiratory capacity through the 4E-BP1-mediated protein translation pathway.
C1 [Goo, Chong Kiat; Lim, Hwee Ying; Ho, Qin Shi; Too, Heng-Phon; Clement, Marie-Veronique; Wong, Kim Ping] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore.
   [Clement, Marie-Veronique] NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore.
RP Wong, KP (reprint author), Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore.
EM bchsitkp@nus.edu.sg
FU National University of Singapore [R-183-000-261-112]; Biomedical
   Research Council [09/1/21/19/603]
FX This work was supported by research grants from National University of
   Singapore (R-183-000-261-112 to KPW) and from the Biomedical Research
   Council (09/1/21/19/603 to MVC and KPW). The funders had no role in
   study design, data collection and analysis, decision to publish or
   preparation of the manuscript.
CR Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881
   Augereau O, 2005, CELL MOL LIFE SCI, V62, P1478, DOI 10.1007/s00018-005-5005-7
   BAGGETTO LG, 1992, CANCER RES, V52, P4935
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x
   Cridge AG, 2010, NUCLEIC ACIDS RES, V38, P8039, DOI 10.1093/nar/gkq686
   de Groof AJC, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-54
   Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532
   Dudkina NV, 2011, P NATL ACAD SCI USA, V108, P15196, DOI 10.1073/pnas.1107819108
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104
   Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079
   Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502
   Hobert JA, 2009, GENET MED, V11, P687, DOI 10.1097/GIM.0b013e3181ac9aea
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Koopman WJH, 2010, ANTIOXID REDOX SIGN, V12, P1431, DOI 10.1089/ars.2009.2743
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Lim HW, 2009, BIOCHEM BIOPH RES CO, V389, P187, DOI 10.1016/j.bbrc.2009.08.121
   Lim HY, 2011, MITOCHONDRION, V11, P437, DOI 10.1016/j.mito.2010.12.015
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Ng LE, 2006, BIOCHEM BIOPH RES CO, V348, P494, DOI 10.1016/j.bbrc.2006.07.089
   Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003
   Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602
   Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7
   Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925
   Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100
   Pesta D, 2012, METHODS MOL BIOL, V810, P25, DOI 10.1007/978-1-61779-382-0_3
   Ragan CI, 1987, MITOCHONDRIA PRACTIC, P79
   Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106
   Saint-Georges Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002293
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   SONENBERG N, 1996, TRANSLATIONAL CONTRO, P245
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7
   Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6
   Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006
   Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105
   Zhang X, 2004, J BIOL CHEM, V279, P43035, DOI 10.1074/jbc.M402759200
   Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034
NR 51
TC 37
Z9 41
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2012
VL 7
IS 9
AR e45806
DI 10.1371/journal.pone.0045806
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 016KP
UT WOS:000309517300054
PM 23049865
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Choi, YJ
   Park, YJ
   Park, JY
   Jeong, HO
   Kim, DH
   Ha, YM
   Kim, JM
   Song, YM
   Heo, HS
   Yu, BP
   Chun, P
   Moon, HR
   Chung, HY
AF Choi, Yeon Ja
   Park, Yun Jung
   Park, Ji Young
   Jeong, Hyoung Oh
   Kim, Dae Hyun
   Ha, Young Mi
   Kim, Ji Min
   Song, Yu Min
   Heo, Hyoung-Sam
   Yu, Byung Pal
   Chun, Pusoon
   Moon, Hyung Ryong
   Chung, Hae Young
TI Inhibitory Effect of mTOR Activator MHY1485 on Autophagy: Suppression of
   Lysosomal Fusion
SO PLOS ONE
LA English
DT Article
ID CELL-DEATH; PROTEIN-DEGRADATION; SIGNALING PATHWAYS; ARPE-19 CELLS;
   GLIOMA-CELLS; CHLOROQUINE; MACROAUTOPHAGY; ACCUMULATION; INDUCTION;
   TRIAZINES
AB Autophagy is a major degradative process responsible for the disposal of cytoplasmic proteins and dysfunctional organelles via the lysosomal pathway. During the autophagic process, cells form double-membraned vesicles called autophagosomes that sequester disposable materials in the cytoplasm and finally fuse with lysosomes. In the present study, we investigated the inhibition of autophagy by a synthesized compound, MHY1485, in a culture system by using Ac2F rat hepatocytes. Autophagic flux was measured to evaluate the autophagic activity. Autophagosomes were visualized in Ac2F cells transfected with AdGFP-LC3 by live-cell confocal microscopy. In addition, activity of mTOR, a major regulatory protein of autophagy, was assessed by western blot and docking simulation using AutoDock 4.2. In the result, treatment with MHY1485 suppressed the basal autophagic flux, and this inhibitory effect was clearly confirmed in cells under starvation, a strong physiological inducer of autophagy. The levels of p62 and beclin-1 did not show significant change after treatment with MHY1485. Decreased co-localization of autophagosomes and lysosomes in confocal microscopic images revealed the inhibitory effect of MHY1485 on lysosomal fusion during starvation-induced autophagy. These effects of MHY1485 led to the accumulation of LC3II and enlargement of the autophagosomes in a dose-and time-dependent manner. Furthermore, MHY1485 induced mTOR activation and correspondingly showed a higher docking score than PP242, a well-known ATP-competitive mTOR inhibitor, in docking simulation. In conclusion, MHY1485 has an inhibitory effect on the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes. MHY1485 also induces mTOR activity, providing a possibility for another regulatory mechanism of autophagy by the MHY compound. The significance of this study is the finding of a novel inhibitor of autophagy with an mTOR activating effect.
C1 [Choi, Yeon Ja; Jeong, Hyoung Oh; Kim, Dae Hyun; Ha, Young Mi; Kim, Ji Min; Chung, Hae Young] Pusan Natl Univ, Coll Pharm, Mol Inflammat Res Ctr Aging Intervent MRCA, Pusan, South Korea.
   [Park, Yun Jung; Park, Ji Young; Song, Yu Min; Moon, Hyung Ryong] Pusan Natl Univ, Coll Pharm, Med Chem Lab, Pusan, South Korea.
   [Heo, Hyoung-Sam] KRIBB, Plant Syst Engn Ctr, Taejon, South Korea.
   [Yu, Byung Pal] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
   [Chun, Pusoon] Inje Univ, Coll Pharm, Gimhae, Gyeongnam, South Korea.
RP Choi, YJ (reprint author), Pusan Natl Univ, Coll Pharm, Mol Inflammat Res Ctr Aging Intervent MRCA, Pusan, South Korea.
EM mhr108@pusan.ac.kr; hyjung@pusan.ac.kr
FU National Research Foundation of Korea (NRF); Korean government (MEST)
   [2009-0083538]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MEST) (No. 2009-0083538). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agarwal A, 2005, BIOORG MED CHEM LETT, V15, P531, DOI 10.1016/j.bmcl.2004.11.052
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Bauvy C, 2009, METHOD ENZYMOL, V452, P47, DOI 10.1016/S0076-6879(08)03604-5
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Cho YS, 2010, ARCH PHARM RES, V33, P1881, DOI 10.1007/s12272-010-1201-6
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hiruma H, 2011, FOLIA HISTOCHEM CYTO, V49, P272, DOI 10.5603/FHC.2011.0038
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Kolmakov KA, 2008, J HETEROCYCLIC CHEM, V45, P1215, DOI 10.1002/jhet.5570450446
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Mizushima N, 2007, AUTOPHAGY, V3, P542
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Noda T, 2009, CELL DEATH DIFFER, V16, P984, DOI 10.1038/cdd.2009.54
   Oh M, 2008, BIOCHEM BIOPH RES CO, V369, P1179, DOI 10.1016/j.bbrc.2008.03.019
   Pous C, 2011, NAT CELL BIOL, V13, P342, DOI 10.1038/ncb0411-342
   Ramser B, 2009, J INVEST DERMATOL, V129, P2419, DOI 10.1038/jid.2009.80
   Richard DJ, 2010, BIOORG MED CHEM LETT, V20, P2654, DOI 10.1016/j.bmcl.2010.02.029
   Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Sturgill TW, 2009, ACS CHEM BIOL, V4, P999, DOI 10.1021/cb900193e
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Tanida I, 2010, METHODS MOL BIOL, V648, P193, DOI 10.1007/978-1-60761-756-3_13
   Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234
   Wang JH, 2011, GASTROENTEROLOGY, V141, P2188, DOI 10.1053/j.gastro.2011.08.005
   Wang XM, 2011, J MOL CELL BIOL, V3, P206, DOI 10.1093/jmcb/mjq038
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Yuk JM, 2012, EXP MOL MED, V44, P99, DOI 10.3858/emm.2012.44.2.032
   Zask A, 2010, BIOORG MED CHEM LETT, V20, P2644, DOI 10.1016/j.bmcl.2010.02.045
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 44
TC 32
Z9 32
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2012
VL 7
IS 8
AR e43418
DI 10.1371/journal.pone.0043418
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 999CI
UT WOS:000308286300051
PM 22927967
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Ho, AL
   Musi, E
   Ambrosini, G
   Nair, JS
   Vasudeva, SD
   de Stanchina, E
   Schwartz, GK
AF Ho, Alan L.
   Musi, Elgilda
   Ambrosini, Grazia
   Nair, Jayasree S.
   Vasudeva, Shyamprasad Deraje
   de Stanchina, Elisa
   Schwartz, Gary K.
TI Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven
   by Tumor Genotype
SO PLOS ONE
LA English
DT Article
ID VIVO ANTITUMOR-ACTIVITY; IN-VIVO; BRAF GENE; TRANSLATIONAL CONTROL;
   MEDIATES RESISTANCE; CELL SUSCEPTIBILITY; KINASE INHIBITOR; REGULATED
   KINASE; B-RAF; PATHWAY
AB Uveal melanomas possess activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathways. MAPK activation occurs via somatic mutations in the heterotrimeric G protein subunits GNAQ and GNA11 for over 70% of tumors and less frequently via V600E BRAF mutations. In this report, we describe the impact of dual pathway inhibition upon uveal melanoma cell lines with the MEK inhibitor selumetinib (AZD6244/ARRY-142886) and the ATP-competitive mTOR kinase inhibitor AZD8055. While synergistic reductions in cell viability were observed with AZD8055/selumetinib in both BRAF and GNAQ mutant cell lines, apoptosis was preferentially induced in BRAF mutant cells only. In vitro apoptosis assay results were predictive of in vivo drug efficacy as tumor regressions were observed only in a BRAF mutant xenograft model, but not GNAQ mutant model. We went on to discover that GNAQ promotes relative resistance to AZD8055/selumetinib-induced apoptosis in GNAQ mutant cells. For BRAF mutant cells, both AKT and 4E-BP1 phosphorylation were modulated by the combination; however, decreasing AKT phosphorylation alone was not sufficient and decreasing 4E-BP1 phosphorylation was not required for apoptosis. Instead, cooperative mTOR complex 2 (mTORC2) and MEK inhibition resulting in downregulation of the pro-survival protein MCL-1 was found to be critical for combination-induced apoptosis. These results suggest that the clinical efficacy of combined MEK and mTOR kinase inhibition will be determined by tumor genotype, and that BRAF mutant malignancies will be particularly susceptible to this strategy.
C1 [Ho, Alan L.; Musi, Elgilda; Ambrosini, Grazia; Nair, Jayasree S.; Vasudeva, Shyamprasad Deraje; Schwartz, Gary K.] Mem Sloan Kettering Canc Ctr, Lab New Drug Dev, New York, NY 10021 USA.
   [de Stanchina, Elisa] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY USA.
   [Ho, Alan L.; Schwartz, Gary K.] Cornell Univ, Dept Med, Weill Med Coll, Ithaca, NY USA.
RP Ho, AL (reprint author), Mem Sloan Kettering Canc Ctr, Lab New Drug Dev, 1275 York Ave, New York, NY 10021 USA.
EM hoa@mskcc.org
FU AstraZeneca
FX The authors have read the journal's policy and have the following
   conflicts: one-time paid consultancy (AstraZeneca), research funding
   (AstraZeneca) was provided to Alan Ho. To clarify, funding in both
   instances were not used or applicable to the study described in this
   submission, but instead to other, unrelated clinical research.
   Selumetinib and AZD8055 were supplied by AstraZeneca for this study.
   There are no other patents, products in development or other marketed
   products to declare. This does not alter the authors' adherence to all
   the PLoS ONE policies on sharing data and materials, as detailed online
   in the guide for authors.
CR Abdel-Rahman MH, 2006, J CLIN ONCOL, V24, P288, DOI 10.1200/JCO.2005.02.2418
   Ambrosini G, 2008, MOL CANCER THER, V7, P890, DOI 10.1158/1535-7163.MCT-07-0518
   Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973
   Braun RD, 2006, INVEST OPHTH VIS SCI, V47, P7, DOI 10.1167/iovs.04.0882
   Calipel A, 2006, J BIOL CHEM, V281, P9238, DOI 10.1074/jbc.M600228200
   Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208
   DUMMER R, 2008, J CLIN ONCOL S, V26
   Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0
   Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422
   Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902
   Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409
   Janssen CS, 2008, BRIT J CANCER, V99, P1673, DOI 10.1038/sj.bjc.6604731
   Kilic E, 2004, MELANOMA RES, V14, P203, DOI 10.1097/cmr.0000130006.46885.a0
   Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200
   LUYTEN GPM, 1993, BIOCHEM BIOPH RES CO, V192, P22, DOI 10.1006/bbrc.1993.1376
   MA D, 1995, INVEST OPHTH VIS SCI, V36, P435
   Maat W, 2008, INVEST OPHTH VIS SCI, V49, P23, DOI 10.1167/iovs.07-0722
   Malaponte G, 2006, CANCER BIOL THER, V5, P225, DOI 10.4161/cbt.5.2.2429
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   Meng JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014124
   Meng JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013026
   Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105
   Motwani M, 1999, CLIN CANCER RES, V5, P1876
   Nair JS, 2009, CLIN CANCER RES, V15, P2022, DOI 10.1158/1078-0432.CCR-08-1826
   Naus NC, 2000, INT J CANCER, V87, P151, DOI 10.1002/1097-0215(20000701)87:1<151::AID-IJC23>3.0.CO;2-1
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954
   Patel M, 2011, CLIN CANC RES
   Rimoldi D, 2003, CANCER RES, V63, P5712
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006
   She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023
   Sun Y, 2005, INVEST OPHTH VIS SCI, V46, P1561, DOI 10.1167/iovs.04-1362
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584
   Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29
   Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765
   Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250
   Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150
   Yu K, 2008, CANCER BIOL THER, V7, P307
   Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598
NR 53
TC 41
Z9 41
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 10
PY 2012
VL 7
IS 7
AR e40439
DI 10.1371/journal.pone.0040439
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 973JD
UT WOS:000306355500042
PM 22808163
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Shoji, K
   Oda, K
   Kashiyama, T
   Ikeda, Y
   Nakagawa, S
   Sone, K
   Miyamoto, Y
   Hiraike, H
   Tanikawa, M
   Miyasaka, A
   Koso, T
   Matsumoto, Y
   Wada-Hiraike, O
   Kawana, K
   Kuramoto, H
   McCormick, F
   Aburatani, H
   Yano, T
   Kozuma, S
   Taketani, Y
AF Shoji, Keiko
   Oda, Katsutoshi
   Kashiyama, Tomoko
   Ikeda, Yuji
   Nakagawa, Shunsuke
   Sone, Kenbun
   Miyamoto, Yuichiro
   Hiraike, Haruko
   Tanikawa, Michihiro
   Miyasaka, Aki
   Koso, Takahiro
   Matsumoto, Yoko
   Wada-Hiraike, Osamu
   Kawana, Kei
   Kuramoto, Hiroyuki
   McCormick, Frank
   Aburatani, Hiroyuki
   Yano, Tetsu
   Kozuma, Shiro
   Taketani, Yuji
TI Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235,
   and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
SO PLOS ONE
LA English
DT Article
ID RENAL-CELL CARCINOMA; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET;
   RAPAMYCIN INHIBITOR; HIGH-FREQUENCY; ANTITUMOR-ACTIVITY; CANCER-CELLS;
   MUTATIONS; PI3K; EVEROLIMUS; PIK3CA
AB The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235-a dual PI3K/mTOR inhibitor-and RAD001-an mTOR inhibitor-in 13 endometrial cancer cell lines, all of which possess one or more alterations in PTEN, PIK3CA, and K-Ras. We also combined these compounds with a MAPK pathway inhibitor (PD98059 or UO126) in cell lines with K-Ras alterations (mutations or amplification). PTEN mutant cell lines without K-Ras alterations (n = 9) were more sensitive to both RAD001 and NVP-BEZ235 than were cell lines with K-Ras alterations (n = 4). Dose-dependent growth suppression was more drastically induced by NVP-BEZ235 than by RAD001 in the sensitive cell lines. G1 arrest was induced by NVP-BEZ235 in a dose-dependent manner. We observed in vivo antitumor activity of both RAD001 and NVP-BEZ235 in nude mice. The presence of a MEK inhibitor, PD98059 or UO126, sensitized the K-Ras mutant cells to NVP-BEZ235. Robust growth suppression by NVP-BEZ235 suggests that a dual PI3K/mTOR inhibitor is a promising therapeutic for endometrial carcinomas. Our data suggest that mutational statuses of PTEN and K-Ras might be useful predictors of sensitivity to NVP-BEZ235 in certain endometrial carcinomas.
C1 [Shoji, Keiko; Oda, Katsutoshi; Kashiyama, Tomoko; Ikeda, Yuji; Nakagawa, Shunsuke; Sone, Kenbun; Miyamoto, Yuichiro; Hiraike, Haruko; Tanikawa, Michihiro; Miyasaka, Aki; Koso, Takahiro; Matsumoto, Yoko; Wada-Hiraike, Osamu; Kawana, Kei; Yano, Tetsu; Kozuma, Shiro; Taketani, Yuji] Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Tokyo 113, Japan.
   [Kuramoto, Hiroyuki] Kitasato Univ, Grad Sch Med Sci, Dept Clin Cytol, Kanagawa, Japan.
   [McCormick, Frank] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Aburatani, Hiroyuki] Univ Tokyo, Genome Sci Div, Res Ctr Adv Sci & Technol, Tokyo, Japan.
RP Shoji, K (reprint author), Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Tokyo 113, Japan.
EM katsutoshi-tky@umin.ac.jp
OI Wada-Hiraike, Osamu/0000-0002-3458-6711
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [19599005, 23592437, 21791544, 20221009, 117100001060]
FX This work was supported by a Grant-in-aid for Scientific Research (C),
   19599005 and 23592437, a Grant-in-Aid for Young Scientists (B), grant
   number 21791544 (to KO), grant number: Scientific Research (S) 20221009
   (to HA), and Next-Generation Cancer Research Project, grant number:
   117100001060 to TY) from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan. The funders had no rule in study
   design, data collection and analysis, decision to publish or preparation
   of the manuscript.
CR Bernstam F-M, 2009, J CLIN ONCOL, V27, P2278
   Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106
   Cao P, 2009, BRIT J CANCER, V100, P1267, DOI 10.1038/sj.bjc.6604995
   Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039
   Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022
   Dan S, 2010, CANCER RES, V70, P4982, DOI 10.1158/0008-5472.CAN-09-4172
   Doll A, 2008, J STEROID BIOCHEM, V108, P221, DOI 10.1016/j.jsbmb.2007.09.020
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   ENOMOTO T, 1991, CANCER RES, V51, P5308
   Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Houghton PJ, 2010, CLIN CANCER RES, V16, P1368, DOI 10.1158/1078-0432.CCR-09-1314
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Ihle NT, 2009, CANCER RES, V69, P143, DOI 10.1158/0008-5472.CAN-07-6656
   Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091
   Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143
   Konstantinidou G, 2009, CANCER RES, V69, P7644, DOI 10.1158/0008-5472.CAN-09-0823
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Mabuchi S, 2007, CANCER RES, V67, P2408, DOI 10.1158/0008-5472.CAN-06-4490
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285
   Minaguchi T, 2001, CLIN CANCER RES, V7, P2636
   Mordant P, 2010, MOL CANCER THER, V9, P358, DOI 10.1158/1535-7163.MCT-09-1014
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Murayama Hosokawa S, 2010, ONCOGENE, V29, P1897
   O'Brien C, 2010, CLIN CANCER RES, V16, P3670, DOI 10.1158/1078-0432.CCR-09-2828
   Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/008-5472.CAN-05-2620
   Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755
   Oza AM, 2011, J CLIN ONCOL, V29, P3278, DOI 10.1200/JCO.2010.34.1578
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Ryan AJ, 2005, CELL TISSUE RES, V322, P53, DOI 10.1007/s00441-005-1109-5
   Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385
   She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023
   She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065
   Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109
   Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106
   Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990
   Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yang JL, 2010, J CANCER RES CLIN, V136, P1303, DOI 10.1007/s00432-010-0781-3
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
NR 46
TC 58
Z9 61
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2012
VL 7
IS 5
AR e37431
DI 10.1371/journal.pone.0037431
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UY
UT WOS:000305342300044
PM 22662154
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Villa-Cuesta, E
   Boylan, JM
   Tatar, M
   Gruppuso, PA
AF Villa-Cuesta, Eugenia
   Boylan, Joan M.
   Tatar, Marc
   Gruppuso, Philip A.
TI Resveratrol Inhibits Protein Translation in Hepatic Cells
SO PLOS ONE
LA English
DT Article
ID EXTENDS LIFE-SPAN; CAP-DEPENDENT TRANSLATION; DIETARY RESTRICTION;
   IN-VIVO; CAENORHABDITIS-ELEGANS; LOW BIOAVAILABILITY; AMPK ACTIVATION;
   S6 KINASE; RAPAMYCIN; CANCER
AB Resveratrol is a plant-derived polyphenol that extends lifespan and healthspan in model organism. Despite extensive investigation, the biological processes mediating resveratrol's effects have yet to be elucidated. Because repression of translation shares many of resveratrol's beneficial effects, we hypothesized that resveratrol was a modulator of protein synthesis. We studied the effect of the drug on the H4-II-E rat hepatoma cell line. Initial studies showed that resveratrol inhibited global protein synthesis. Given the role of the mammalian Target of Rapamycin (mTOR) in regulating protein synthesis, we examined the effect of resveratrol on mTOR signaling. Resveratrol inhibited mTOR self-phosphorylation and the phosphorylation of mTOR targets S6K1 and eIF4E-BP1. It attenuated the formation of the translation initiation complex eIF4F and increased the phosphorylation of eIF2 alpha. The latter event, also a mechanism for translation inhibition, was not recapitulated by mTOR inhibitors. The effects on mTOR signaling were independent of effects on AMP-activated kinase or AKT. We conclude that resveratrol is an inhibitor of global protein synthesis, and that this effect is mediated through modulation of mTOR-dependent and independent signaling.
C1 [Villa-Cuesta, Eugenia; Tatar, Marc] Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA.
   [Boylan, Joan M.; Gruppuso, Philip A.] Brown Univ, Dept Pediat, Providence, RI 02912 USA.
   [Boylan, Joan M.; Gruppuso, Philip A.] Rhode Isl Hosp, Providence, RI USA.
RP Villa-Cuesta, E (reprint author), Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA.
EM Eugenia_Villa-Cuesta@brown.edu
FU National Institutes of Health [R01HD24455, R01AG024360]; American
   Parkinson Disease Association [529302]
FX This work is supported by National Institutes of Health grant R01HD24455
   (to P. A. G.), R01AG024360 (to M. T.) and American Parkinson Disease
   Association grant 529302 (to M. T.). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anand P, 2006, J NUTR, V136, P27
   Anekonda TS, 2006, BRAIN RES REV, V52, P316, DOI 10.1016/j.brainresrev.2006.04.004
   Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625
   Anisimov VN, 2010, CELL CYCLE, V9, P188, DOI 10.4161/cc.9.1.10407
   Armour SM, 2009, AGING-US, V1, P515, DOI 10.18632/aging.100056
   Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5
   Athar M, 2009, ARCH BIOCHEM BIOPHYS, V486, P95, DOI 10.1016/j.abb.2009.01.018
   BALLARD FJ, 1986, BIOCHEM J, V233, P223, DOI 10.1042/bj2330223
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x
   Bishayee A, 2009, CANCER PREV RES, V2, P409, DOI 10.1158/1940-6207.CAPR-08-0160
   Bishayee A, 2009, CHEM-BIOL INTERACT, V179, P131, DOI 10.1016/j.cbi.2008.11.015
   Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188
   Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010
   Campisi J, 2009, AGING CELL, V8, P221, DOI 10.1111/j.1474-9726.2009.00475.x
   CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.tb20498.x
   Delmas D, 2000, ONCOL REP, V7, P847
   Dolinsky VW, 2009, CIRCULATION, V119, P1643, DOI 10.1161/CIRCULATIONAHA.108.787440
   Efeyan A., 2009, CURR OPIN CELL BIOL
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hursting SD, 2010, CARCINOGENESIS, V31, P83, DOI 10.1093/carcin/bgp280
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jimenez RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007373
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200
   Kaeberlein M, 2007, AGING CELL, V6, P415, DOI 10.1111/j.1474-9726.2007.00314.x
   Kaeberlein M, 2007, PLOS GENET, V3, P655, DOI 10.1371/journal.pgen.0030084
   Kaeberlein M, 2010, BIOESSAYS, V32, P96, DOI 10.1002/bies.200900171
   Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782
   KAPAHI P, 2004, SCI AGING KNOWLEDGE, pPE34
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Lancon A, 2004, BIOCHEM BIOPH RES CO, V316, P1132, DOI 10.1016/j.bbrc.2004.02.164
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lin JN, 2010, J AGR FOOD CHEM, V58, P1584, DOI 10.1021/jf9035782
   Liu ML, 2010, J BIOL CHEM, V285, P36387, DOI 10.1074/jbc.M110.169284
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Luong N, 2006, CELL METAB, V4, P133, DOI 10.1016/j.cmet.2006.05.013
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059
   Montgomery J. L., 2002, Methods in Cell Science, V24, P123, DOI 10.1023/A:1024498316958
   Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857
   Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112
   Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682
   Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x
   Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534
   Pirola L, 2008, IUBMB LIFE, V60, P323, DOI 10.1002/iub.47
   PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229
   Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2
   Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434
   Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205
   Robert F, 2009, EXPERT OPIN THER TAR, V13, P1279, DOI 10.1517/14728220903241625
   Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221
   Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006
   Sonenberg N., TRANSLATIONAL CONTRO
   Treiber G, 2009, EXPERT REV ANTICANC, V9, P247, DOI 10.1586/14737140.9.2.247
   Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482
   Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038
   Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a
   Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Wei M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000467
   Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Yu CW, 2002, PHARM RES-DORDR, V19, P1907, DOI 10.1023/A:1021414129280
   Zhang JD, 2006, BIOCHEM J, V397, P519, DOI 10.1042/BJ20050977
   Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034
NR 80
TC 14
Z9 14
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2011
VL 6
IS 12
AR e29513
DI 10.1371/journal.pone.0029513
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 897SP
UT WOS:000300677000045
PM 22242130
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Munk, R
   Ghosh, P
   Ghosh, MC
   Saito, T
   Xu, M
   Carter, A
   Indig, F
   Taub, DD
   Longo, DL
AF Munk, Rachel
   Ghosh, Paritosh
   Ghosh, Manik C.
   Saito, Takeshi
   Xu, Mai
   Carter, Arnell
   Indig, Fred
   Taub, Dennis D.
   Longo, Dan L.
TI Involvement of mTOR in CXCL12 Mediated T Cell Signaling and Migration
SO PLOS ONE
LA English
DT Article
ID HEMATOPOIETIC PROGENITOR CELLS; MAMMALIAN TARGET; PROTEIN-KINASE;
   CHEMOKINE; PATHWAY; ACTIVATION; RECEPTOR; LYMPHOCYTES; SDF-1-ALPHA
AB Background: CXCL12 is a pleiotropic chemokine involved in multiple different processes such as immune regulation, inflammatory responses, and cancer development. CXCL12 is also a potent chemokine involved in chemoattraction of T cells to the site of infection or inflammation. Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that modulates different cellular processes, such as metabolism, nutrient sensing, protein translation, and cell growth. The role of mTOR in CXCL12-mediated resting T cell migration has yet to be elucidated.
   Methodology/Principal Findings: Rapamycin, an inhibitor of mTOR, significantly inhibits CXCL12 mediated migration of both primary human resting T cells and human T cell leukemia cell line CEM. p70(S6K1), an effector molecule of mTOR signaling pathway, was knocked down by shRNA in CEM cells using a lentiviral gene transfer system. Using p70(S6K1) knock down cells, we demonstrate the role of mTOR signaling in T cell migration both in vitro and in vivo.
   Conclusions: Our data demonstrate a new role for mTOR in CXCL12-induced T cell migration, and enrich the current knowledge regarding the clinical use of rapamycin.
C1 [Munk, Rachel; Ghosh, Paritosh; Ghosh, Manik C.; Saito, Takeshi; Longo, Dan L.] NIA, Lymphocyte Cell Biol Unit, NIH, Baltimore, MD 21224 USA.
   [Xu, Mai; Carter, Arnell; Taub, Dennis D.] NIA, Clin Immunol Sect, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA.
   [Indig, Fred] NIA, Res Resources Branch, NIH, Baltimore, MD 21224 USA.
RP Munk, R (reprint author), NIA, Lymphocyte Cell Biol Unit, NIH, Baltimore, MD 21224 USA.
EM ghoshp@grc.nia.nih.gov
RI Longo, Dan L./F-6022-2011
FU National Institutes of Health (NIH), National Institute on Aging
FX This research was supported by the Intramural Research Program of the
   National Institutes of Health (NIH), National Institute on Aging. There
   is no current external funding source for this study. The research was
   conducted as a part of the official duty of an employee in the National
   Institutes of Health. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Finlay D, 2010, ANN NY ACAD SCI, V1183, P149, DOI 10.1111/j.1749-6632.2009.05134.x
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Ghosh MC, 2009, BLOOD, V114, P1366, DOI 10.1182/blood-2008-08-175869
   Ghosh MC, 2009, BLOOD, V113, P575, DOI 10.1182/blood-2008-04-151803
   Harris Thurl E, 2003, Sci STKE, V2003, pre15
   Hashimoto I, 2008, EUR J CANCER, V44, P1022, DOI 10.1016/j.ejca.2008.02.043
   Karin N, 2010, J LEUKOCYTE BIOL, V88, P463, DOI 10.1189/jlb.0909602
   Kremer KN, 2003, J IMMUNOL, V171, P360, DOI 10.4049/jimmunol.171.1.360
   Kumar A, 2006, IMMUNITY, V25, P213, DOI 10.1016/j.immuni.2006.06.015
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Murooka TT, 2008, BLOOD, V111, P4892, DOI 10.1182/blood-2007-11-125039
   NORMAN MR, 1977, CANCER RES, V37, P3785
   Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Sinclair LV, 2008, NAT IMMUNOL, V9, P513, DOI 10.1038/ni.1603
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313
   Vicente-Manzanares M, 2005, BLOOD, V105, P3026, DOI 10.1182/blood-2004-07-2925
   Vila-Coro AJ, 1999, FASEB J, V13, P1699
   Voermans C, 2001, EXP HEMATOL, V29, P1456, DOI 10.1016/S0301-472X(01)00740-8
   Wang JH, 2008, CANCER RES, V68, P10367, DOI 10.1158/0008-5472.CAN-08-2780
   Ward SG, 2006, TRENDS IMMUNOL, V27, P80, DOI 10.1016/j.it.2005.12.004
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Zhang SL, 2011, BLOOD, V117, P1228, DOI 10.1182/blood-2010-05-287821
   Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342
NR 29
TC 13
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2011
VL 6
IS 9
AR e24667
DI 10.1371/journal.pone.0024667
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 819CO
UT WOS:000294803200036
PM 21931802
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Gwinn, DM
   Asara, JM
   Shaw, RJ
AF Gwinn, Dana M.
   Asara, John M.
   Shaw, Reuben J.
TI Raptor is Phosphorylated by cdc2 during Mitosis
SO PLOS ONE
LA English
DT Article
ID CELL-CYCLE; MAMMALIAN TARGET; PROTEIN-KINASE; RAPAMYCIN MTOR; S6
   KINASE-1; COMPLEX; GROWTH; 4E-BP1; TRANSLATION; INHIBITOR
AB Background: The appropriate control of mitotic entry and exit is reliant on a series of interlocking signaling events that coordinately drive the biological processes required for accurate cell division. Overlaid onto these signals that promote orchestrated cell division are checkpoints that ensure appropriate mitotic spindle formation, a lack of DNA damage, kinetochore attachment, and that each daughter cell has the appropriate complement of DNA. We recently discovered that AMP-activated protein kinase (AMPK) modulates the G2/M phase of cell cycle progression in part through its suppression of mammalian target of rapamycin (mTOR) signaling. AMPK directly phosphorylates the critical mTOR binding partner raptor inhibiting mTORC1 (mTOR-raptor rapamycin sensitive mTOR kinase complex 1). As mTOR has been previously tied to mitotic control, we examined further how raptor may contribute to this process.
   Methodology/Principal Findings: We have discovered that raptor becomes highly phosphorylated in cells in mitosis. Utilizing tandem mass spectrometry, we identified a number of novel phosphorylation sites in raptor, and using phosphospecific antibodies demonstrated that raptor becomes phosphorylated on phospho-serine/threonine-proline sites in mitosis. A combination of site-directed mutagenesis in a tagged raptor cDNA and analysis with a series of new phosphospecific antibodies generated against different sites in raptor revealed that Serine 696 and Threonine 706 represent two key sites in raptor phosphorylated in mitosis. We demonstrate that the mitotic cyclin-dependent kinase cdc2/CDK1 is the kinase responsible for phosphorylating these sites, and its mitotic partner Cyclin B efficiently coimmunoprecipitates with raptor in mitotic cells.
   Conclusions/Significance: This study demonstrates that the key mTOR binding partner raptor is directly phosphorylated during mitosis by cdc2. This reinforces previous studies suggesting that mTOR activity is highly regulated and important for mitotic progression, and points to a direct modulation of the mTORC1 complex during mitosis.
C1 [Gwinn, Dana M.; Shaw, Reuben J.] Dulbecco Ctr Canc Res, Mol & Cell Biol Lab, La Jolla, CA USA.
   [Shaw, Reuben J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.
   [Asara, John M.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.
   [Asara, John M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Gwinn, DM (reprint author), Dulbecco Ctr Canc Res, Mol & Cell Biol Lab, La Jolla, CA USA.
EM shaw@salk.edu
FU National Institutes of Health [P01 CA120964, R01 DK080425]; American
   Cancer Society
FX The work was supported in part from grants from the National Institutes
   of Health to R.J.S. and J.M.A. (P01 CA120964), and to R.J.S. (R01
   DK080425); and from the American Cancer Society (R.J.S.). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Acosta-Jaquez HA, 2009, MOL CELL BIOL, V29, P4308, DOI 10.1128/MCB.01665-08
   Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014
   Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   FOSTER KG, 2009, J BIOL CHEM
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Greenberg VL, 2005, ONCOGENE, V24, P4851, DOI 10.1038/sj.onc.1208624
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5
   Hornbeck PV, 2004, PROTEOMICS, V4, P1551, DOI 10.1002/pmic.200300772
   Hou ZB, 2007, J BIOL CHEM, V282, P6922, DOI 10.1074/jbc.M607836200
   Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040
   Nakashima A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002223
   Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077
   Petersen J, 2007, NAT CELL BIOL, V9, P1263, DOI 10.1038/ncb1646
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4
   Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5
   Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200
   Smith EM, 2008, EMBO J, V27, P1005, DOI 10.1038/emboj.2008.39
   THOREEN CC, 2009, J BIOL CHEM
   Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547
   Vazquez-Martin A, 2009, CELL CYCLE, V8, P2385, DOI 10.4161/cc.8.15.9082
   Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
NR 33
TC 34
Z9 36
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 12
PY 2010
VL 5
IS 2
AR e9197
DI 10.1371/journal.pone.0009197
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 554ZC
UT WOS:000274474600017
PM 20169205
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU King, FW
   Fong, S
   Griffin, C
   Shoemaker, M
   Staub, R
   Zhang, YL
   Cohen, I
   Shtivelman, E
AF King, Frank W.
   Fong, Sylvia
   Griffin, Chandi
   Shoemaker, Mark
   Staub, Rick
   Zhang, Yan-Ling
   Cohen, Isaac
   Shtivelman, Emma
TI Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through
   Inhibition of mTOR and Induction of ER Stress
SO PLOS ONE
LA English
DT Article
AB The aqueous extract of Anemarrhena asphodeloides (BN108) induces apoptosis in various cancer cell lines but is significantly less cytotoxic in non-transformed cells. Chemical fractionation of BN108 showed that its cytotoxicity is associated with timosaponins, steroidal saponins of coprostane type. Timosaponin BII (TBII) is a major saponin in BN108, but it shows little cytotoxicity. A much less abundant TAIII induces cell death in tumor cells but not in normal cells, reproducing the selectivity of the total extract BN108. Glycosidase treatment, by removing the extra sugar moiety in TBII, converts it to TAIII and confers cytotoxic activity. Analysis of the mechanisms of death induced by TAIII revealed activation of two distinct pro-apoptotic pathways: first, inhibition of mTORC1 manifested in much reduced phosphorylation of mTORC1 targets; second, induction of endoplasmic reticulum stress culminating in phosphorylation of eIF2 alpha and activation of caspase 4. These pro-apoptotic pathways are activated by TAIII selectively in tumor cells but not in normal cells. Both pathways play a causative role in TAIII cytotoxicity, as restoration of either mTOR activity or relief of ER stress alone offer only partial protection from TAIII. Inhibition of mTORC1 and induction of ER stress apparently contribute to the induction of the previously reported autophagic response in TAIII-treated cells. TAIII induced autophagy plays a protective role in TAIII induced death signaling, and failure to mount autophagic response is associated with heightened sensitivity to TAIII induced apoptosis. The multiple death-promoting and apparently tumor-selective responses to TAIII, its ability to inhibit mTORC1, and the possibility of further enhancing its cytotoxicity by pharmacological inhibition of autophagy, make TAIII an attractive candidate for development as a cancer therapeutic agent.
C1 [King, Frank W.; Fong, Sylvia; Griffin, Chandi; Shoemaker, Mark; Staub, Rick; Zhang, Yan-Ling; Cohen, Isaac; Shtivelman, Emma] BioNovo Inc, Emeryville, CA USA.
RP King, FW (reprint author), BioNovo Inc, Emeryville, CA USA.
EM emmas@bionovo.com
CR Audas TE, 2008, MOL CELL BIOL, V28, P3952, DOI 10.1128/MCB.01439-07
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Carra S, 2009, J BIOL CHEM, V284, P5523, DOI 10.1074/jbc.M807440200
   Colgan SM, 2007, INT J BIOCHEM CELL B, V39, P1843, DOI 10.1016/j.biocel.2007.05.002
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014
   Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200
   Diaz-Troya S, 2008, AUTOPHAGY, V4, P851, DOI 10.4161/auto.6555
   Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Harding HP, 2005, CELL METAB, V2, P361, DOI 10.1016/j.cmet.2005.11.005
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   KAWASAKI T, 1963, Chem Pharm Bull (Tokyo), V11, P1221
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   KOVACS WJ, 2008, J BIOL CHEM
   Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JC126390
   Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7
   Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227
   Radhakrishnan A, 2008, CELL METAB, V8, P512, DOI 10.1016/j.cmet.2008.10.008
   Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5
   Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200
   Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   SAITO S, 1994, CHEM PHARM BULL, V42, P2342
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Shoemaker M, 2005, PHYTOTHER RES, V19, P649, DOI 10.1002/ptr.1702
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002
   Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022
   Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596
   Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3
   Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653
   Zhang JY, 1999, CLIN CHIM ACTA, V289, P79, DOI 10.1016/S0009-8981(99)00160-6
NR 43
TC 37
Z9 43
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2009
VL 4
IS 9
AR e7283
DI 10.1371/journal.pone.0007283
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 501BO
UT WOS:000270354100029
PM 19789631
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

EF